



 ABBOTT

At Abbott, we're continuing to strengthen the resilience of our company so that we can shape the future of healthcare and help more people in more places lead fuller lives through better health. This is the foundation of how we operate and how we plan to deliver long-term impact.

The data presented here reflects 2025 performance unless otherwise stated.

On The Cover:

Greta Hansen, a student at the University of Wisconsin, donates blood during Abbott and the Big Ten's "We Give Blood" drive on campus in October.

Table of contents

04	About Abbott	29	Protect a healthy environment
05	Our 2030 Sustainability Plan progress	30	Energy and greenhouse gas emissions
15	Innovate for access and affordability	32	Water stewardship
16	Make access and affordability core to new product innovation	33	Waste management
17	Transform care for chronic diseases, malnutrition, and infectious diseases	35	Packaging
18	Advance health access through partnerships	36	Commitment to our customers
21	Responsibly connect data, technology, and care	37	Maintaining a culture of quality
22	Security and privacy by design	39	Strong, resilient global supplier network
23	Enterprise cybersecurity	40	Supply chain resilience
23	AI data principles	41	Strategic supply chain initiatives
24	Build the workforce of tomorrow	42	Standards of business conduct
25	Talent acquisition	43	Ethics and integrity
25	Understanding employee sentiment	44	Board oversight
26	Employee development	44	Risk management
26	Employee well-being	45	Sustainability governance and prioritization
27	Employee health and safety	47	Appendix
28	Human rights		

A Caution Concerning Forward-Looking Statements: Some statements in this report may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological, and other factors that may affect Abbott's operations are discussed in Item 1A, "Risk Factors," in our Annual Report on Form 10-K for the year ended Dec. 31, 2025, and are incorporated herein by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.



Dear Abbott Stakeholder,
Abbott has been making a positive difference in the world for 138 years now. That's sustainability in action. To us, it's both a principle and a practice.

Sustainability is implicit in our business at Abbott, and that's how we go about it — as a business goal, with all the intentionality that demands.

Sustaining the enterprise

Our first goal and responsibility is to keep our company healthy and productive so it can continue to deliver the many benefits it provides to the literally billions of people who depend on it.

Doing so hinges on our success as an innovator — creating new healthcare technologies to address the world's most urgent chronic health challenges and making them accessible to more people. Maintaining a strong and productive innovation pipeline is our top priority, and our consistent investment and effective management have kept it highly productive, with Abbott recently being named #4 on *Fortune's* list of America's Most Innovative Companies.

And we'll be bringing that innovation to more people than ever through our acquisition this year of Exact Sciences, a leader in cancer screening and precision oncology diagnostics. Our new Cancer Diagnostics business brings Abbott into one of the most important areas in healthcare, and our global presence will allow us to scale these technologies and bring them to more people in more places than ever before.

And, of course, all of our positive impact is dependent on the people who are our company — our 122,000¹ colleagues around the world, for whom Abbott provides meaningful work and opportunity to build fulfilling careers and financial security.

Sustaining community

Our ongoing investment in our business and in our colleagues helps us strengthen communities around the world by improving their human and economic health. And, as engaged citizens, we build on these organic contributions with programs designed to address needs, increase health access, and raise resilience. A leading example is our work to build health and combat chronic diseases through education. Expanding on our established community initiatives, this year we launched a new educational curriculum with Sesame Workshop to inspire more children and their families to build preventative healthy habits early.

Sustaining our commitment

We intend for Abbott to be here for generations to come, because we believe so deeply in its purpose: helping people live fuller lives through better health. We've been doing this worthy work since 1888 — so we naturally think and plan for the long term. Making a difference requires determination, it requires patience, and it requires a fundamental optimism about the future. These are all core attributes of Abbott. To us, sustainability means being able to help more people in more places, in more ways than ever before — and that's what we're here for.

Thank you for your interest in, and support of, our vital work.

Robert B. Ford
Chairman of the Board
and Chief Executive Officer
June 18, 2026

About Abbott

We believe a sustainable future starts with health. For 138 years, we've been improving people's health, tackling some of the world's most pressing health problems through innovative products and technologies. Given our long history and perspective, we think and act for the long term as a responsible company and good corporate citizen. Over the past five years alone, we've invested about \$14 billion in research and development, over \$10 billion in capital expenditures to keep providing our products to the people who need them, nearly \$6 billion in employee benefits to help ensure that our colleagues have security and peace of mind, and paid nearly \$9 billion in taxes.

Our core Values guide everything we do:

Pioneering

We see needs first and deliver game-changing solutions

Achieving

We focus relentlessly on delivering for our stakeholders

Caring

We treat the people who depend on us as if they are our own family

Enduring

We know that everything we do today should contribute to a stronger tomorrow

Our portfolio includes:

Diagnostic systems and tests performed in laboratories, at the patient's bedside, in doctors' offices, or in the home to support better and more timely decisions for people and their doctors.



Our acquisition of Exact Sciences provides Abbott a leadership position in cancer diagnostics, enabling us to expand access to earlier detection, personalized treatment, and proactive monitoring for dozens of cancers.

Medical Devices that use the most advanced technologies to keep hearts healthy, treat chronic pain and movement disorders, and give people the personalized glucose data they need to live healthy.



Nutrition products backed by science that build and maintain health and strength at all ages. The portfolio spans pediatric nutrition, adult and therapeutic nutrition, and performance products.



Medicines, Abbott's growing portfolio of trusted medicines and biologic injectables — including biosimilars — help broaden access to important treatments for millions of people in low- and middle-income countries.



Abbott in numbers

\$44.3B
total 2025
revenue

160+
countries where
Abbott is present

54
consecutive years of
rising dividends

\$2.9B
investment in R&D

122,000*
employees

Recognized performance

Fortune World's Most Admired Companies

Since 1984; No. 1 in medical products and equipment in 2026

Fortune America's Most Innovative Companies

For four consecutive years, ranking No. 4 in 2026

TIME 100 Most Influential Companies

Named a 'Pioneer' company

Reprtrak Most Reputable Companies

Among 100 most reputable companies globally

Dow Jones Best-In-Class Index

More than 20 years on global sustainability index

2026 Gallup Exceptional Workplace Award

For excellence engaging employees and investing in their growth and development

Our 2030 Sustainability Plan progress

Launched in 2020, our 2030 Sustainability Plan supports our central focus of helping more people in more places live their healthiest possible lives.

In Japan, Kimiko Oshima relies on Abbott's *Tactiflex* ablation catheter, *Sensor Enabled*, to treat her atrial fibrillation.

Our 2030 Sustainability Plan

Our top priority is to innovate for access and affordability

Make access and affordability core to new product innovation

Transform care for chronic diseases, malnutrition, and infectious diseases

Advance health access through partnership

Biosimilars

We continued to expand our offerings of biosimilar medications in low- and middle-income countries around the globe to treat a range of conditions — including autoimmune diseases and cancer — providing broader access for millions worldwide. [\(Page 17\)](#)

Exact Sciences

Our acquisition of Exact Sciences' life-changing diagnostics will help more people detect and manage cancer at its earliest stages. [\(Page 17\)](#)

Blood donation drive

Since partnering with the Big Ten Conference to launch the "We Give Blood" drive, donations have helped save hundreds of thousands of lives. [\(Page 19\)](#)

~2 billion lives improved through Abbott products and services in 2025*

Sustainability in everything we do

Build the diverse, innovative workforce of tomorrow

~\$13M

contributed to the retirement accounts of employees from the *Freedom 2 Save* program [\(Page 27\)](#)

Ensure a resilient, diverse, and responsible supply chain

~37M

pounds of packaging impacted through sustainable design programs [\(Page 35\)](#)

Responsibly connect data, technology, and care

~8,600

Abbott people trained on artificial intelligence (AI) to date [\(Page 21\)](#)

Protect a healthy environment

~160

megaliter reduction in water use achieved through efforts from Alliance for Water Stewardship Core Certified Sites** and sites implementing our internal water stewardship practices [\(Page 32\)](#)

*Total number of lives improved was adjusted for indirect overlap between businesses using a binomial probability model, and only adjusted for direct overlap within a business where data is currently available to support the adjustment.

**Alliance for Water Stewardship Certified Core site. For more information, visit a4ws.org.

Progress against our 2030 Sustainability Plan

Innovate for access and affordability

Our 2030 goals guide the delivery and democratization of life-changing technologies and products to transform and deliver care through our products, partnerships, and programs.

2030 Goal

Progress and notes

Make access and affordability core to new product innovation

Integrate access, affordability, and data insights as design principles into our R&D work and portfolio.

- Over the last 10 years, our organic business growth has been driven by expanding access rather than price increases. Volume grew at an average rate of 6.8%, while prices grew 0.2% annually over the same period.
- Received U.S. FDA approval and CE Mark in Europe for *Volt*, our pulsed field ablation (PFA) system that integrates mapping and ablation in a single catheter to deliver targeted energy, which streamlines workflow and reduces procedure time for cardiac ablation procedures.
- Received FDA clearance and CE Mark for the *Amplatzer Piccolo* Delivery System, used with the *Piccolo Occluder* to treat premature infants — some weighing as little as 2 pounds — with a hole in their heart, expanding access to a minimally invasive option that can be lifesaving.
- Gained FDA approval for *Tendyne*, our first-of-its-kind transcatheter mitral valve replacement system. *Tendyne* replaces the mitral valve through a minimally invasive procedure and is available in multiple valve sizes to adapt to a wide range of needs.
- Introduced next-generation delivery system for our *Proclaim* dorsal root ganglion (DRG) neurostimulation platform, making electrode placement easier during procedures. *Proclaim* DRG remains the only FDA-approved DRG technology for treating complex regional pain syndrome Types 1 and 2 of the lower extremities, conditions considered among the most painful.
- Added Android™ compatibility to *Lingo*, our over-the-counter continuous glucose monitor. Along with Apple iOS™, this expansion gives millions more people access to real-time glucose data, empowering informed choices that help support overall well-being.

Transform care for chronic diseases, malnutrition, and infectious diseases

- Support global efforts to address noncommunicable diseases, including diabetes and cardiovascular disease.
- Innovate to transform the standard of care for diabetes, and support efforts to bend the diabetes curve through innovative technology, prevention and education, early diagnosis, treatment, and nutrition.
- Deliver breakthrough technologies, improve clinical outcomes, and impact the lives of people with, or at risk of, cardiovascular disease.
- Introduced *Libre Assist*,² an artificial intelligence (AI)-powered feature in the *Libre* app³ that helps people make more informed, in-the-moment meal-time decisions, and deepens their understanding of their body's unique glucose response to food.⁴ When users upload a photo of their meal, *Libre Assist* uses AI to show a prediction of that meal's potential glucose impact⁴ and offers personalized recommendations⁵ designed to help lower that impact. After eating, people can see how the meal actually affected their glucose levels using data from *FreeStyle Libre* CGM systems. This feedback helps a person make informed decisions in the future.
- Randomized clinical trial results from our Healthy Food Rx program in Stockton, California, confirmed the effectiveness of Abbott's Food is Medicine approach to help people living with diabetes eat healthier and improve their diabetes self management.

Progress against our 2030 Sustainability Plan

Innovate for access and affordability (continued)

2030 Goal

Progress and notes

Transform care for chronic diseases, malnutrition, and infectious diseases (continued)

- Support global efforts to address noncommunicable diseases, including diabetes and cardiovascular disease.
 - Innovate to transform the standard of care for diabetes, and support efforts to bend the diabetes curve through innovative technology, prevention and education, early diagnosis, treatment, and nutrition.
 - Deliver breakthrough technologies, improve clinical outcomes, and impact the lives of people with, or at risk of, cardiovascular disease.
-
- Deliver scalable, integrated solutions to help reduce preventable deaths and infectious diseases (malaria, hepatitis B and C, HIV, COVID-19, and others) with diagnostics, treatment, and education programs, especially in high-prevalence areas.
- Delivered community-centric health access programming to provide health screenings and education for diabetes and cardiovascular disease through healthcare centers and community partners to about 49,000 people in Illinois, Minnesota, and California.
 - Since 2023, the Abbott Center for Malnutrition Solutions has provided nearly 22,000 Mid-Upper Arm Circumference (MUAC) z-score tapes to partners and health workers in 16 countries to support implementation of malnutrition screening. Some 450 health workers and volunteers received training to screen for malnutrition and build referral networks to primary care facilities, resulting in screening of more than 118,000 children.
-
- Advanced surveillance efforts through the Abbott Pandemic Defense Coalition by developing eight new prototype assays and expanding global access to our research-use-only tests to support responses to disease outbreaks. Coalition sites conducted pathogen-agnostic surveillance that enabled early detection of multiple emerging threats, including outbreaks of Venezuelan equine encephalitis virus. The coalition published 30 peer-reviewed studies and strengthened its data systems by enrolling more than 10,000 cases into electronic clinical platforms, improving readiness for future infectious disease challenges.
 - Continued partnership with the Coalition for Global Hepatitis Elimination to support the Hepatitis Evaluation to Amplify Testing and Treatment (HEAT) project that we helped launch in 2020. To date, we have provided support to eight countries, enabling them to evaluate their hepatitis disease burden and testing capacity, develop a Hepatitis C Elimination Tool, and conducted nine Hep Test webinars reaching more than 1,000 stakeholders. In 2025, these efforts advanced national hepatitis strategies by strengthening policy dialogue in India and contributing to Pakistan's federal commitment to a Hepatitis C Virus elimination plan.
 - Ongoing support of the Global Fund and its Laboratory Systems Integration Fund helped strengthen laboratory and surveillance systems across 59 countries in Africa, Asia-Pacific, and Latin America, improving diagnostic capacity, and early detection and response. Between 2024 and 2025, supported systems detected 15 outbreaks in West Africa, while expanding quality assurance, and improving the reliability of diagnostic services for patients across 35 countries.
 - For more than a decade, Abbott has donated diagnostic systems, tests, and reagents in support of The Carter Center's efforts to eliminate blinding trachoma in Ethiopia's Amhara region, which bears more than half of the country's trachoma burden. In 2025, our support enabled the testing of more than 31,000 samples for the Chlamydia trachomatis infection and helped inform global trachoma program policies and guidelines.

Progress against our 2030 Sustainability Plan

Innovate for access and affordability (continued)

2030 Goal

Progress and notes

Advance health access through partnership

Expand affordable access to healthcare for underserved and at-risk communities, including women and children, by delivering innovative, decentralized models of care that advance prevention and early diagnosis, improve nutrition, provide quality treatment and care, and lower total costs.

- Through social investing and Abbott Fund programs, we provided decentralized healthcare services that helped nearly 5 million people access care close to where they live.
- Twenty years after Hurricane Katrina, we continue to strengthen our disaster resilience strategy in high-risk communities across the United States. We prepositioned nearly \$2 million in critical products at community health centers and food banks, and awarded targeted grants to help communities better prepare for, respond to, and recover from disruptions.
- To build on our 25-year partnership, we expanded our emergency care efforts in Tanzania by opening two new village emergency clinics in regions vulnerable to outbreaks. With dedicated holding areas to isolate suspected infectious disease cases, the clinics are the country's first village-level models for early containment. In total, five clinics are operational, serving nearly 9,000 patients, with about 5% requiring emergency or lifesaving care. Over the past decade, we have helped train more than 250 emergency medicine doctors and nurses in Tanzania, in addition to the training of more than 20,000 health workers.
- With support from Abbott engineers and Abbott Fund, the National Children's Home was built in Tanzania in 2021. Since then, we've continued to integrate sustainability into operations, establishing an aquaponics system to raise fish and grow plants in a closed-loop ecosystem, using about 10% of the water needed for traditional agriculture. By the end of 2025, the system produced nearly 500 pounds of fish and over 575 pounds of vegetables, providing healthy food for children and income to support the center's operations.
- Partnered with Seed Global Health to complete a needs assessment and multi-year implementation plan at the Chatinkha Maternity Unit at Queen Elizabeth Hospital in Blantyre, Malawi. This work will serve as the foundation for the redesign of the maternity unit into a Center of Excellence and strengthen capacity to deliver high-quality training and education in obstetrics, gynecology, and midwifery.
- Harnessing technology that makes donating more comfortable, we partnered with blood centers in nearly 30 countries to attract the next generation of blood donors. Available in 15 languages, our first-of-its-kind mixed-reality platform lets donors choose an immersive Zen garden or planetary adventure, helping donors reduce anxiety during donation.
- As part of our ongoing efforts to make clinical trials more inclusive, Abbott implemented targeted outreach for all investigational device exemption (IDE) studies within our Medical Devices business. We're also providing financial support for academic scholarships for medical students and developing new clinical research models for clinics serving underrepresented communities.

Progress against our 2030 Sustainability Plan

Innovate for access and affordability (continued)

2030 Goal

Progress and notes

Advance health access through partnership (continued)

Partner with stakeholders to improve health outcomes by advancing standards and building access to affordable, integrated solutions.

- Abbott, the Big Ten collegiate athletics conference, and its 18 universities partnered for the “We Give Blood” drive, inspired more than 80,000 donations — four times the drive’s 2024 donation total — saving nearly 250,000 lives. With the most donations, the University of Wisconsin received \$1 million from Abbott for student and community health.
- Teaching kids how to stay healthy to reduce their risk of developing chronic disease later in life is the cornerstone of our *Future Well* Kids program, and we’ve been focusing recent efforts on ways to expand and scale the program to reach more communities around the world. In 2025, through our licensing partnership with the Real Madrid Foundation and its coaches, staff, and volunteers, we delivered more than 60,000 hours of our *Future Well* Kids curriculum, reaching more than 5,500 children in 11 countries. Additionally, a new licensing agreement with the Boys & Girls Club of Lake County, Illinois, will deepen engagement by bringing monthly courses to more than 600 students in the local area.
- Because we also know that the earlier kids begin healthy behaviors, the more likely they are to maintain them throughout their lifetimes, Abbott and Sesame Workshop are partnering to create educational resources for preschool-aged children and their families. This global program is designed to encourage development of healthy habits related to exercise, rest, and nutrition at an early age (3-5 years old), to help prevent chronic illness in the future.
- Through programs such as Healthy Food Rx, we continue to collaborate with local partners to better integrate healthy nutrition into the care and management of chronic disease. In 2026, we will expand our Food is Medicine program to help more communities across the U.S. through national partnerships with the National Association of Community Health Centers and Feeding America. Together, we will develop tools, training, and certification programs for health centers, and create shared processes that enable food banks and clinics to work together.
- Worked with the AmeriCares India Foundation to upgrade primary health centers (PHC), strengthen frontline health worker training on noncommunicable diseases (NCDs) and infection prevention and control, and expand community awareness on NCD prevention. We upgraded 64 PHCs in 2025, and we’re committed to upgrading more than 300 PHCs across 12 states by the end of the program in 2026, improving access to quality, affordable care for up to nearly 10 million people in underserved communities.
- Partnered with MotoAmerica, making it the first professional sports organization to use our *i-STAT* TBI rapid blood test for on-site concussion evaluation. The test delivers results in about 15 minutes, helping clinicians make faster decisions trackside.
- Expanded the HeartMates community of people and caregivers impacted by heart conditions by 94%, hosting a dozen HeartMates Huddles — virtual and in-person events where members gather to share their experiences, learn from one another, and celebrate their successes — providing them opportunities to build meaningful connections.

Progress against our 2030 Sustainability Plan

Sustainability in everything we do

Our 2030 goals also guide actions for our people, partners, supply chain, and environment — goals which we are advancing and, in some cases, have already exceeded.

2030 Goal	Progress and notes
Build the diverse, innovative workforce of tomorrow	
Provide 2 million development and job opportunities for current and future employees.	<ul style="list-style-type: none"> Created more than 417,000 development and job opportunities for current and future employees in 2025. This brings our total to more than 1.6 million since the launch of our 2030 Plan, surpassing our original goal of 1 million, which we have since updated to 2 million.
Create opportunities in Abbott's science, technology, engineering, and math (STEM) programs and internships for more than 200,000 young people.	<ul style="list-style-type: none"> Created more than 19,000 STEM opportunities globally for young people in 2025, bringing our total to more than 150,000 since the launch of our 2030 Plan, exceeding our original goal of 100,000, which we have since updated to 200,000.
Continue to create a meaningful employee experience and advance Abbott's culture.	<ul style="list-style-type: none"> Recognized by Gallup as a recipient of the Exceptional Workplace Award, which acknowledges organizations that transform the way people work through employee engagement and sustained investment in people development. 90% of employees completed the Your Voice Counts survey that asks questions to measure employee satisfaction.
Support workforce representation that is reflective of the communities we serve around the globe. <ul style="list-style-type: none"> – Achieve at least 45% female representation across our global management team. – Achieve at least 45% female representation in STEM roles. 	<ul style="list-style-type: none"> 44% of global management positions are filled by women. 46% female representation in STEM roles.
Anticipate Abbott's future workforce needs and achieve talent readiness.	<ul style="list-style-type: none"> Approximately 96% of our people leaders have participated in the Leading with Impact training program, which helps develop stronger managers. In 2025, we continued offering training on AI and Microsoft Copilot. We launched a new course focused on applying advanced prompting techniques to orchestrate multi-step workflows, design simple multi-agent workflows to enhance efficiency and collaboration, and recognize how AI will continue evolving and how to stay future-ready.
Continue to drive 100% leadership accountability by tying executive compensation to talent and succession planning targets. Maintain or improve rates of internal succession for leadership roles.	<ul style="list-style-type: none"> All Abbott corporate officers, including our Chairman and CEO, carry a human capital goal. In 2025, 92% of leadership roles were filled based on succession plans.

Progress against our 2030 Sustainability Plan

Sustainability in everything we do (continued)

2030 Goal	Progress and notes
Build the diverse, innovative workforce of tomorrow (continued)	
<p>Support the financial security of employees by helping those with college debt save for retirement, expanding Abbott's <i>Freedom 2 Save</i> program by providing \$10 million in matching contributions to participants' retirement accounts.</p>	<ul style="list-style-type: none"> • Since the program was conceived, we've contributed nearly \$13 million to the retirement accounts of employees who put at least 2% of eligible pay toward student loan repayment. With these contributions, we surpassed our original goal of \$10 million, six years early.
<p>Fill 50% of targeted new jobs with internal talent by upskilling, cross-skilling, and creating learning opportunities.</p>	<ul style="list-style-type: none"> • More than 50%⁶ of targeted new jobs filled internally.
<p>Continue to provide industry-leading programs that help people achieve their personal health and well-being.</p>	<ul style="list-style-type: none"> • In recognition of World Day of Mental Health on October 10, we built awareness of our global Employment Assistance Programs throughout the month. We work to reduce stigmas surrounding seeking help for emotional and mental well-being and encourage employees to take care of themselves and their families.
Responsibly connect data, technology, and care	
<p>Be a trusted healthcare leader in secure and responsible data collection, use, management, and privacy to help protect our patients and customers; empower them to make better, more complete decisions about their health; and drive innovation through insights and analytics.</p>	<ul style="list-style-type: none"> • Established an AI Governance Council and Data Use and Ethics Council for all Abbott businesses. Also established GenAI Center of Excellence, building out an AI talent and acumen program with more than 8,600 employees trained on AI thus far. • Continued leadership on efforts to strengthen enterprise and product cybersecurity at Abbott and across the healthcare industry. Our cyber team has implemented automatic monitoring for security vulnerabilities across thousands of software packages used throughout our businesses, and are using enhanced technology to better assess vendor risks. And our Chief Information Security Officer serves as the Chair of the Health Sector Coordinating Council (HSCC) Cyber Working Group (CWG), working with other public and private-sector partners to address critical infrastructure needs for healthcare cybersecurity in the U.S. • Protecting customer data along the customer journey is central to securing and maintaining trust. Through our Global Consent Management program, we review consent language to ensure it is clear, concise, and transparent about how and why personal data is used. Our Digital program has strengthened U.S. cookie banners to provide clear user choices and straightforward explanations of tracking technologies and their categorization. To embed these principles consistently, we established a monitoring program that helps ensure systems are developed in alignment with our Privacy by Design standards. • The Medical Technology Advisory Council (MTAC) — made up of technology leaders from a number of healthcare delivery organizations — serves as a strategic innovation advisory group, helping Abbott identify high-impact opportunities for proprietary discovery, cross-business integration, and meaningful health outcome improvements powered by data and technology.

Progress against our 2030 Sustainability Plan

Sustainability in everything we do (continued)

2030 Goal	Progress and notes
Ensure a resilient, diverse, and responsible supply chain	
<p>Certify that newly contracted direct material spends incorporate responsibility requirements.</p>	<ul style="list-style-type: none"> • We are integrating social responsibility clauses into applicable procurement contracts, detailing our values and expectation that suppliers uphold our Supplier Guidelines and remediate any identified issues.
<p>Ensure ethical sourcing from all suppliers with high-risk sustainability factors through 100% auditing.</p>	<ul style="list-style-type: none"> • More than 90% of direct material suppliers by spend screened for sustainability risk in 2025. • More than 550 suppliers engaged through due-diligence activities to address sustainability risks and opportunities in 2025.
<p>Increase small business spend to support supply chain strength and resilience.</p>	<ul style="list-style-type: none"> • With a focus on global supply chain resilience, we expanded in-region outreach and events for existing and prospective suppliers around the world. • We hosted the second annual Supplier Symposium to provide a platform for networking, exploring opportunities with existing and prospective suppliers, and sharing Abbott's focus on health and access.
<p>Continue to help safeguard our supply chain to mitigate single-source and supply shocks.</p>	<ul style="list-style-type: none"> • In 2025, Abbott announced investments of more than \$500 million to expand domestic production across the U.S.
Protect a healthy environment	
<p>Reduce absolute Scope 1 and 2 carbon emissions by 30%, from a 2018 baseline, by the end of 2030, consistent with the objectives of the Science-Based Targets initiative (SBTi).</p>	<ul style="list-style-type: none"> • 14% absolute reduction in Scope 1 and 2 emissions in 2025 (versus 2018 baseline).⁷ • Corporate sustainability funds awarded to 22 projects completed in 2025, with 26 projects completed since the dedication of the fund in 2023, yielding a reduction of approximately 12,600 metric tons CO₂e.
<p>Work with our key carbon-intensive suppliers to implement sustainable programs to reduce our Scope 3 carbon emissions.</p> <p>Our SBTi goal calls for 82% of our suppliers by emissions covering purchased goods and services and upstream transportation and distribution to have science-based targets by 2026.</p>	<ul style="list-style-type: none"> • In 2025, we engaged with suppliers representing over 45% of Abbott's purchased goods and services and upstream transportation and distribution emissions. • Approximately 43% of our suppliers by emissions — covering purchased goods and services and upstream transportation and distribution — have science-based targets.

Progress against our 2030 Sustainability Plan

Sustainability in everything we do (continued)

2030 Goal	Progress and notes
<p>Protect a healthy environment (continued)</p>	
<p>Achieve water stewardship certification at all high-water-impact manufacturing sites in water-stressed areas.</p>	<ul style="list-style-type: none"> In 2025, Abbott's facilities in Karachi, Pakistan, and Jhagadia, India, achieved Alliance for Water Stewardship (AWS) Core Certification,* bringing the total number of Abbott manufacturing sites to 10 of our 11 high-water-impact manufacturing sites in water-stressed areas.
<p>Implement accredited water stewardship management practices in more than 75% of all manufacturing sites operating in water-stressed areas.</p>	<ul style="list-style-type: none"> Implemented Abbott's internal water stewardship management practices at six additional manufacturing sites, bringing the total number of sites implementing practices to 12. This represents about 50% of Abbott manufacturing sites operating in water-stressed areas not classified as high impact.
<p>Work with 50 key suppliers in high-water-stressed areas to reduce water quality and quantity risks to Abbott and the community.</p>	<ul style="list-style-type: none"> We continued to engage with key suppliers to reduce risks associated with water quality and quantity in 2025. In 2025, we engaged with 85 suppliers to provide capability-building resources and trainings related to water management practices to help enhance the resilience of our supply chain.
<p>Address 50 million pounds of packaging through high-impact sustainable design programs that:</p> <ul style="list-style-type: none"> Employ circularity principles through smart design and material selection. Eliminate and reduce materials. Improve the energy efficiency of Abbott's products. Optimize packaging, pallet, and truckload efficiency. 	<ul style="list-style-type: none"> More than 37 million pounds of packaging impacted through sustainable design programs in 2020–2025. This includes: <ul style="list-style-type: none"> Approximately 4.9 million pounds of packaging transitioned to more circular options. More than 32 million pounds of material eliminated or reduced.
<p>Reduce waste impacts using a circular economy approach to achieve and maintain at least a 90% diversion rate.</p>	<ul style="list-style-type: none"> Approximately 93% waste diversion rate⁸ achieved in 2025. In 2025, two additional manufacturing facilities were certified under Abbott's internal Zero Waste-to-Landfill Program. This brings our total to 43 manufacturing facilities certified since our internal program began in 2012.
<p>Engage with key suppliers to reduce the environmental impact of materials sent to Abbott that become waste in our operations, and develop and track supplier waste diversion initiatives.</p>	<ul style="list-style-type: none"> In 2025, we initiated, advanced, or completed engagements with more than 20 suppliers to explore opportunities to improve inbound materials management across Abbott's supply chain.

*Alliance for Water Stewardship Certified Core site. For more information, visit a4ws.org.

Innovate for access and affordability

We can have our greatest possible impact on human health by improving access to care all around the world.

Ed Heierman, a senior associate research fellow in our Diagnostics business. He led the technical development of *AbbottLink*, enabling real-time remote monitoring of instrument health and ability to analyze and maintain Abbott medical devices worldwide, even remotely — which helps labs manage costs and increase efficiency.

Make access and affordability core to new product innovation

Our product design, development, manufacturing, and commercialization processes are guided by a clear set of design principles. We leverage novel technologies — as well as our global presence, strategic partnerships, and community insights — to create measurable, real-world change.

Abbott's Design Principles

Design for broader reach

Build an innovative portfolio that reaches more people, including new geographies and communities with limited access to care.



Design for access

Identify and overcome barriers to access and adoption, prioritizing inclusive design, as well as manufacturing, distribution, and technology strategies across the value chain.



Design to optimize reach and value

Make intentional decisions throughout the design process to optimize four factors: people reached, consumer benefit, business value, and societal value.



These principles have been integrated into our processes since 2022, helping us identify barriers to access for products in development and address opportunities to optimize reach.

First-of-their-kind devices expand access

Helping hearts keep the beat

The heart is the engine of the human body, and Abbott's product innovations are helping more people around the world make sure theirs are working as well as they should. Throughout 2025, Abbott innovations garnered regulatory approvals to treat more people around the world.

Electrophysiology

About 12 million people in the United States and 8 million Europeans over 65 are living with atrial fibrillation (AFib), numbers that are expected to double over the next decades.^{9,10,11} AFib also increases the risk of stroke fivefold.¹⁰ Abbott technologies put precision in doctors' hands:

- **Volt** — our pulsed field ablation (PFA) system integrates mapping and ablation in a single catheter to deliver targeted energy — received FDA approval and CE Mark in 2025.
- **TactiFlex, Duo Sensor Enabled** — with the ability to deliver radiofrequency energy and PFA energy — was granted Breakthrough designation by the FDA in 2025 and CE Mark in 2026.

These minimally invasive systems are designed to reduce the likelihood of repeat ablations while minimizing complications.

Cardiac Rhythm Management

Abbott delivers advanced solutions for diagnosing and treating heart rhythm disorders.

- **AVEIR** — our next generation of leadless pacemakers, which include atrial, ventricular, and dual-chamber leadless systems. Our AVEIR CSP LP, which is in early human feasibility studies, received FDA Breakthrough designation in 2025.

Structural Heart

- **Tendyne** — a first-of-its-kind device — was approved by the FDA to replace leaky mitral valves without open-heart surgery.
- **TriClip** — another first-of-its-kind device — received regulatory approval in Japan for patients with tricuspid regurgitation. And results presented in March from the TRILUMINATE clinical trial showed *TriClip* significantly reduced the rate of heart failure-related hospitalizations.
- **Navitor** — Abbott's transcatheter aortic valve implantation (TAVI) system — received an expanded indication for aortic stenosis, making it available to more people.
- **Piccolo** — our smallest *Amplatzer* occluder designed to optimize procedures for preemies with a hole in their heart — was granted FDA approval and CE Mark.

Chronic pain relief, wherever people are

Chronic pain affects more than 1 in 5 people in the U.S., and they typically pay more in healthcare expenses and lost productivity each year.¹²

Analysis presented at the North American Neuromodulation Society (NANS) meeting in January 2026 showed Abbott's spinal cord stimulation (SCS) therapy helped patients reduce their pain-related care visits by an average of 75% after five years of SCS use.¹³

Abbott also received FDA approval for prone MRI scans for people with our chronic pain devices. Prone MRIs are essential for diagnosing conditions that require face-down positioning, including breast cancer.

And our *NeuroSphere* digital health app, built on its connected-care capabilities, introduces live assistance for remote support. The app incorporates the *NeuroSphere* Virtual Clinic, giving people the flexibility to receive care from their doctor wherever they are.¹⁴

Transform care for chronic diseases, malnutrition, and infectious diseases

Our approach

Innovating new solutions for disease management is just one aspect of enhancing quality of care.

Abbott is also working to expand capabilities in disease detection and prevention. We're partnering to educate more people to help them live healthier lives.

Expanding access to trusted medicines

By combining Abbott's high-quality standards with local market needs, our medicines help expand access to essential treatments and improve health outcomes for millions worldwide.

Our portfolio spans cardiovascular, metabolic, gastrointestinal, respiratory, central nervous system, women's health, pain management, and oncology, emphasizes quality and affordability, and is tailored to meet regional needs.

In 2025, Abbott expanded its offering of biosimilars — with equivalent safety and efficacy to the originator biologic medicine — including the first denosumab biosimilar in Thailand for cancer-related bone loss. Abbott is providing a more affordable and accessible treatment option for an estimated 3 million people.

In 2025, Peru became the first country in Latin America to approve serplulimab, a next-generation immunotherapy biologic treatment for extensive-stage small-cell lung cancer, significantly expanding access to an innovative treatment in a country where lung cancer is the second leading cause of cancer-related death, and where most patients are diagnosed at late stages with few effective alternatives.

This year in China, our pre- and post-menopausal therapy product for women was included in the country's National Reimbursement Drug List coverage, increasing its accessibility.

Bending the diabetes curve

Abbott is leveraging its industry-leading glucose-sensing technology to help more people, with and without diabetes, track key health metrics.

Our *Libre* portfolio of continuous glucose monitors is the most widely used biowearable worldwide,¹⁵ helping more than 8 million people¹⁶ better manage their glucose.^{16,17,18,19}

In 2025, we launched a new feature on the *Libre App*³ called *Libre Assist*,² leveraging AI to predict how food choices may affect glucose levels,⁴ provide personalized suggestions,⁵ and confirm glucose impact.

Abbott has also entered into partnerships to allow *Libre Plus* sensors to work with automated insulin delivery (AID) systems, reducing manual calculations for people who depend on insulin pumps.^{15,20,21}

And Abbott has expanded our biowearables leadership with *Lingo* — a glucose tracking system that's available without a prescription for people who want data and insights on their metabolic health.

Expanding at-home cancer screening

Abbott's acquisition of Exact Sciences makes it a leader in cancer screening and precision oncology diagnostics with market-leading tests, including *Cologuard*, *Onctotype Dx*, and the recently announced *Cancerguard* test, a cutting-edge diagnostic that can detect more than 50 types of cancer.

While Exact Sciences has been concentrated primarily in the U.S., Abbott's global reach will bring these important products to millions of people around the world, expanding access to these life-changing diagnostics to help more people detect and manage cancer at its earliest, most treatable stages.

HeartMates: Making connections, building communities

The Abbott HeartMates program, now in its third year, hosted a dozen HeartMates Huddles in 2025. At these virtual and in-person events, people who are living with cardiac conditions — and those providing care — gather to share life experiences, learn from each other, and celebrate their successes, providing them opportunities to build meaningful connections. The HeartMates community grew by 94% in 2025, and Abbott is committed to increasing the number of Huddles in 2026.

For 2025's holiday season, Abbott partnered with Hallmark Channel to produce "The More the Merrier," an original movie. This partnership — the first of its kind for the network and Abbott — was Hallmark Channel's No. 1 "Countdown to Christmas" movie for 2025.

Innovation recognition

2025 Edison awards:

Eterna - Gold in Chronic Conditions Treatment Solutions

i-STAT Alinity TBI Test - Gold in Emergency & On-Site Health Solutions

Espirit BTK System - Gold in Minimally Invasive and Implantable Devices

TriClip - Silver in Minimally Invasive and Implantable Devices

Lingo - Bronze in Personal Health Monitoring



Advance health access through partnerships

Supporting Food is Medicine efforts

Building on Abbott's leadership in nutrition and health technologies, we're also working to advance Food is Medicine approaches that help prevent and treat chronic diseases like diabetes and heart disease. Through a variety of efforts and funding, Abbott and Abbott Fund are working with groups across the country to design and implement programs that provide accessible, community-based nutrition solutions.

Launched in 2021, our Healthy Food Rx program has reached more than 1,700 participants through 2025. Healthy Food Rx provides home-delivered healthy food boxes and nutrition education to residents in Stockton, California, where 60% of the population has diabetes or pre-diabetes.

In 2025, late-breaking research presented at the American Diabetes Association's 85th Scientific Sessions showed that Healthy Food Rx helped people living with diabetes. This study was one of the few randomized controlled clinical trials examining the impact of Food

is Medicine programs. Conducted by the Public Health Institute Center for Wellness and Nutrition (PHI CWN), the clinical trial assessed the impact of Abbott's Healthy Food Rx for people living with diabetes in a highly food insecure, low-income community.

Study results showed that Healthy Food Rx helped people to eat better and feel healthier, with participants reporting improved diet quality with more vegetables and fruit, and significantly improved health status. Participants also reported strong satisfaction — 97% used all or most of the food, 67% shared the food with two or more people, and 99% were likely to recommend the program to others.

Abbott also committed to a multi-year partnership to scale up Food is Medicine approaches with the National Association of Community Health Centers (NACHC), a nonprofit organization dedicated to expanding access to high-quality, community-responsive healthcare for America's medically underserved populations, reaching nearly 52 million people across 17,000+ locations.

Building on the positive impact of our initial support for NACHC's Innovation Incubator projects to help health centers address barriers to care related to technology in 2023 and access to nutritious foods in 2024, we broadened our focus in 2025 to launch a new initiative aimed at advancing Food is Medicine across NACHC's national network.

This longer-term strategic effort aims to respond to chronic disease by expanding access to healthy foods and addressing malnutrition in community health centers across the country. We're working together to empower and inform health centers, many of whom have food bank or food kitchen partners, to integrate nutrition in overall chronic disease management to support improved health outcomes. This includes developing flexible tools and education to support broader implementation, as well as developing a health center certification model to guide and recognize health center progress and sharing of best practices.

Helping kids build healthy habits

Chronic conditions like diabetes, heart disease and high blood pressure often begin developing in childhood. As leaders in the prevention, diagnosis, and management of chronic disease, Abbott has been working for well over a century to help people live fuller, healthier lives around the world — and that starts with children.

Building a healthier future starts with healthy habits, and the earlier kids begin, the greater likelihood those habits will stick.

- **Sesame Workshop:** We're teaming up with Sesame Workshop, home to beloved "Sesame Street" characters, to deliver tools and resources that make healthy living fun, accessible, and achievable. Designed for children 3-5 years old, the program provides free, multilingual resources including activity pages and storybooks for children, caregivers and educators, and a course for healthcare professionals to help them support families.
- **Future Well Kids:** Inspiring children ages 10-13 to take charge of their health through nutrition, physical activity, and hydration to help prevent chronic diseases like Type 2 diabetes, cardiovascular disease, and preventable cancer. Abbott employee volunteers deliver this curriculum in under-resourced schools near our facilities.

In the past five years, *Future Well Kids* has been offered in Colombia, India, Ireland, Mexico, the United Kingdom, and the U.S., working with 50 unique partner schools in more than 375 classrooms, reaching more than 10,000 kids. We also offer a program-licensing model through which we train staff of select community partners. In 2025, the Real Madrid Foundation delivered the program across soccer camps in 11 countries, and the Boys & Girls Club of Lake County implemented *Future Well Kids* in 8 club locations in Illinois.

KinderSure combats early-childhood stunting

Proper nutrition in early childhood is essential, and deficiencies can have lasting effects²² on a child's overall health, growth, and development. Globally, 181 million children under the age of 5 are living in severe poverty during early childhood.²³ In Latin America, approximately 12% of those kids suffer from stunting, which can lead to lifelong physical and cognitive impairments.

To help combat stunting in Colombia, Abbott launched *KinderSure*, a low-cost, specialized protein micronutrient supplement enriched with high-quality protein and 25 micronutrients.

Saving lives through blood donation


In the time it takes you to read this paragraph, nearly 30 people will need blood.²⁴ In 2025, Abbott — a global leader in blood screening — and the 18 universities of the Big Ten collegiate athletics conference partnered to help save nearly 250,000 lives through blood donation, an increase of 319% from our 2024 "We Give Blood" drive. First-time donors increased more than 240%, including doubling student donations. The initiative was recognized by *Fortune* magazine's "Change the World" list. The competition tracked donations made in each school's name, and the University of Wisconsin held off 2024 champion, the University of Nebraska, to receive \$1 million from Abbott to use for improving student and community health.

Increasing access to quality healthcare in India

Since 2021, Abbott in India has supported the upgrading of primary health centers (PHC) to health and wellness centers across the country. Working with AmeriCares India Foundation, Abbott supported the improvement of 64 PHCs in 2025, expanding access to improved healthcare to nearly 2 million people. Overall, 216 PHCs across 12 Indian states have been upgraded, benefitting nearly 7 million people.

In 2025, Abbott, through its partners, trained more than 3,000 frontline health workers on noncommunicable diseases, expanding community awareness and infection prevention and control. In all, more than 12,000 health workers have been trained since the program's inception.

And we're reaching more people, with a more than 50% increase in laboratory diagnostic tests overall, including a 60% increase in diabetes consultations. For people living with hypertension, visits increased by 55% in the year. The improvements have expanded access for those who can benefit most, and built trust among surrounding communities seeking healthcare in the PHCs.



Abbott and Sesame Workshop are partnering on educational resources for preschool-aged children and their families to help turn healthy habits into everyday routines.

When disaster strikes, we're there, at the ready

When disaster strikes, every moment matters.

Communities need food, hydration, and medical care right away, but large-scale relief takes time. In 2005, Hurricane Katrina marked a turning point, highlighting the need for more proactive, community-focused preparedness.

2025 marked the 20th anniversary of Hurricane Katrina — and nearly two decades of our proactive programs with Feeding America and Direct Relief to build resilience before storms hit. Together, in 2025, we pre-positioned nearly \$2 million of disaster-ready nutrition and medical supplies in hurricane-prone regions, providing an immediate first wave of support.

With Feeding America, we stock ready-to-use “Abbott Disaster Relief Packs” in Florida, Louisiana, Puerto Rico, and Texas. Assembled annually by Abbott volunteers, each pack provides three days of essential nutrition, including *PediaLyte*, *Ensure*, and *PediaSure*. In 2025, 4,000 packs supported approximately 12,000 people.

Through Direct Relief, we've equipped 70 community clinics with “disaster relief modules” containing first-aid supplies and essential medicines. Each module is capable of supporting 350 patients for a month, extending the reach to 24,500 people across the clinic network.

But resilience requires more than a quick response. We also help food banks and clinics strengthen their year-round capacity, investing in infrastructure, systems, and training so they can continue serving communities during and after a storm.

Over the past decade, Abbott and Abbott Fund have provided more than \$65 million in products and funding to support these proactive programs, as well as broader disaster relief and long-term recovery.

Beyond disaster resilience, we continue to find new ways to help address essential needs. In 2025, we were among the first to support Direct Relief's Respiratory Test-to-Treat initiative, providing 27,756 *BinaxNOW* COVID-19/Flu A&B Combo Self-Tests to about 480 health facilities. And to support families with limited access to government nutrition programs, we provided \$1 million in nutritional products to Feeding America and \$250,000 in cash to the Northern Illinois Food Bank.



Abbott employees volunteer at food banks to help address key community needs.

Responsibly connect data, technology, and care

At every step, people deserve to have their data protected — and to benefit from the continued innovation their data makes possible.



We conduct privacy and security assessments and embed data protection into our products and services.

Responsibly connect data, technology, and care

We are committed to secure and responsible data collection, use, management, and privacy to protect our patients and customers; empower them to make better, more complete decisions about their health; and drive innovation through data-driven insights.

We are focused on implementing comprehensive security standards for Abbott devices, products, and systems. That commitment guides our approach to data protection and responsible data use across our businesses.

Security and privacy by design

To identify potential privacy and cybersecurity risks, we conduct risk assessments and embed data protection into the products and services we design and develop.

Our companywide cybersecurity and privacy policies are based on industry frameworks and are supported by standards, processes, testing, and training. The policies are designed to drive compliance, consistency, and employee understanding of the importance of appropriate cybersecurity and privacy controls throughout the product development life cycle.

Product cybersecurity

Our product cybersecurity organization partners across Abbott to help create products and systems that are secure by design and maintain security throughout the product life cycle. This includes secure development, testing, and ongoing security monitoring and maintenance.

Abbott online and/or hosted products and services that process personal data maintain industry-recognized certifications. We continuously monitor the policy and regulatory environment and bolster our solutions to align to the latest digital standards.

Enhancing our security efforts

To advance our commitment to data transparency and align with current industry standards, we have implemented an Abbott cybersecurity portal. The platform, which is open to healthcare delivery organizations (HDOs), enhances the speed and ease with which these customers can access relevant product documentation. In 2025, there was a 60% increase in the number of HDOs using the portal.

Industry partnerships

We stay at the forefront of cybersecurity and privacy by actively engaging the healthcare community and influencing new standards through multistakeholder partnerships and shared best practices.

In January 2025, Abbott's Chief Information Security Officer (CISO) was elected Chair for the Health Sector Coordinating Council (HSCC) Cybersecurity Working Group (CWG) and delivered the keynote address to the 2025 Healthcare Information and Management Systems Society (HIMSS) Cybersecurity Forum outlining strategic planning for stable cybersecurity by 2029. The HSCC is a coalition of more than 400 healthcare organizations and government partners working together to strengthen cybersecurity across the entire sector. In this role, our CISO leads the partnership with industry stakeholders and policymakers to recommend and implement cybersecurity policies and best practices.

The principles of data use

Each day, the people who use Abbott products trust us with information about their health. It is a privilege to learn from our customers, and our goal is to be transparent, responsible, and intentional in our approach to data collection and use.

Our commitment to industry standards and the following principles is reflected in Abbott's data management policies and programs. In 2025, a new impact principle was introduced to further build on our three established guiding principles for data use, all aimed at building trust with stakeholders.

Transparent

in communicating to people and letting them know how their data will be used



Responsible

in our role in enabling the power of data and also in its appropriate use and protection



Intentional

in how we connect our technology, what data we collect, and how we use it and protect it



Impactful

in how we deliver data-informed solutions that make life better for humans



Enterprise cybersecurity

We aim to create a strong cybersecurity foundation by reducing cybersecurity risks through:

- Education and awareness
- Building cybersecurity into our systems and applications
- Implementing incident monitoring and response
- Protection of sensitive data
- Supply chain cybersecurity
- Disaster recovery planning efforts

Enhancing our cyber and data strategies

Cybersecurity is everyone's responsibility. We continue to strengthen internal awareness of cybersecurity, including updating cybersecurity capability training to offer employees a variety of role-based learning paths, such as mentorship and certification. Companywide training customized for specific functions within the organization helps employees and contractors better understand company policies and emerging cybersecurity risks.

Evolving our Medical Device Cybersecurity Council

Our Medical Device Cybersecurity Council has evolved into the Medical Technology Advisory Council (MTAC) to address the risks and opportunities of emerging technologies across healthcare. The MTAC consists of key external advisors and focuses on providing insight into the integration of novel hardware and software technologies — e.g., intelligent biosensors, agentic artificial intelligence (AI), secure computing platforms, real-time data infrastructures — within current and future healthcare delivery environments. MTAC's purpose is to advise Abbott on how best to integrate these technologies across our offerings, in regulated devices, nutrition platforms, and diagnostics, to provide the greatest benefit while minimizing risks.

MTAC serves as a strategic innovation advisory group, helping support the use of data, AI, and other emerging technologies to enable personalized, secure, and connected health solutions that serve clinical users and consumers.

Additionally, Abbott businesses have dedicated cybersecurity leaders who help address risks by looking at how cybersecurity controls are applied across Abbott's operations. Regional security leaders in key geographies support local and regional cybersecurity requirements.

AI data principles

Technology and data are transforming healthcare, helping us better manage health and wellness, accelerate innovation, tackle business challenges, and expand access to care. And perhaps the most transformative tool available today is AI.

AI holds great promise for improving access to care and optimizing clinical research, product performance, patient care, and productivity. The stakes are high, and AI must be managed, applied, and interpreted responsibly and safely, with our continued commitment to transparency, scientific standards, and excellence.

Our use of AI must remain guided by our values — pioneering, achieving, caring, enduring — and always in service of improving lives.

Abbott's approach to AI is built on five key principles:



Responsible

We are focused on improving healthcare around the world and helping people live healthier lives. We will be intentional with our use of AI. We will use AI to deliver meaningful solutions, but we will not sacrifice our principles in pursuit of AI. This means that we will uphold scientific standards, ensure there is human oversight and accountability, and continue to review and determine when it makes sense to deploy AI solutions and when it does not.



Safe

We will not use AI in any way that could negatively impact the quality or safety of any of our products. We will design our AI systems to be safe, secure, and protect data and privacy appropriately. We will test AI systems internally and, when outside perspective would help, with external partners to ensure they are ready to deploy before use.



Transparent

We will be transparent about our use of AI and how we use the data people share with us. We will be responsive in communicating with people who have questions about our AI systems or features.



Fair

We will use representative and inclusive data sets whenever possible to inform and train our AI systems. Our goal is to minimize the potential for stereotyping and unfair bias in our AI models, and we will continually work to test, analyze, correct, and improve our systems.



Impactful

We believe AI should make life better for humans. AI has the potential to affect all aspects of society, and we will strive to deliver AI solutions to positively impact people. We will leverage AI-enabled technologies and tools to make life-changing products and services more accessible around the world.

Build the workforce of tomorrow

At Abbott, we take our purpose of helping people live healthier, fuller lives to heart. Regardless of their role, Abbott people know their work truly matters because what we do has a tremendous impact on the lives of the people we serve.

Them bani Sigidi, based in Johannesburg, South Africa, works in our Rapid Diagnostics business.

Building the best workforce

People count on us to develop solutions that help them improve their health. We rely on the innovative ideas, commitment, dedication, and life experiences of our workforce to bring those solutions to life.

In return, we offer an environment that provides opportunities for our people to develop and grow in their careers, the security to take care of themselves and their families through physical, emotional, financial, and social well-being, and the ability to be part of a global community working together to help people lead healthier lives.



Helping interns grow their most essential skills

Among recent college graduates, 1-in-4 believe they lack the necessary skills to begin their new careers.²⁵ And 1-in-6 hiring managers agree with them.²⁶ What's missing? It's not technical talent. It's the essential skills fundamental to a workplace: preparation and professionalism. Where previous generations honed those abilities through first-hand job experience, recent graduates have been limited to classroom and remote, distant, and solitary learning.

It's become such a challenge, a recent survey of those hiring managers found significant hesitation to hire people who recently completed college.²⁵

We have a solution. In 2025, more than a 1,000 Abbott interns around the world registered and participated in CareerRx, a career check-up built into the company's summer internship program.

Through a personalized development program, interns self-assess strengths and weaknesses, working with Abbott mentors to improve presentation and public speaking, general workplace etiquette, critical thinking and problem solving, and teamwork.

Talent acquisition

Our talent acquisition team helps us build the innovative workforce of tomorrow through an integrated strategy that includes early-career programs and hiring the best people at all levels to build our talent pool.

Expanding our STEM pipeline

We are committed to creating an environment that fuels creativity and inspires innovation, and we work to ensure that we have a variety of perspectives on our team to make that happen. To that end, we have an active presence at major STEM conferences and look to identify the next generation of STEM talent through our high-school and college internship programs.

Understanding employee sentiment

We provide an environment where all employees can be themselves and feel proud about coming to work each day. We actively listen to employees to better understand their expectations and how we can best meet them. Through our Your Voice Counts survey, we ask employees questions that address their sentiment about basic needs, contributions, teamwork, and growth. We also include a question to measure employee satisfaction. In 2025, the Your Voice Counts survey was completed by 90% of our employees.

Employee development

Abbott people can build new skills and gain new perspectives by accessing growth and development opportunities — such as mentoring, leadership training, and personalized career development tools — at every stage of their careers. These programs are designed to support the development of all our colleagues.

We offer a variety of opportunities to support employee development. In 2025, more than 57,000 employees engaged in at least one formal development opportunity. For more information on our employee training and development opportunities, see abbott.com.

Abbott Global Development Week

Abbott's Global Development Week encourages employees to explore the range of resources available to help them realize their full potential and build their best careers. In May 2025, as part of Global Development Week, more than 27,000 employees participated in trainings designed to help them develop new skills to enhance their performance. Employees around the world attended more than 300 virtual webinars, panel discussions, and educational sessions in that week. More than 230 leaders served as instructors, facilitating and engaging employees through live webinars and leadership panels.

Leading With Impact

Frontline managers play a vital role in building a supportive, inclusive, and rewarding work environment. Launched in 2021, our Leading with Impact program is a two-time Brandon Hall Group Excellence Award winner, a global benchmark for recognizing learning, talent, and workforce development.

In 2025, we launched a second program, Leading with Impact II, that focuses on three critical leadership competencies: Empathy, Feedback, and Courage.

During the program, participants practice giving feedback and having difficult conversations with an interactive AI avatar. We continue to run both programs to further the development of our new managers and engage our workforce. More than 1,800 new managers participated in Leading with Impact I in 2025, and over 13,000 managers participated in Leading with Impact II in 2025. In total, 96% of our managers at Abbott have participated in the Leading with Impact program since it launched.

Valuing every employee

We strive to maintain an inclusive culture where each person can be themselves at work and everyone is valued for their contributions.

Our employee networks are open to all employees and provide opportunities for mentorship, networking, and community. With approximately 23,000 members overall, our employee networks provide additional ways for colleagues to develop meaningful connections with others around the world with similar areas of interest and advance their professional development. For detailed insights into our workforce, please visit abbott.com.

Employee well-being

Exercise Across Abbott encourages healthy habits and strengthens teams

Our annual Exercise Across Abbott event is an accessible, high-impact way to foster well-being, teamwork, and connection among our employees. It is a health and wellness challenge that's always a highlight of the Abbott calendar. In 2025, we had more than 50,000 employees worldwide engage with the program, our highest participation to date.



Shehla Zafar, a project director, is a member of the Women Leaders of Abbott employee network.

Supporting employees to help them thrive

We believe that leading a life filled with purpose and passion starts with being physically and mentally healthy. We encourage our employees to prioritize their emotional and mental well-being, offering a suite of benefits and support services to help them.

Our employees rely on our holistic benefits program to provide them and their families with the security of knowing that, when they need help, they will find it. Employees have access to Employee Assistance Programs and various other benefits worldwide, such as parenting and financial coaching, on-site counseling, and special events centered on physical and mental health. Many of these programs are designed to meet the local and regional needs of our employees.²⁷

In the U.S., for example, employees have access to personalized, confidential mental health resources for themselves and their covered family members. Outside the U.S., we offer tailored programs, such as our “BeStrong” wellness strategy in India that consolidates physical, emotional, financial, and social benefits; “Mind Matters” in Europe and the Middle East that connects employees with training tools and resources to support their overall well-being; and “Vida Plena,” an integrated health and wellness strategy in Latin America.

We also work to further reduce the stigma of seeking help for emotional and mental well-being. We actively communicate about emotional well-being and share testimonies from employees who have benefited from our programs. By encouraging open conversations and sharing personal stories, we create a culture that supports talking about emotional well-being and normalizes seeking help. This approach helps to break down barriers and raise awareness among employees about the benefits we offer and how to use them.

Through our benefits and programs, we foster a culture that values and promotes the holistic health of our employees. By creating a workplace where well-being is a priority, we help our colleagues thrive personally and professionally, empowering them to lead fulfilling lives.

Financial well-being

Our financial and retirement programs help Abbott people build a solid financial future for themselves and their families.

We work to make sure our employees are compensated fairly and without discrimination — regardless of race, ethnicity, or gender.

Fair compensation is based on three concepts:

- Base salaries and benefits that are market competitive
- Annual and long-term incentives that are linked to performance, with a balance of short- and long-term financial and strategic objectives
- Compensation that encourages behavior consistent with the ethical values in Abbott’s Code of Business Conduct

We conduct pay equity reviews that consider the market, gender, race, ethnicity, job grade, and position levels where applicable. We assess these reviews and make pay adjustments, when necessary, to make sure our employees are compensated equitably for their contributions.

In addition to providing equitable compensation, we help employees build an ownership stake in Abbott. Offerings (where applicable) include retirement savings programs, employee stock purchase plans, and restricted stock units (RSUs) awarded as long-term incentives.

Freedom 2 Save

Our first-in-the-nation *Freedom 2 Save* program helps U.S. employees save for retirement while repaying student loans. Those putting at least 2% of eligible pay toward student loan repayments receive a 401(k) contribution of 5% from Abbott.

Fortune magazine cited the groundbreaking nature of this program when it named Abbott to its Change the World list, which recognizes companies that deliver shared value by making an important social impact.

To date, we’ve contributed nearly \$13 million to *Freedom 2 Save* participants’ 401(k)s, surpassing our goal of \$10 million in matching contributions by 2030. Our *Freedom 2 Save* model was codified in 2023 by the U.S. federal government through the SECURE 2.0 Act.

FreeU

Since its inception, more than 430 people have enrolled in our *FreeU* offering, a virtual program to help U.S. colleagues pursue their bachelor’s degrees on flexible schedules and at no personal cost when combined with our tuition reimbursement program. Abbott pays 100% of the cost of tuition, required core classes, textbooks, and academic advising.

Employee health and safety

Keeping employees and contractors healthy and safe is paramount for Abbott. The Divisional Vice President of Environment, Health, and Safety (EHS) chairs our EHS Leadership Council, which is made up of business and global EHS leaders who develop and drive our EHS programs, including those related to employee health and safety.

We evaluate commercial operations, manufacturing, R&D sites, and other sites on a regular basis. Using an EHS scorecard, we monitor performance and use the results to develop action plans aimed at reducing health and safety risks at the business level. We apply a risk-based approach and follow the hierarchy of controls when prioritizing actions. We also consult with workers and, where they exist, workers’ representatives.

For additional information on Abbott’s health and safety programs, see [Pages 61-62](#).

Human rights

We are committed to protecting human rights. Our processes for managing human rights risks are embedded throughout the business, encompassing workforce policies, ethics and compliance programs, supply chain management, and more. We regularly evaluate risk exposure, including annual risk assessment of identified suppliers in our supply chain.

We aim to proactively identify and mitigate potential human rights impacts across our operations and supply chain, including risks of:

- Discrimination and unequal pay
- Unsafe working conditions
- Human trafficking
- Child labor
- Forced or bonded labor

We maintain policies — including our Code of Business Conduct and policy on workplace harassment — that reinforce our zero tolerance for any discrimination. They detail steps for reporting instances of workplace harassment or discrimination and clearly define escalation processes.

Anti-harassment training

Every two years, U.S. employees are required to complete workplace anti-harassment training covering a variety of scenarios, including sexual harassment.

Our global problem-solving policy encourages employees and management to maintain open lines of communication, calling attention to issues as they arise. The policy also details alternative steps employees can take to resolve issues or concerns.

We investigate all reported allegations of harassment or discrimination in a confidential manner and, where necessary, take corrective action. Consequences for employees include disciplinary action up to and including termination. Read more about our processes for reporting, investigating, and addressing instances of harassment and discrimination on [Page 68](#).

All employees must adhere to relevant laws and Abbott's policies, procedures, principles, and standards. Our Code of Business Conduct prohibits illegal and inappropriate labor conditions and cruel or inhumane treatment.

Human rights in our supply chain

In our supply chain, we establish human rights expectations for prospective and existing suppliers. We detail our expectations through our Supplier Guidelines and conduct screening, assessment, auditing, and monitoring of higher-risk suppliers to identify and mitigate potential risks, including those related to human rights. For further information, see [Page 40](#), and additional disclosures on [supply chain due diligence](#).

We also address human rights risks in our other business relationships, including through our Third-Party Compliance Process, which requires Abbott businesses, subsidiaries, and affiliates outside the U.S. to complete due diligence before engaging third-party companies. This involves screening companies, identifying high-risk partners, and monitoring and mitigating any potential risks, including human rights risks. For further information, see additional disclosures on supply chain due diligence.

Find more about our discrimination and harassment prevention approach on [Page 68](#), compensation and benefits on [Page 27](#), and health and safety on [Pages 27 and 61-62](#).

Protect a healthy environment

We rely on natural resources to manufacture and supply products that help people around the world live healthier, fuller lives. We are committed to using them responsibly to preserve a healthy environment — now and for future generations.

Our Kilkenny, Ireland, facility has nearly 600 solar panels, and features tanks for collecting rainwater to use on-site. During construction, no soil went to landfill.

A unified approach to environmental programs

We're working across our operations and with key suppliers to sustainably manage our water use and minimize our environmental footprint by reducing carbon emissions and expanding our use of renewable energy. We are also working to reduce the environmental impact of our product packaging and minimizing waste across our broader operations through reuse and recycling approaches.

Each Abbott business sets annual environmental targets, and we track progress on many Environmental Health and Safety (EHS) key performance indicators (KPIs) as part of Abbott's quarterly EHS scorecard that is shared with executive leadership. This helps us maintain progress toward our 2030 targets and identify areas for improvement on a continuous basis. For additional information on our EHS governance, see [Pages 62-63](#).

Our global EHS team works with our cross-divisional Energy Council and supply chain teams to reduce our emissions, focusing on:

- Energy efficiency in manufacturing operations
- Low-carbon energy investments
- Transportation fleet efficiency
- Supply chain carbon footprint

Our energy and air emissions recording and reduction programs are outlined in our energy policy, technical standards, and energy guidelines.

For information on our climate risk management and energy management, see [Pages 62-63](#).

Science-based emission targets²⁸

Abbott's near-term science-based greenhouse gas (GHG) emission reduction targets, which were approved by the Science Based Targets initiative (SBTi) in 2022, include Scope 1 and 2 targets that align with a well below 2°C trajectory.

To reach our goal of reducing absolute Scope 1 and 2 emissions by 30% by 2030 versus 2018 (target boundary includes land-related emissions and removals from bioenergy feedstock), we have a program that targets reductions through:

- Operational energy efficiency and reduced energy demands
- Purchase of renewable energy
- Electrification of industrial processes, spaces, and fleets
- Conversion to cleaner-fuel options
- Integration of sustainable engineering technologies and concepts into projects
- Site-specific business and manufacturing carbon reduction goals²⁹

Actions to achieve our targets are driven by our energy policy, practices, and strategic plan. For more information, see [Pages 62-63](#).

Scope 3 emissions are estimated annually using the GHG Protocol Corporate Value Chain (Scope 3) Accounting and Reporting Standard, referring to the categories⁷ applicable to Abbott. We are working with key carbon-intensive suppliers to reduce our Scope 3 footprint. See [Page 41](#), for more information on Scope 3 emissions.

Capital investments in energy infrastructure and emission reductions

In 2025, 22 energy-efficiency projects were completed using funds from our dedicated environmental sustainability capital fund, which provides \$15 million annually.

One notable project completed in 2025 was an alternative fuel implementation project in Baddi, India. The site installed a steam generation boiler that combusts biomass, reducing the consumption of fossil fuels at the site. Through this initiative, the site can expect to reduce about 3,900 metric tons of Carbon dioxide equivalent (CO₂e) emissions annually.

Our 2025 energy and greenhouse gas reduction performance

Through 2025, we achieved a 14% absolute reduction in Scope 1 and 2 emissions (versus the 2018 baseline). In 2025, our Scope 1 and 2 emissions decreased by 4% compared with 2024 and when adjusted for sales, emissions decreased by 9%.



Renewable energy use

In 2025, we purchased about 370 million kWh of low-carbon and renewable energy, resulting in savings of about 96,000 metric tons of CO₂e. These savings were complemented by the roughly 9.1 million kWh generated from solar installations at 19 of our sites.

Energy and greenhouse gas emissions

We're working to deliver results against near-term, science-based targets to reduce carbon emissions.

Abbott aims to reduce absolute Scope 1 and 2 carbon emissions by 30% from the 2018 baseline by the end of 2030.



Energy efficiency in our manufacturing operations

We are continuing to target Scope 1 and 2 emission reductions by focusing on operational energy efficiency and reducing energy demands at our manufacturing facilities. Additionally, we seek to identify opportunities to improve energy performance.

Energy and emissions reduction projects resulted in approximately 28 million kWh annual energy savings and approximately 24,000 metric tons of CO₂e emissions reduced. Examples of actions implemented in 2025 include the following:

- India, China, Singapore, Malaysia, and Ireland: Upgraded belt-driven heating, ventilation, and air conditioning (HVAC) fan systems with more efficient motor technology, improving safety and reducing energy use. These efforts are expected to save about 3,935,000 kWh of electricity and about 1,700 metric tons of CO₂e emissions each year.
- Tipp City, Ohio, United States: Installed a combined heat and power (CHP) system that captures and uses heat created by electricity generation, while saving about 1,500 metric tons of CO₂e emissions annually.
- Zwolle, Netherlands: Expanded use of their hot water network to serve more equipment, decreasing the demand for steam and natural gas while saving about 3,201,000 kWh of energy and about 570 metric tons of CO₂e emissions annually.

Investing in electrification and renewable energy

Abbott is continuing to invest in opportunities to electrify our business and in renewable energy to drive down emissions. For example, in 2025:

- Heerlen, Netherlands, and Jhagadia, India: Replaced natural-gas systems with heat pumps, lowering natural gas use, saving about 1,859,000 kWh of energy and about 1,400 metric tons of CO₂e each year.
- United States, Ireland, India, and Colombia: Four sites added solar power generation. Together, these systems will produce about 1,106,000 kWh of renewable electricity and reduce about 260 metric tons of CO₂e emissions annually.
- Singapore: Started using biomass steam produced off-site, reducing steam generated from natural gas. This change is expected to save about 6,300 metric tons of CO₂e emissions each year.

Sustainable facility design

Our 30,000-square-meter facility in Kilkenny, Ireland, produces *FreeStyle Libre 3* sensors, the latest generation in Abbott's world-leading continuous glucose monitoring portfolio for people living with diabetes.

The facility was built with sustainability in mind. The site is fully electric, powered by six air-to-water heat pumps; has nearly 600 solar panels on the roof, and features tanks for collecting rainwater to use on-site. During construction, no soil went to landfill. It was instead used in a sustainable landscape that includes a walking track for colleagues and wildflower plantings to provide a habitat for local pollinators.

The site also achieved Leadership in Energy and Environmental Design (LEED) certification in 2025 according to LEED v4 for Building Design and Construction; Warehouses and Distribution Centers at the Silver certification level.

* Abbott estimates Scope 3 emissions using the GHG Protocol Corporate Value Chain (Scope 3) Accounting and Reporting Standard. The spend-based emission factor source applied to some of the categories, including Purchased Goods and Services, Capital Goods, and Transportation and Distribution, was updated during the reporting period. As a result, year-over-year emissions may not be directly comparable.

Water stewardship

We are committed to responsible water use in the communities where we operate. We have established water-stewardship targets at our manufacturing sites operating in water-stressed areas. By conducting risk evaluations and opportunity assessments at these sites, we support the development of comprehensive water-stewardship plans. These plans are created through a stakeholder-inclusive process to mitigate risks and promote sustainable water balance at each site. Understanding our own internal water use and how our use impacts the catchments that we source water from and discharge water to, is key to our stewardship efforts.

Water management principles

Our water management approach centers on four principles as communicated through our position statement on access to clean water:

- **Reduce:** Continuously work to improve water-use efficiency in our operations
- **Prevent:** Manage water discharges that could adversely impact human health or the environment
- **Educate:** Emphasize to our employees and suppliers the importance of protecting groundwater and other water resources vulnerable to overuse or contamination and the role they play in doing so
- **Engage:** Develop and apply key water management principles and best practices across our company

We tailor this approach and our efforts to mitigate potential risks to local circumstances for business continuity. See [Pages 63-64](#), for more information on water management.

Water stewardship certification

We are working to achieve water stewardship certification at all high-water-impact manufacturing sites in water-stressed areas and are implementing accredited water-stewardship management practices in more than 75% of all manufacturing sites operating in water-stressed areas. Thirty five Abbott manufacturing sites operate in areas of water stress. Of those, 57% use fewer than 15 million gallons (57 megaliters) of water. Considering basin water stress, basin water depletion level, and water usage, Abbott classified 11 manufacturing sites as high-water-impact facilities and aims for each site to achieve Alliance for Water Stewardship (AWS) Certification* by 2030.

In 2025, three additional Abbott high-water-impact sites — located in Korangi and Landhi in Karachi, Pakistan, and Jhagadia, India — achieved AWS Core certification,* bringing Abbott's total to 10 out of 11 sites.

AWS Certification indicates site commitment to:

- Good water governance
- Sustainable water balance
- Good water-quality status
- Important water-related areas
- Safe water, sanitation, and hygiene (WASH)

As part of the AWS certification journey, the Karachi, Pakistan, site implemented a portfolio of water-efficiency and reuse initiatives that are collectively expected to reduce site water consumption by an estimated 15%. These reductions will be realized progressively over the coming years through phased implementation. We're making cooling systems more efficient, repurposing treated water, recovering water from steam and wastewater, maintaining rainwater-collection areas, and installing more efficient faucets triggered by motion sensors.

The site also engaged with stakeholders and the community to meet WASH deficiencies at a secondary school. The project will directly benefit enrolled students and staff by facilitating access to safe and clean drinking water.

The site also developed a comprehensive emergency response and mitigation plan for water risk. The plan was formally reviewed and endorsed by the Landhi Association of Trade and Industry (LATI).

Our Jhagadia, India, site engaged with the community and stakeholders on activities that included awareness programs, and tree plantations in two villages near the Important Water Related Areas (IWRAs).

Additionally, Abbott identified manufacturing sites as being in water-stressed areas but did not classify these as high-water-impact sites. In 2025, six of these sites implemented Abbott's internally accredited water stewardship management practices, bringing the total to 12 manufacturing sites.

*Alliance for Water Stewardship Certified Core site. For more information, visit a4ws.org.

Our 2025 water stewardship performance

In 2025, Abbott continued our efforts to reduce our water use and impacts. While total water intake increased by about 3% since 2024, when adjusted for sales, water intake decreased by about 2%. Sites operating in water-stressed areas increased their water use by nearly 2% compared to 2024, and when adjusted for sales, water use decreased by about 3%. Overall, water reduction projects in 2025 resulted in approximately 240 megaliters of water savings.

Efficient water use in water-stressed areas

Abbott is committed to efficient water use and reducing water use at our sites. We continued to implement projects in 2025 with this strategy in mind. For example:

- **Altavista, Virginia, United States:** Installed additional monitoring equipment to increase the amount of hot water reused in the boiler system. These upgrades are expected to save about 120 megaliters of water each year, along with about 8,986,000 kWh of natural gas and about 1,600 metric tons of CO₂e emissions.
- **Baddi, India:** Optimized purified water use in the site's Clean In Place (CIP) process by installing more efficient spray nozzles and shortening cleaning cycles. These upgrades, which reduce the amount of purified water needed for equipment cleaning, are projected to save about 4 megaliters each year.
- **Jiaxing, China:** Rerouted condensed water from the evaporator system to the cooling towers for reuse, with projected annual savings of about 6 megaliters of water.
- **Cimanggis, Indonesia:** Reused reverse osmosis (RO) system effluent water in cooling towers. This effort is expected to save about 4 megaliters of water each year.

Waste management


Products have potential impacts on human health and the environment at every stage of their life cycle. We are committed to reducing these impacts beyond the manufacturing phase.

Our waste management program establishes requirements that drive effective waste management across our manufacturing operations and commits us to finding efficient ways to reduce the volume and hazardous characteristics of our waste. It also helps support proper disposal practices. We have standards and waste efficiency guidelines addressing hazardous and nonhazardous waste, as well as beneficial use³⁰ activities to drive Abbott's waste management program.

Abbott has established targets and programs to reduce waste impacts, using a circular economy approach to achieve and maintain at least a 90% waste diversion rate⁸ in our operations. Progress on targets and program objectives are actively monitored.

For more information on our waste management and hazardous and chemical waste management programs, see [Page 64](#).

Our operational waste footprint



*Sum of percentages listed does not equal 100% due to rounding.

Our 2025 waste management performance

Our circular economy approach continues to help Abbott divert more than 90% of our waste from landfills. In 2025, we reached a rate of approximately 93% by diverting approximately 60% of materials to beneficial use and a further 34% away from incineration without energy recovery and landfill. Waste increased by about 2% versus the previous year. When adjusted for sales, waste decreased by about 3%.

We established an internal Zero Waste-to-Landfill standard in 2012. Since then, 43 manufacturing and 13 non-manufacturing sites have been certified to the standard.

In 2025, two additional Abbott manufacturing facilities — Penang, Malaysia, and Gyeonggi-do, South Korea — received Zero Waste-to-Landfill certification.

Improving waste diversion and reducing waste

In alignment with our goal to maintain a waste diversion rate of 90%, we seek opportunities to move waste away from landfill and incineration without energy recovery. We also seek opportunities to reduce waste generated at our sites.

Improving waste diversion at manufacturing operations

In total, our 2025 waste initiatives resulted in an increase of approximately 610 metric tons of waste diverted through improved waste management practices. For example, in 2025:

- Liberty, South Carolina, United States: Reused wastewater — which made up 10-15% of the site's total waste — for fuel blending, resulting in the diversion of about 270 metric tons of this waste each year from landfilling.
- Pleasanton, California, United States: Recycled hard plastics from raw material packaging, resulting in the diversion of about 3 metric tons of plastic waste from landfilling annually.
- Minnetonka, Minnesota, United States: Changed to stationary compactors from open-top containers for waste collections, resulting in the diversion of about 90 metric tons of waste each year from landfilling to incineration with energy recovery.

Reducing waste at manufacturing operations

Abbott continues to look for ways to reduce the generation of waste at the site level. In total, our 2025 waste initiatives resulted in approximately 100 metric tons of waste eliminated. For example, in 2025:

- Shanghai, China: Reduced supplier component packaging, projected to save about 11 metric tons of recycled waste each year.
- Ottawa, Canada: Implemented changes to injection molding design and tooling to reduce plastic waste. These changes are expected to eliminate about 11 metric tons of polyethylene terephthalate glycol (PETG) and thermoplastic elastomer (TPE) from landfills each year.
- Alajuela, Costa Rica: Conducted a review of the waste generated by various products and operational processes and identified several recycled wastes that could be returned to the supplier for direct reuse, resulting in the reduction of almost 40 metric tons of waste annually.
- Hangzhou, China: Switched from using a cleaning solvent to an alternate cleaning method using water, resulting in the reduction of about 2 metric tons of waste annually.

Packaging

Our packaging design and manufacturing processes comply with applicable regulations, while balancing the need for protecting both our products and the planet.

Through multiple efforts, including the Sustainable Packaging Guiding Principles implemented in 2020, Abbott aims to address 50 million pounds of packaging through high-impact sustainable design programs by 2030. More than 37 million pounds of packaging were impacted through sustainable design programs from 2020 to 2025.

Our Sustainable Packaging Guiding Principles, illustrated to the right, inform existing packaging upgrades and target new, more sustainable designs.

Recognizing the impact our packaging can have on the environment, we're designing for recyclability, efficiency, and increasingly positive impact. Our Sustainable Packaging Council has designed a database for reporting predicted progress against business projections for packaging projects.

These figures guide Abbott functions and our businesses as they collaborate to design and manufacture packaging with environmental sustainability in mind.

To better understand and to estimate material circularity, our businesses conduct analyses of their primary packaging portfolios. In the 2025 Nutrition business analysis, it is estimated that the business utilized about 109,000 metric tons of material to place approximately 3.1 billion primary packages on market. About 22% of this packaging utilizes recycled content and/or renewable materials, and we estimate 80% of our packaging is designed for recycling. Additionally, about 9% of all Nutrition primary packaging by weight is made from post-consumer recycled materials.³¹

Our 2025 packaging performance

We maintain a detailed road map for sustainable packaging projects, including capital investment and environmental sustainability benefits. We collect packaging project metrics across our various businesses and monitor progress with a KPI tracking system to help ensure that we are on track to achieve our 2030 packaging commitment.

Our businesses actively identify and implement programs to minimize the environmental impact of our packaging. For example, our Core Diagnostics and Medicines businesses have eliminated some physical paper leaflets and informational instructions by replacing them with electronic versions. The information is accessed digitally and approximately 166,000 pounds of material will be eliminated from the waste stream.

The Nutrition business continued with the Phase 2 roll-out of the tethered cap design in 2025. By the end of the year, all production of single-serve liquid reclosable plastic bottles at the Zwolle, Netherlands, site incorporated the tethered caps. The new lighter-weight closure design delivers a plastic weight reduction of about 2.3 million pounds annually.

Our Sustainable Packaging Guiding Principles

Optimize material efficiency

- Eliminate unnecessary components
- Reduce packaging materials



Employ circularity principles

- Consider alternative materials
- Design for disassembly
- Design for recyclability
- Design for reuse
- Utilize renewable materials
- Integrate recycled content



Enhance packaging systems

- Optimize shipping efficiency
- Provide consumer direction
- Improve carbon footprint



Commitment to our customers

Every day, people around the world rely on Abbott to provide life-changing products and services. Delivering high-quality, safe, and effective products and technologies is fundamental to our business.

When Vijay Bali's doctors recommended a pacemaker, he was determined to maintain his active lifestyle without compromising arm mobility — especially for golf. That is why he opted for Abbott's AVEIR VR LP.



The Abbott Customer Pledge

At Abbott, we all put the people we serve at the center of everything we do. We make our products and services as if they were for our own families. We live Abbott's purpose of creating a healthier world, where everyone can have better, fuller lives. We know that every one of us plays a vital role in bringing our life-changing solutions around the globe to the people who need them.

Maintaining a culture of quality

We have a quality management program that includes documented quality management system (QMS) standards, corresponding training and compliance assessments, and closely monitored corrective action, if needed. These processes are in place for all of our products, and we are committed to continually assessing and improving these processes as information, technologies and practices evolve to support our patients and customers. To underscore their importance and priority, our Vice President, Regulatory, Quality, and Compliance reports directly to our Chairman and CEO.

Corporate Quality oversees more than 20 communities of practice made up of global subject matter experts focused on areas of our quality system. Divisional quality leaders participate in the Quality Council, sponsored by the Vice President of Regulatory, Quality and Compliance. These forums delve into emerging issues, share best practices and learnings from events to improve processes, and foster a culture that continuously improves. In addition, over 150 Abbott employees participate in the development and maintenance of global standards through work with standards organizations.

We also work with our suppliers to promote the same commitment to quality and safety through qualification programs, audits, and other tools.

Quality management system

Abbott's QMS model and metrics are continuously reviewed to track site-, business-, and company-level performances. The model is implemented at a global level, and incorporated into each division and site. Risk management is an element of the QMS, and is implemented across the life cycle of Abbott products.

We capture and apply key learnings and best practices, including those from external intelligence; and industry-specific issues are examined and escalated, as appropriate. We analyze root causes for performance indicators and take appropriate corrective actions.

To enhance data analysis and decision-making, Abbott Quality and Regulatory (AQR) and advanced-analytics teams are increasingly harnessing machine learning and artificial intelligence to modernize risk identification.

We conduct compliance auditing at the site, division, and corporate levels. Each operating business maintains a QMS and performs audits in line with governing regulations. Surveillance results inform continuous improvement initiatives.

Supplier quality audits and assessments are completed by internal Abbott teams following a risk-based approach determined by the goods or services, including monitoring key performance metrics and supplier corrective actions, as required.

Our quality system is based on established regulations and industry standards that govern the quality framework for Abbott businesses. We have policies, processes, and procedures that encompass the total product life cycle, including the design of cybersecurity controls, to help support quality design, product safety, and efficiency at every stage.

Our operations cross the globe, with 89 manufacturing sites, and oversight from more than 100 quality and regulatory agencies. Our quality framework drives regulatory compliance wherever we operate.

New employees who impact the quality system are trained on QMS elements, with an annual QMS refresher course delivered to existing and part-time personnel.



Independent quality certifications

Our manufacturing sites adhere to applicable QMS regulations and requirements, including current Good Manufacturing Practices (GMP). Abbott’s QMS and Quality Manual integrate relevant International Organization for Standardization (ISO) standards and are implemented at manufacturing sites, as applicable.

Our manufacturing operations hold relevant GMP certifications, including ISO 13485, ISO 9001, Safe Quality Food (SQF), and country certification, for quality management systems, including 100% of applicable Abbott finished device manufacturing sites are certified under ISO 13485. One hundred percent of our international nutrition manufacturing sites are ISO 22000 certified, and all applicable sites are also ISO 9001 certified. Our nutrition manufacturing operations maintain certifications relevant to food safety, as well. One hundred percent of domestic nutrition finished goods manufacturing sites hold SQF Food Safety certification.

Across Abbott, our sites are granted certifications based upon compliance with various standards, as relevant and appropriate, including³² but not limited to the following:

- ISO 9001:2015, ISO 13485:2016, ISO/Independent Ethics Committee (IEC) 17025:2017, and ISO 22000:2018
- National Sanitation Foundation International
- Food Safety Assurance
- Hazard Analysis Critical Control Points (HACCP)
- Association for the Advancement of Medical Instrumentation (AAMI)
- American Society for Testing and Materials International (ASTM)
- International Society for Pharmaceutical Engineering (ISPE)

Regulatory agency feedback

Regulatory agencies around the world regularly assess our quality performance across our locations.

2025 FDA Class I and Class II recalls		
Business	Class I	Class II
Medical Devices	3	10
Diagnostics	0	9
Medicines ³³	N/A	N/A
Nutritionals	0	0

Quality inspections and audits		
	2024	2025
Quality/regulatory inspections by global health authorities	450	467
% resulting in zero observations	78%	83%
FDA site inspections	18	19
% resulting in zero observations	89%	68%
Average number of observations per inspection	0.33	0.58
Internal, independent, corporate-level audits to help support compliance with Abbott quality standards	126	140

FDA enforcement action		
	2024	2025
Warning letters issued	0	0
Seizures	0	0
Form 483s	2	6
Consent decrees issued	0	0



Abbott Nutrition’s analytical lab in Cootehill, Ireland.

Strong, resilient global supplier network

We are dedicated to improving the sustainability and resilience of our global supply chain.

Minakshi Pisal supplies milk to Abbott's dairy partner from her farm in Maharashtra, India. She manages her cattle with strong hygiene and animal-care practices, supporting responsible and sustainable dairy production.



A multifaceted supply chain

Abbott works to develop and maintain a global supplier network that is strong, responsible, and resilient.

Our global network, comprising approximately 59,000 suppliers located in more than 160 countries, makes it possible for us to deliver life-changing products to people around the world.

Supply chain resilience

Managing supplier risk

We detail our expectations through our Supplier Guidelines and assess, audit, and monitor high-risk suppliers to identify and mitigate potential sustainability risks. We have a formal, risk-based program to conduct sustainability due diligence, focused on direct and select indirect suppliers:

- Screening suppliers to identify potential sustainability risk
- Assessing potentially high-sustainability-risk suppliers
- Conducting on-site audits of select high-risk suppliers, following globally recognized standards
- Remediating identified adverse impacts

Our Supply Chain Due Diligence Program works to minimize sustainability impacts associated with human rights, labor, and the environment; reduce reputational and continuity risks; and monitor conformance with our Supplier Guidelines.

In 2025, our due diligence program activities included screening more than 90% of direct suppliers by spend, evaluating more than 550 potentially high-sustainability-risk suppliers through due diligence activities including, where necessary, completing on-site audits.

Through our 2025 due diligence program, we engaged with suppliers to address worker health and safety, environment, and supply chain management practices.

For further information, see additional disclosures on [supply chain due diligence](#).

Operational resilience

Our Supply Chain Resilience Program helps safeguard our business and supply chain against unforeseen events. We leverage intelligence and analytics to monitor issues that could impact our operations and those of our suppliers, including financial health, political instability, acute and chronic weather events, labor shortages, and inadequate capacity.

Through the Supply Chain Resilience Program, we map suppliers and components that are directly traceable to Abbott's finished products. To anticipate potential disruptions, we continue to expand our program to include select sub-tier supplier data. We apply a variety of risk and resilience indicators to guide how we assess topics at different supply, product, or business points.

In 2025, Abbott announced investments of \$500 million for operational and supply chain expansions, helping to strengthen U.S. domestic manufacturing capacity and supply chain resilience. With 89 manufacturing sites around the world, as well as decades of experience, we continue to build on our supply chain redundancy and resilience as we navigate evolving environments. In addition to expanding capacity, we are making targeted investments to strengthen the reliability of existing operations. This work includes infrastructure upgrades that help strengthen power resilience, protect product supply, and improve long-term sustainability and operational performance. We also worked closely with suppliers on improving flexibility and continuity in response to rapidly changing global market conditions.

Designing for supply

Early decisions in product development can have large impacts later.

Through our Design for Supply initiative — with increased collaboration between our R&D and Supply Chain teams — we're developing design principles and supplier engagement models that address risk throughout the product development life cycle, from design to scaled production, helping ensure manufacturing capabilities and supply chain resilience.

This effort equips teams with knowledge, tools, and industry-leading perspectives on risk-informed product design and supply chain development practices.

Enhancing our base of suppliers

We are expanding access to new suppliers — of varying size and across multiple geographies — to build a more resilient ecosystem that can help withstand disruptions and support meaningful economic empowerment.

In 2025, Abbott hosted its U.S. Supplier Symposium, bringing together existing and prospective suppliers to advance transparent sourcing, business opportunities, and our commitment to building a stronger, more localized supply base that supports the regions where we operate.

Abbott's inclusion of small businesses generates \$5.3 billion in economic output³⁴ and supports more than 23,000 jobs in the United States — fueling economic mobility, expanding opportunity, and building the foundations for healthier, fuller lives in the communities we serve.

Additionally, Abbott supported local small business relationships in key markets outside the U.S. in more than 15 geographies.

For small business performance indicators, see Appendix section, [Page 50](#).

Strategic supply chain initiatives

We collaborate with suppliers to address shared sustainability impacts. Our supply chain initiatives focus on human rights, labor practices, and environmental performance to drive action and inform business strategies.

Through our 2025 strategic initiatives and due diligence program, we continued to collaborate with suppliers in key sourcing categories, engaging more than 6,000 suppliers on sustainability risks and opportunities and influencing more than 50% of our supply chain spend. In addition, Abbott incorporates supplier sustainability into overall supplier performance and relationship management processes to strengthen alignment with suppliers on key sustainability expectations.

Supply chain emissions management⁷

Scope 3 emissions account for approximately 88% of Abbott's carbon footprint. Our Science Based Target initiative (SBTi) Scope 3 target calls for 82% of our suppliers by emissions covering purchased goods and services and upstream transportation and distribution to have SBTi-approved targets by 2026.

As of 2025 year-end, approximately 43% of our suppliers by emissions covering purchased goods and services and upstream transportation and distribution have adopted SBTi-approved science-based targets, and an additional 4% have committed through the SBTi to adopt science-based targets. In addition, Abbott engaged with suppliers representing over 45% of Abbott's purchased goods and services and upstream transportation and distribution emissions to collaborate on carbon data and opportunities to reduce emissions. Our current Scope 3 goal is unlikely to be met due to varying levels of supplier readiness, a complex supply base, and suppliers adopting alternative emissions targets that are not aligned with SBTi. We remain committed to delivering meaningful, long-term emissions reductions within areas under our control while preparing for increasing regulatory requirements, which require significant organizational resources to address.

Supply chain water management

We are committed to responsible water use in communities where we source and operate. We screen to identify suppliers sourcing to Abbott from high-water-stressed areas to explore opportunities to improve resilience, business continuity, and the management of water quality and quantity risks.

Since 2020, we have engaged 12 suppliers toward our goal of working with 50 suppliers to reduce water-related risks across our supply chain. In 2025, we hosted a Supplier Water Summit in partnership with a strategic supplier and also met with suppliers to share tools and guidance aimed at improving water management practices. Approximately 85 suppliers participated in training and engagement activities, and we continue to work with them to track actions implemented as a result. Also, we expanded our relationship with the Alliance for Water Stewardship by sponsoring a supplier to participate in an accelerator program to drive water stewardship in the Dezhou, Yellow River Delta water basin in China.

Strengthening India's dairy value chain

Since 2022, our partnership with TechnoServe has advanced dairy production in India. In 2025, Abbott funded tuition for a dozen women pursuing dairy animal husbandry and dairy technology studies. More than 30 women are now employed in milksheds that supply Abbott.

Our efforts also include water sustainability interventions — including stainless-steel troughs, insulated tanks, and rehabilitated check dams — to improve clean water access crucial to dairy production in drought-prone regions.

Through this partnership, our work with more than 12,000 dairy farmers has embedded best practices and technical knowledge within local communities, creating networks of local leaders and peer mentors.

Animal welfare in dairy

We are committed to improving conditions for animals in our dairy supply chain by supporting the Five Freedoms of Animal Welfare recognized by the World Organisation for Animal Health. In 2025, approximately 99% of the milk we procured (by spend) was certified to animal welfare standards.

Reuse and responsible waste management

We partner with key suppliers to responsibly dispose of waste generated by our operations, including diverting as much as possible from landfill and incineration without energy recovery.

Our technical standard for waste vendor evaluation and approval provides a consistent method for evaluating and approving off-site waste disposal facilities and brokers to identify and minimize risks and liabilities associated with the management and disposal of waste.

We maintain an IT standard for evaluating and approving vendors for electronic disposition, promoting responsible recycling and, where viable, resale of used IT assets. In 2025, we continued our partnership with IT asset disposition vendors to recycle more than 158 metric tons and resell over 48 metric tons of electronic equipment.

Waste diversion with inbound material suppliers

Abbott's EHS, Procurement, and Supply Chain teams are committed to working with key suppliers on waste diversion initiatives for both the waste we generate in our operations and the inbound materials that become waste.

We have engaged with 44 suppliers to improve inbound materials management across Abbott's supply chain since 2020. In 2025, we initiated, advanced, or completed engagements with more than 20 suppliers to explore opportunities to improve inbound materials management across Abbott's supply chain.

Standards of business conduct

Acting ethically and with integrity is foundational to building trust in Abbott, our solutions, and the care we deliver.

Maria Warren works in *Alinity n* development in our Irving, Texas, operations.

Ethics and integrity

Our Global Ethics and Compliance (OEC) Program reflects the fundamental elements of an effective corporate compliance program as detailed in the U.S. Department of Health and Human Services Office of Inspector General guidance. The program is regularly reviewed by an independent, external party who offers suggestions for refinements or improvements.

Written standards of conduct

Our Code of Business Conduct, available in over two dozen languages, is foundational to ethical conduct at Abbott. Every employee is required to read and certify adherence to the code annually. It outlines our company values and the expectation for our employees to live them every day. For more information, see [Page 68](#).

Processes for reporting concerns

Our code emphasizes employees' responsibility to report concerns or noncompliance. We have defined avenues and processes for asking questions and reporting suspected or actual violations of our code, policies, or procedures. This includes our SpeakUp tool — available 24 hours per day and seven days per week — through which employees and external parties can confidentially and (where permitted) anonymously raise concerns of potential misconduct. Abbott has a strict policy against retaliation in any form for reporting concerns.

Auditing and monitoring

OEC personnel supporting each Abbott business unit and country perform an annual risk assessment to identify and address areas of potential compliance risk. Based on assessment outcomes, they then establish monitoring plans for the year, which includes selecting a risk-based sampling of interactions with healthcare professionals and reviewing supporting documentation to assess compliance with Abbott's policies. Abbott conducts sales and marketing compliance audits of global operations to assess the effectiveness of our compliance programs.

Processes for investigations and corrective actions

All reports of potential code violations, including those related to discrimination and harassment, are thoroughly investigated. Any employee violating our Code of Business Conduct, policies, or procedures is subject to appropriate disciplinary action, which may include termination. Employees refusing to cooperate with investigations, or knowingly reporting false concerns, or ones intended to threaten, intimidate, or retaliate, may also be subject to disciplinary action.

Third-party compliance

Third parties with whom Abbott works (for example, distributors and marketing partners promoting and selling Abbott products) are expected to hold themselves to the same ethical and legal compliance standards as Abbott does. We detail our expectations in our Third-Party Guidelines, available online in multiple languages. We also maintain processes for completing due diligence before engaging third parties, including screening the third party and mitigating identified potential risks, as well as monitoring third-party activities after engagement. An e-learning platform provides and tracks required online training for third parties undergoing due diligence.

Training and communications

Legal and Ethics Resource Network (LERN) is our global training platform, available to all employees and third-party workers. LERN content, including courses and certifications, is available in over two dozen languages. The LERN program also shares practical guidance on recognizing and responding to legal and ethical issues. In 2025, more than 99.7% of active employees completed the annually assigned Code of Business Conduct training course and certification.

Compliance leadership, training, and communication are detailed on [Pages 67-70](#).

Board oversight

The Board has risk oversight responsibility for Abbott, which it administers directly and with assistance from its Committees. Throughout the year, the Board and its Committees engage with management to discuss a wide range of enterprise risks, such as risks related to Abbott’s businesses, enterprise and product cybersecurity, product quality and regulatory compliance, litigation, and human capital management. The Board also oversees and monitors business strategy. It conducts an annual in-depth review of the long-term strategy and areas of focus for Abbott and its businesses. The Board also regularly engages with management throughout the year to review and discuss the strategic planning for Abbott’s businesses, including operating and financial plans, strategic business priorities and initiatives, and key risks and opportunities. These reviews include discussions of matters such as global talent management and succession planning, global market dynamics and changes in regulatory and competitive landscapes, supply chain initiatives and sustainability programs, and significant corporate actions such as acquisitions and capital expenditures.


Risk management

Our enterprise risk management (ERM) process evaluates the likelihood, impact, and velocity of risks that could potentially impact business performance. At Abbott, we have four reportable business segments, with 13 global businesses, each with unique markets, competitors, and risks. In order to maintain the flexibility required to appropriately manage the unique risks within each business, risk management is a core job responsibility for our executive leaders, who identify, own, and manage the risks embedded within their respective businesses. This drives a culture that aligns ownership with business strategy.

Our ERM Network team — a group with representatives from across various corporate functions, led by Abbott’s Vice President of Internal Audit — integrates ERM throughout Abbott by working with management to establish a risk management framework that identifies, assesses, and manages key risk exposures. In carrying out these responsibilities, the ERM Network convenes at least on a quarterly basis to evaluate key ERM risks, including the assessment of emerging risks, clarifying risk ownership, and summarizing key mitigation plans.

The ERM Network facilitates a standardized approach to identify, measure, mitigate, and report the most significant risks identified in the assessment process, which includes a risk survey. The survey seeks feedback from our global leaders on enterprise residual risk exposure, and the results are presented to the Audit Committee.

The top enterprise risks are prioritized and used to inform strategic action plans. The Board exercises risk oversight by focusing on high-priority areas identified, including cybersecurity and data protection, product quality and regulatory compliance, and sustainability.



Sustainability governance and prioritization

Operating sustainably is key to the future of healthcare. Our 2030 Sustainability Plan formalizes our commitment to improve lives. Embedding sustainability into our governance structure sets this plan as a priority, making it a shared responsibility.

To build our 2030 Sustainability Plan, an in-depth two-year planning process began with a detailed analysis of more than 200 topics relevant to internal and external stakeholders. We prioritized by impact to our long-term business strategy, our Enterprise Risk Management (ERM) process, and our most important Environmental, Social, and Governance (ESG) topics. To have the greatest impact, we must get our innovative healthcare solutions to the most people who need them, work to protect the environment, ensure a responsible supply chain, build the workforce of tomorrow, and responsibly connect technology and care. Senior management continues to review and assess these priorities at least annually.

ESG-linked compensation

Our 2030 Sustainability Plan is integrated into our business plans, financial planning processes, and existing governance structures, including oversight from our Board of Directors. Overall responsibility for sustainability sits with management, and our Leadership Covenant reinforces this by explicitly stating that senior leaders are accountable for the achievement of Abbott’s 2030 Sustainability Plan. Each senior leader is responsible for taking actions in their organizations that help achieve our targeted sustainability goals. Any officer who does not fulfill the covenant can receive a reduction of up to 100% of their annual incentive and/or long-term incentive awards.

To learn more, visit the executive compensation section in our [2026 Proxy Statement](#).

Sustainability governance

Senior management establishes and manages Abbott’s sustainability policies and practices. The Board provides oversight through its Public Policy Committee.

Global Sustainability Team

Leads strategy implementation across global operations and oversees sustainability performance and reporting

Reports to:

- Senior Vice President, Global Marketing & External Affairs, serving as Abbott’s chief marketing, communications, and sustainability officer, who reports to our Chairman and CEO

Sustainability Goal Leads & Operations Functions

Responsible for managing execution and enterprise-wide operationalization of our 2030 Sustainability Plan

Representatives from:

- Global Environment, Health & Safety
- Ethics & Compliance
- Quality & Regulatory Affairs
- IT & Cybersecurity
- Human Resources
- Supply Chain
- Legal
- Finance
- Research & Development
- Investor Relations
- Public Affairs
- Government Affairs
- Global Procurement
- Commercial Operations
- Affiliate operations in key markets

ESG Disclosures Committee

Responsible for monitoring regulatory, legal, and financial reporting requirements and advises on company approach and readiness

Representatives from:

- Global Environment, Health & Safety
- Ethics & Compliance
- Quality & Regulatory Affairs
- IT & Cybersecurity
- Human Resources
- Operations & Procurement
- Legal
- Finance
- Research & Development
- Investor Relations
- Public Affairs
- Government Affairs
- Internal Audit
- Tax
- Treasury

Global Operations Council

Oversees strategy execution for all operations, using internal assessments, risk profiles, and industry best practices to improve performance

Members:

- Executive Sponsor: Vice President, Chief Operations & Procurement Officer
- Co-Sponsor: Vice President, Nutrition, Supply Chain
- Senior leaders, including three Corporate Officers & 42 Divisional Vice Presidents

Global Citizenship Advisory Council

External advisors who provide guidance on strategic issues, including risks and opportunities

Areas of expertise:

- Environmental sustainability, climate, supply chain resilience, and ESG governance
- Health equity, access, and social drivers of health
- Public and global health systems
- Food and nutrition security, including Food is Medicine approaches
- Capacity building and community development

Endnotes

1. Employee total includes Exact Sciences, acquired March 23, 2026. Unless otherwise specified, reported data excludes Exact Sciences and its operations.
2. *Libre Assist* is a feature within *Libre* app that uses generative AI to provide information on how foods could impact your glucose levels. Generative AI may not always be accurate, and it should not be used to make treatment decisions.
3. The *FreeStyle Libre* systems apps are only compatible with certain mobile devices and operating systems. Please check our website for more information about device compatibility before using the apps. Use of the *FreeStyle Libre* systems apps may require registration with *LibreView*.
4. Predicted glucose impact is based on user-provided food data and may differ from actual impact, which depends on sensor readings and factors like activity, stress, medication, and alcohol. For personalized advice, consult your healthcare provider.
5. Personalized food suggestions are based on food preference information input by the user.
6. This percentage represents internal hires for nonentry-level positions. Entry-level positions are excluded from this calculation due to the nature of the job requirements.
7. Abbott estimates Scope 3 emissions using the GHG Protocol Corporate Value Chain (Scope 3) Accounting and Reporting Standard. Transportation and Distribution includes Upstream and Downstream activities. Scope 3 estimations may be adjusted annually to account for data availability and methodology enhancements. Sourcing category spend allocations are subject to change year over year in alignment with business strategy. Energy consumed in buildings and vehicles that are leased to Abbott (leased assets) is included in Scope 1 and 2. Abbott pays for the majority of transportation of products to retailers and customers and therefore includes these emissions under Upstream Transportation and Distribution. Abbott's estimated Scope 3 footprint excludes known sources in Purchased Goods and Services, Downstream Transportation, Processing of Sold Products, and Investments categories. Collectively, these omissions are estimated to be less than 2% of our total Scope 3 footprint.
8. Abbott's diversion rate is calculated as follows: (total waste + beneficial use - landfill and incineration without energy recovery)/(total waste + beneficial use). Waste with an unknown disposal fate is included with landfill fate. Waste noted as "other, diverted" reflects waste diverted from landfill and incineration without energy recovery. Waste generation data does not include materials that are reused beneficially.
9. CDC. Atrial Fibrillation Fact Sheet. <https://www.cdc.gov/heart-disease/about/atrial-fibrillation.html>, 14 May, 2024.
10. CDC. About Atrial Fibrillation. <https://www.cdc.gov/heart-disease/about/atrial-fibrillation.html>, 8 Oct. 2025. Accessed 15 Oct. 2025.
11. Fact Sheets for Press. European Society of Cardiology. (n.d.-a). <https://www.escardio.org/news/press/>
12. Guy GP Jr, Miller GF, Legha JK, et al. Economic Costs of Chronic Pain-United States, 2021. *Med Care*. 2025;63(9):679-685. doi:10.1097/MLR.0000000000002181.
13. Deer T, Pilitsis J, Dickerson D, Abd-Elseyed A, Falowski S, Hagedorn J, Hunter C, Petersen EA, Sayed D, Skaribas I, Tomycz N, Benison AM, Bettampadi D, Hu Y, Chuang JS, Roberts GJ, Ram Y, Burton A, Lad N. Spinal Cord Stimulation Reduces Pain-Related Healthcare Utilization: A Real-World Data Analysis. Las Vegas (NV): North American Neuromodulation Society; 2026.
14. Anywhere with a Wi-Fi or cellular connection and sufficiently charged patient controller.
15. Data on file, Abbott Diabetes Care, Inc. Based on the number of users worldwide for the *FreeStyle Libre* portfolio compared to the number of users for other leading personal use sensor based glucose monitoring systems.
16. Evans, M. *Diabetes Therapy* (2022). <https://doi.org/10.1007/s13300-022-01253-9>
17. Study was performed with the outside U.S. version of the *FreeStyle Libre* 14-day system. Data is applicable to *FreeStyle Libre* (2 or 3 as applicable) system, as feature sets are similar as *FreeStyle Libre* 14-day system, excluding alarms.
18. Miller, Brandner et al. HbA1c Reduction After Initiation of the *FreeStyle Libre* System in Type 2 Diabetes Patients on Long-Acting Insulin or Non-Insulin Therapy. <https://doi.org/10.2337/db20-84-LB>
19. Leelarathna et al (FLASH-UK): Leelarathna, L. *New England Journal of Medicine* (2022).
20. Based on the number of pump users having the ability to connect with *Libre* technology.
21. Based on product features including up to (14 or 15)-day wear period, automatic readings every minute, accuracy data, and single-app setup with AID systems.
22. Stewart CP, Iannotti L, Dewey KG, Michaelsen KF & Onyango AW. Contextualizing complementary feeding in a broader framework for stunting prevention. *Maternal and Child Nutrition* 2013;9(Suppl 2):27-45.
23. Child Food Poverty: Nutrition deprivation in early childhood. UNICEF 2024 Child Nutrition Report. <https://data.unicef.org/resources/child-food-poverty-report-2024/>
24. American Red Cross. U.S. Blood Supply Facts. <https://www.redcrossblood.org/donate-blood/how-to-donate/how-blood-donations-help/blood-needs-blood-supply.html>. Accessed 27 Apr. 2026.
25. Leckrone, Bennett. "Colleges Aren't Preparing Gen Z for Jobs: Report." *BestColleges*, 14 Feb. 2025. www.bestcolleges.com/news/colleges-are-not-preparing-gen-z-for-jobs/. Accessed 29 Apr. 2026.
26. "1 in 6 Companies Are Hesitant to Hire Recent College Graduates." *Intelligent*, 13 Sept. 2024. www.intelligent.com/1-in-6-companies-are-hesitant-to-hire-recent-college-graduates/. Accessed 29 Apr. 2026.
27. Eligibility for nonsalary benefits follows local regulations and practices. In most countries, this means we offer benefits to full-time employees and part-time employees working more than a certain number of hours, as defined by local regulations. We typically provide benefit programs above and beyond government requirements.
28. Scope 1 emissions result from owned and controlled sources. Scope 2 emissions are produced during the generation of purchased electricity and energy. Unless specified otherwise, emissions are calculated according to the Greenhouse Gas Protocol Scope 2 market-based method.
29. Manufacturing sites that produce more than 25,000 metric tons of CO₂e annually are required to set additional carbon reduction goals.
30. Abbott defines beneficial use activities as sending material, that otherwise would have been waste, off-site to be used as an effective substitute for a commercial product or commodity. Beneficial use material is used as is or in substantially the same form as it was generated.
31. Reporting data is calculated using projected annual volumes from internal planning sources and consulting various external industry references to categorize packaging as recyclable, renewable, and/or using recycled content.
32. This list represents a sample of the standards our sites maintain and that are frequently used as indicators of product quality.
33. Abbott does not distribute medicines in the U.S.
34. Based on approximately \$2 billion in direct spend with U.S.-based small businesses in 2025 and following a commonly used economic input-output model that captures direct, indirect, and induced impacts across the supply chain.

Appendix

We align our reporting with respected ESG reporting frameworks, including the Global Reporting Initiative (GRI), Sustainability Accounting Standards Board (SASB), United Nations Sustainable Development Goals (UNSDGs), and Task Force on Climate-related Financial Disclosures (TCFD).

Abbott's policies and standards guide our business decisions, ethical conduct, and commitment to the environment. We strive for transparency by providing information on policies and standards applicable to each priority area. These documents are available on the [Policies page](#) of our website.

Reporting feedback

Development of our sustainability strategy was informed by the expertise of several external sources. These experts also guide stakeholder engagements, the development of our [Responsibility webpages](#), and the production of this report.

We gratefully acknowledge the counsel we receive from SLR Consulting and Abbott's Global Citizenship Advisory Council, among others.

We welcome feedback on our report. Send us an email at responsibility@abbott.com to share yours.

External assurance

We engaged Apex Companies, an independent assurance provider, to conduct limited assurance of selected 2025 environmental (including Scope 1, 2, and 3 Greenhouse Gas Emissions; Energy Consumption; Water Intake, Water Consumed in Process, and Water Discharge; Hazardous and Non-hazardous Waste Generation; and Volatile Organic Compound (VOC) Emissions) and safety data (including Lost Time Case Rate, Recordable Injury or Illness Case Rate, Fatalities, and Vehicle Accidents per Million Miles). Our website includes a PDF of the [Independent Limited Assurance Statement](#).

Scope of this report

All financial information is stated in U.S. dollars.*

All data reflects Abbott's activities, with a focus on 2025 results. The boundary of our reporting, unless otherwise noted, is all activities under Abbott's global, operational control as consolidated in our financial reporting. Unless otherwise specified, reported data excludes Exact Sciences and its operations. The acquisition of Exact Sciences was completed on March 23, 2026.

Abbott trademarks and products in-licensed by Abbott are shown in italics in the text of this report.



*Foreign Currency Translation — Generally, functional currencies other than the U.S. dollar are translated into U.S. dollars using average exchange rates for the period.

Stakeholder engagement

We pursue a continuous dialogue with a range of stakeholders, including patients, customers, employees, suppliers, partners, shareholders and other investors, financial and sustainability analysts, rating agencies, governmental bodies, the media, nongovernmental organizations (NGOs), and educational and research institutions through a variety of channels. Regular communication with key stakeholders enables us to identify important trends and developments in society and in our business.

In addition to the partnerships highlighted in the report, a selection of our activities in 2025 include:

Internal engagement

Abbott uses a variety of tactics to help foster employee engagement, including:

- Abbott World intranet site and myHR portal
- All-employee Chairman and CEO Communications
- Annual all-employee meeting with our Chairman and CEO
- Annual all-employee engagement survey and other ad hoc surveys
- Business and functional town hall meetings
- Employee network groups
- Let's Talk sessions
- Manufacturing site huddles
- Quarterly leadership forums
- Weekly HR briefings for managers
- Regular news digest

* NPS is an externally recognized metric for customer satisfaction. Internally, it is used as a key indicator of our ability to continuously meet customers' needs.

External engagement

Health access partners

As a global healthcare company, Abbott collaborates with partners worldwide to address barriers to health. We lead change by contributing our expertise where it's needed, creating new models for health care systems, improving nutrition, and addressing other social needs. Our partners in these efforts include:

- Americares India Foundation
- Direct Relief
- Feeding America
- National Association of Community Health Centers
- The Global FoodBanking Network
- Seed Global Health

STEM education

We work to inspire the next generation of innovators and to help build our workforce of tomorrow. Our education partners include:

- American Council on Education
- Arizona Project WET
- Center of Science and Industry
- Happy Code Organization
- SMILE Foundation
- STEMConnector

Environment

We collaborate across our industry and leverage global networks to help us minimize our environmental footprint. Collaborators include:

- Alliance for Water Stewardship
- National Association for Environmental Health, Safety, and Sustainability Management
- Responsible Minerals Initiative
- Responsible Business Alliance
- Science Based Targets Initiative
- U.S. Green Building Council

Industry associations

We collaborate with various regulatory and scientific organizations to share perspective and data on global health and key policy matters.

We are also members of various U.S. trade organizations that engage in lobbying and other political activity to represent our needs and the needs of our industry, and customers.

Healthcare organizations

To help us better understand emerging health needs, we partner with various organizations, including:

- American Diabetes Association
- Health Information Sharing and Analysis Center
- Institute for Health Equity, a part of Norton Healthcare
- Medical Device Innovation Consortium
- Public Health Institute
- World Health Organization

Supply chain

We work with a broad range of organizations to help build a resilient supply chain with diversified sources. These groups include:

- Domestic Manufacturing Supply Chain Alliance
- Pharmaceutical Supply Chain Initiative
- Supplier Ethical Data Exchange

Customer and consumers

We employ a broad range of communication and engagement vehicles to help ensure that we clearly understand our customers' and consumers' needs.

- Business and country representatives
- Clinical trials
- Customer call centers
- Customer meetings
- Field service representatives
- Focus groups
- Net Promoter Score (NPS) surveys*
- Social media and community engagement

Key financial metrics

Sales Worldwide	2023	2024	2025
Dollars in Millions	\$40,109	\$41,950	\$44,328

R&D Investment	2023	2024	2025
Dollars in Millions	\$2,741	\$2,844	\$2,942

Dividends Paid	2023	2024	2025
Dollars in Millions	\$3,556	\$3,836	\$4,116

Affordability & Pricing	Total Abbott Net Sales Price Change (Year-Over-Year %)	Global Consumer Price Index ^a (Year-Over-Year %)
2025	+0.7%	+3.1%
2024	+3.5%	+4.6%
2023	+2.6%	+5.7%
2022	-0.3%	+7.9%
2021	-1.5%	+3.9%
2020	-0.4%	+1.7%

Social Investing^b	2023	2024	2025
Dollars in Millions	\$75.7	\$101.7	\$86.0

2025 Social Investing	(Dollars in millions)
Cash contributions	\$39.9
In-kind giving, product, or service donations ^c	\$39.2
Administrative costs	\$6.0
Time or employee volunteering	\$0.9
Total	\$86.0

U.S. Employee Giving Campaign Results	2023	2024	2025
Dollars in Millions	\$15.0	\$14.4	\$14.4

Key social metrics^d

Employees

Employees (Global)	2023	2024	2025
	114,000	114,000	115,000

Management Positions (U.S.) ^e	2023	2024	2025
Women	44%	44%	45%
Men	56%	56%	55%
Undisclosed* (Gender)	–	–	<1%
Minorities	35%	35%	36%
Non-minorities	65%	65%	62%
Undisclosed* (Minority Status)	–	–	3%

2025 Management Positions (Global)	Men	Women
Junior Management Positions	56%	44%
Top Management Positions	64%	36%

2025 Full-Time Employees By Age Group (Global)

<30 Years Old	18%
30–50 Years Old	63%
>50 Years Old	19%

2025 Employee Turnover Rate (Global)

Total Employee Turnover Rate	15%
Voluntary Employee Turnover Rate	10%

Small Business: Performance Metrics

Total Global Small Business Spend ^f (Micro, Small, Medium)	2020 ^g	2023	2024	2025
Dollars in Millions	\$1,745	\$2,368	\$2,268	\$2,510

Health and safety

Occupational Illness Frequency Rate (Employee and Contractor)	2023	2024	2025
Illnesses per Million Hours	0.28 ^h	0.18	0.15

Lost Time Injury and Illness Case Rate (Cases per 100 Workers ⁱ)	2023	2024	2025
Total Employee and Contractor	0.16	0.19	0.16
Employee	0.17	0.21	0.18
Contractor	0.06	0.05	0.06

Recordable Injury and Illness Case Rate	2023	2024	2025
Cases per 100 Workers ⁱ	0.29	0.32	0.30

Global Vehicle Accident Rate (Field-Based Employees Only)	2023	2024	2025
Accidents per Million Miles Driven	2.86	2.91	2.85

Fatalities (Employees and Contractors)	2023	2024	2025
	0	0	1

Reported data excludes Exact Sciences and its operations, as the acquisition closed on March 23, 2026.

* 2025 is the first year in which Undisclosed is reported as a separate category in the Global Sustainability Report.

Totals and percentage changes may differ from listed metrics due to rounding. To ensure data accuracy, the most accurate number has been used.

Refer to [Page 58](#) for metrics endnotes.

Key Environmental Metrics — Energy and Emissions^d

Energy and emissions global performance

Scope 1 and 2 Carbon Emissions (1,000 Metric Tons CO ₂ e)	2018 ^a	2023	2024	2025
Total (Scope 1 and 2) Market-Based CO ₂ e Emissions ^{i,k}	987	904	889	853
Total (Scope 1 and 2) Location-Based CO ₂ e Emissions	1,063	975	974	949
Purchased Fuels (Scope 1) CO ₂ e Emissions ^l	525	495	489	491
Refrigerant (Scope 1) CO ₂ e Emissions ^m	12	10	14	9
Total Direct (Scope 1) CO ₂ e Emissions	537	504	503	499
Purchased Energy (Scope 2) Market-Based CO ₂ e Emissions ^{k,n}	450	400	386	353
Purchased Energy (Scope 2) Location-Based CO ₂ e Emissions ⁿ	526	471	471	449

Scope 1 and 2 Carbon Emissions Intensity - Normalized to Sales (Metric Tons CO ₂ e per \$ Million Sales)	2023	2024	2025
Total (Scope 1 and 2) Market-Based CO ₂ e Emissions ^k	23	21	19
Total (Scope 1 and 2) Location-Based CO ₂ e Emissions	24	23	21
Total Direct (Scope 1) CO ₂ e Emissions	13	12	11
Purchased Energy (Scope 2) Market-Based CO ₂ e Emissions ^{k,n}	10	9	8
Purchased Energy (Scope 2) Location-Based CO ₂ e Emissions ⁿ	12	11	10

Totals and percentage changes may differ from listed metrics due to rounding. To ensure data accuracy, the most accurate number has been used. Refer to [Page 58](#) for metrics endnotes.

Key Environmental Metrics — Energy and Emissions^d

Energy and emissions global performance (continued)

Scope 1 and 2 CO₂e Emissions by Division (1,000 Metric Tons CO ₂ e — Market-Based Factors)	2023	2024	2025
Corporate	255	251	254
Diagnostics	109	96	93
Medicines	133	129	117
Medical Devices	89	88	81
Nutritionals	319	326	308

Scope 1 and 2 CO₂e Emissions Intensity by Division — Normalized to Sales (Metric Tons CO ₂ e per \$ Million Sales)	2023	2024	2025
Diagnostics	11	10	10
Medicines	26	25	21
Medical Devices	5	5	4
Nutritionals	39	39	36

Scope 1 and 2 Carbon Emissions by Energy Source^e (1,000 Metric Tons CO ₂ e — Market-Based Factors)	2023	2024	2025
Stationary Sources			
Electricity (Purchased)	393	379	346
Natural Gas	345	346	345
Fuel Oils	5	4	4
Coal	—	—	—
Miscellaneous Fuels	14	12	12
Purchased Steam, Hot Water, and Chilled Water	6	5	5
Biofuels	<1	<1	<1
Generated Electricity (Cogeneration)	—	—	—
Generated Electricity (Renewables)	—	—	—
Stationary Sources Total	763	746	713
Mobile Sources			
Sales Fleet Gasoline and Compressed Natural Gas	102	106	107
Sales Fleet Diesel	19	13	13
Sales Fleet Electric Vehicles (EVs)	1	2	2
Aviation Fuel	7	6	6
Plant/Shuttle Fleet (Diesel, Gasoline, E85, and Propane)	2	2	1
Mobile Sources Total	132	129	131

Totals and percentage changes may differ from listed metrics due to rounding. To ensure data accuracy, the most accurate number has been used. Refer to [Page 58](#) for metrics endnotes.

Key Environmental Metrics — Energy and Emissions^d

Energy and emissions global performance (continued)

Scope 3 Carbon Emissions by Category ^a (1,000 Metric Tons CO ₂ e)	2025
Upstream	
1: Purchased Goods and Services	3,835
2: Capital Goods	236
3: Fuel- and Energy-Related Activities (Not Included in Scope 1 or Scope 2)	215
4: Upstream Transportation and Distribution	800
5: Waste Generated in Operations	7
6: Business Travel	168
7: Employee Commuting	253
8: Upstream Leased Assets	–
Downstream	
9: Downstream Transportation and Distribution	–
10: Processing of Sold Products	–
11: Use of Sold Products	562
12: End-of-Life Treatment of Sold Products	86
13: Downstream Leased Assets	–
14: Franchises	–
15: Investments	–

Biogenic Emissions	2023	2024	2025
1,000 Metric Tons	0.7	1.1	15.6

Scope 1 and 2 CO ₂ e Emissions by Greenhouse Gas (1,000 Metric Tons — Market-Based Factors)	2023	2024	2025
CO ₂ (Scope 1)	493	488	490
CO ₂ (Scope 2)	397	383	350
CH ₄ (Scope 1)	<1	<1	<1
CH ₄ (Scope 2)	<1	<1	<1
N ₂ O (Scope 1)	<1	<1	<1
N ₂ O (Scope 2)	<1	<1	<1
Hydrofluorocarbons (HFCs) (Scope 1)	9	14	9
HFCs (Scope 2)	–	–	–
Perfluorocarbons (PFCs) (Scope 1)	–	<1	–
PFCs (Scope 2)	–	–	–
SF ₆ (Scope 1)	–	–	–
SF ₆ (Scope 2)	–	–	–
NF ₃ (Scope 1)	<1	<1	<1
NF ₃ (Scope 2)	–	–	–

Other Emissions (1,000 Metric Tons)	2023	2024	2025
Volatile Organic Compound (VOC) Emissions	1.23	1.08	1.16
Sulfur Oxide (SOx) From Combustion ^a	0.05	0.04	0.04
Nitrous Oxide (NOx) From Combustion ^a	0.31	0.31	0.31
Particulate Matter	0.08	0.07	0.07

Totals and percentage changes may differ from listed metrics due to rounding. To ensure data accuracy, the most accurate number has been used. Refer to [Page 58](#) for metrics endnotes.

Key Environmental Metrics — Energy and Emissions^d

Energy and emissions global performance (continued)

Scope 1 and 2 Energy Consumption (1,000 Gigajoules)	2023	2024	2025
Purchased Fuels (Scope 1) ⁱ	9,061	8,998	9,027
Purchased Energy (Scope 2) ⁿ	4,751	4,823	4,926
Total	13,812	13,821	13,953

Energy Consumption by Source (1,000 Gigajoules)

Stationary Sources

Electricity (Purchased)	4,485	4,555	4,542
Natural Gas	6,896	6,906	6,884
Fuel Oils	68	52	57
Coal	–	–	–
Miscellaneous Fuels	180	159	157
Purchased Steam, Hot Water, and Chilled Water	119	107	205
Biofuels	6	10	14
Generated Electricity (Cogeneration)	123	130	131
Generated Electricity (Renewables)	14	18	33

Stationary Sources Total

Mobile Sources

Sales Fleet Gasoline and Compressed Natural Gas	1,513	1,570	1,612
Sales Fleet Diesel	272	189	189
Sales Fleet EVs	10	13	15
Aviation Fuel	104	89	93
Plant/Shuttle Fleet (Diesel, Gasoline, E85, & Propane)	23	22	20

Mobile Sources Total

Scope 1 and 2 Energy Consumption Intensity — Normalized to Sales (Gigajoules per \$ Million Sales)	2023	2024	2025
Purchased Fuels (Scope 1) ⁱ	226	215	204
Purchased Energy (Scope 2) ⁿ	118	115	111
Total	344	329	315

Renewable Energy Consumption (1,000 Gigajoules)

Generated On-Site From Renewables	14	18	33
Energy Purchased From Renewable Sources	845	998	1,035

Purchased Energy Consumption By Type (1,000 Gigajoules)

Grid-Sourced Electricity	3,639	3,558	3,507
Energy Purchased From Renewable Sources	845	998	1,035
Electricity Consumed Total	4,485	4,555	4,542
% of Grid-Sourced Electricity	81%	78%	77%
% of Purchased Renewable Energy	6%	7%	7%
% of Grid-Sourced of Total Energy	26%	26%	25%

Totals and percentage changes may differ from listed metrics due to rounding. To ensure data accuracy, the most accurate number has been used. Refer to [Page 58](#) for metrics endnotes.

Key Environmental Metrics — Water^d

Water global performance

Water global performance (Megaliters)	2023	2024	2025	% Change From 2024 to 2025
Water Withdrawal ^r	13,386	13,504	13,973	3%
Water Withdrawal — Water-Stressed Sites ^{r, s}	6,671	6,561	6,698	2%
Water Consumed In Process	2,273	2,347	2,526	8%
Total Water Discharged (Impaired)	8,797	8,873	9,328	5%
Total Water Discharged (Non Impaired)	2,316	2,284	2,119	-7%

Water Withdrawal by Source ^r (Megaliters)	2025
Fresh Surface Water	634
Groundwater	3,944
Municipal Supply	9,238
Rainwater	24
Other	132
Total Water Intake	13,973

Water Global Performance — Normalized to Sales (Megaliters per \$ Million Sales)	2023	2024	2025	% Change From 2024 to 2025
Water Withdrawal Intensity ^r	0.33	0.32	0.32	-2%
Water Withdrawal Intensity — Water-Stressed Sites ^{r, s}	0.17	0.16	0.15	-3%
Water Consumed In Process Intensity	0.06	0.06	0.06	2%
Total Water Discharged Intensity (Impaired)	0.22	0.21	0.21	-1%
Total Water Discharged Intensity (Non Impaired)	0.06	0.05	0.05	-12%

Water Recycled	2025
Megaliters	1,389

Totals and percentage changes may differ from listed metrics due to rounding. To ensure data accuracy, the most accurate number has been used. Refer to [Page 58](#) for metrics endnotes.

Key Environmental Metrics — Waste^d

Waste Global Performance

Waste Global Performance (Metric Tons)	2023	2024	2025	% Change From 2024 to 2025
Total Waste [†]	70,126	69,446	71,023	2%
Total Hazardous Waste [†]	11,030	9,692	8,844	-9%
Total Nonhazardous Waste [†]	59,095	59,754	62,179	4%

Waste Global Performance — Normalized to Sales (Metric Tons per \$ Million Sales)	2023	2024	2025	% Change From 2024 to 2025
Total Waste Intensity [†]	1.7	1.7	1.6	-3%
Total Hazardous Waste Intensity [†]	0.3	0.2	0.2	-14%
Total Nonhazardous Waste Intensity [†]	1.5	1.4	1.4	-2%

Beneficial Use [¶]	2023	2024	2025
Metric Tons	102,864	105,045	105,488

2025 Beneficial Use by Waste Type [¶]	Metric Tons	Percentage
Food waste	1,507	1%
Construction & Demolition	4,760	5%
Nutrition byproduct	67,310	64%
Corrugate/Cardboard	959	1%
Wood	4,888	5%
Production Waste	3,717	4%
Unused Product Waste	3,814	4%
Other	18,533	18%
Total	105,488	100%

Breakdown of Total Waste by Fate ^{†,¶} (Metric Tons)	2023	2024	2025
Landfilled	11,732	9,253	9,544
Incinerated (Without Energy Recovery)	3,127	2,064	2,049
Incinerated (With Energy Recovery)	23,063	20,101	21,746
Recycled	31,789	37,836	37,158
Other, Diverted	415	193	525
Total	70,126	69,466	71,023

Breakdown of Hazardous Waste by Fate ^{†,¶} (Metric Tons)	2023	2024	2025
Landfilled	311	426	553
Incinerated (Without Energy Recovery)	1,970	1,035	1,154
Incinerated (With Energy Recovery)	5,320	4,763	4,222
Recycled	3,101	3,408	2,790
Other, Diverted	328	61	125
Total	11,030	9,692	8,844

Breakdown of NonHazardous Waste by Fate ^{†,¶} (Metric Tons)	2023	2024	2025
Landfilled	11,420	8,827	8,992
Incinerated (Without Energy Recovery)	1,157	1,029	896
Incinerated (With Energy Recovery)	17,743	15,338	17,523
Recycled	28,688	34,429	34,368
Other, Diverted	88	132	400
Total	59,095	59,754	62,179

Totals and percentage changes may differ from listed metrics due to rounding. To ensure data accuracy, the most accurate number has been used. Refer to [Page 58](#) for metrics endnotes.

Key Environmental Metrics — Waste^d

Waste Global Performance (continued)

Diversion Rate* (Percentage)	2023	2024	2025
	91.4%	93.5%	93.4%

IT Equipment Resold and Recycled (Metric Tons)	2023	2024	2025
Total Resold	76	76	48
Total Recycled	240	243	158

Total Cumulative Packaging Addressed** (Pounds)	2023	2024	2025
Cumulative Packaging Addressed	29,961,437	31,285,900	37,472,146
Employing Circularity Principles	1,668,739	2,234,526	4,941,606
Optimizing Material Efficiency	28,292,698	29,051,374	32,530,540

EHS fines, notices, and inspections

EHS fines, notices of violation, and government agency inspections

EHS Fines (U.S. Dollars)	2023	2024	2025
Environmental Fines	\$625	\$0	\$0
Health and Safety Fines	0	\$18,462	\$ 7,479
Total	\$625	\$18,462	\$ 7,479

EHS Notices of Violation	2023	2024	2025
	5	5	2

EHS Government Agency Inspections	2023	2024	2025
	531	565	493

Totals and percentage changes may differ from listed metrics due to rounding. To ensure data accuracy, the most accurate number has been used. Refer to [Page 58](#) for metrics endnotes.

Metrics endnotes

All environmental data has been adjusted to account for acquisitions and divestitures, in accordance with the methodology prescribed in the World Resources Institute (WRI) and World Business Council for Sustainable Development Greenhouse Gas Protocol (GHGP). Unless otherwise specified, reported data excludes Exact Sciences and its operations, acquired March 23, 2026. We report data from acquisitions as soon as is practical. With the exception of supplier small business spend, scope 3 metrics, and where we report one year of data, our metrics tables include data for the following: the reporting year, the two years prior to the reporting year, and a baseline year, where applicable.

- (a) Global CPI is calculated using the total headline CPI for each country, weighted by Abbott's geographic revenue exposure. CPI values are gathered from S&P Global, as of March 15, 2026, which sources data from each country's respective statistical agency or reporting institution. Revenue data for weighting is consistent with the net sales price change as reported in Abbott's annual 10-K filing.
- (b) Abbott Fund, citizenship, business contributions, and product donations.
- (c) Abides by the World Health Organization guidelines for product donation.
- (d) Per our environmental, health, and safety metrics reporting protocols, metrics data published in previous years were adjusted in this report to reflect minor corrections, method adjustments, etc.
- (e) These percentages are as of December 31, 2025. Percentages represent a count of U.S. employees, excluding Domesco Medical Import-Export Joint-Stock Corporation.
- (f) Supplier small business spend is aligned with the U.S. government's fiscal year (October 1–September 30). Spend data represents global suppliers with global spend for 2025 reporting. International spend data has been applied retroactively for 2020-2024 data.
- (g) This is the baseline year.

- (h) Occupational Illness Frequency Rate increased due to internal data validation that reclassified cumulative trauma-related injuries as illnesses.
- (i) Annual incident rates are calculated per 100 employees, assuming the average employee works 40 hours per week and 50 weeks per year. This is equivalent to 200,000 hours worked.
- (j) Progress toward our 2030 carbon goal is reported using the GHGP Scope 2 market-based methodology.
- (k) Scope 2 emissions are calculated using the GHGP market-based methodology. Per the GHGP, where market-based information is not available, location-based results have been used as proxy.
- (l) Reported Purchased Fuels Scope 1 sources consist of fuel consumed by manufacturing, R&D, and warehouse facilities under Abbott's control, sales fleet, and other Abbott vehicles.
- (m) Per the GHGP, Scope 1 refrigerant CO₂e emissions include only those covered in the Kyoto Protocol.
- (n) Reported Scope 2 sources consist of energy directly purchased by Abbott, such as electricity, steam, and heated or chilled water, as well as emissions from leased locations. Unless specified otherwise, emissions are calculated according to the GHGP Scope 2 market-based method.
- (o) Abbott's non-energy consumption GHG emissions, such as refrigerant releases and process air emissions, are omitted. The total CO₂ equivalents from non-energy sources are noted in the Total Emissions (Scope 1 and 2) table.
- (p) Abbott estimates Scope 3 emissions using the GHG Protocol Corporate Value Chain (Scope 3) Accounting and Reporting Standard. Transportation and Distribution includes Upstream and Downstream activities. Scope 3 estimations may be adjusted annually to account for data availability and methodology enhancements. Sourcing category spend allocations are subject to change year over year in alignment with business strategy. Energy consumed in buildings and vehicles that are leased to Abbott (leased assets) is included in Scope 1

and 2. Abbott pays for the majority of transportation of products to retailers and customers, and, therefore, includes these emissions under Upstream Transportation and Distribution. Abbott's estimated Scope 3 footprint excludes known sources in Purchased Goods and Services, Downstream Transportation, Processing of Sold Products, and Investments categories. Collectively, these omissions are estimated to be less than 2% of our total Scope 3 footprint.

- (q) This reflects emissions from fuel combusted by manufacturing, R&D, and warehouse facilities under Abbott's control.
- (r) Water withdrawal is equivalent to water intake.
- (s) Water-stressed locations have been determined using the World Resource Institute (WRI) Aqueduct global water risk mapping tool. Sites rated as having high or extremely high baseline water stress in the tool are classified as being water-stressed.
- (t) Waste generation data does not include materials that are reused beneficially.
- (u) Abbott defines beneficial use activities as sending material, that otherwise would have been wasted, off-site to be used as an effective substitute for a commercial product or commodity. Beneficial use material is used as is or in substantially the same form as it was generated.
- (v) Abbott's diversion rate is calculated as follows: (total waste + beneficial use - landfill and incineration without energy recovery)/(total waste + beneficial use). Waste with an unknown disposal fate is included with landfill fate. Waste noted as "other, diverted" reflects waste diverted from landfill and incineration without energy recovery.
- (w) Savings based on annualized calculations.

Disclosures:

Access and Affordability

Pricing

In addition to building access and affordability into new products and services, we continually work to increase access to our existing products. Over the last 10 years, we prioritized our business growth, expanding access over price increases. Volume grew at an average rate of 6.8%, while prices grew 0.2% annually over the same period.*

As part of our 2030 Sustainability Plan, we have an intentional focus on designing sustainable access and affordability into our life-changing technologies so that we can make them widely available at affordable prices to people who need them. Pricing, however, is only one of the factors that determines affordability. Abbott also is advocating for systems and approaches that broaden access while minimizing additional costs for consumers and payers. In 2025, Abbott's product pricing reflected the company's approach, with an annual global net sales price change of 0.7%, which compares to a global consumer price index (CPI)** of 3.1% for 2025, and a global consumer price index for health of 3.7%. The CPI metric is modified from the metric provided by the SASB by substituting a global CPI for the U.S. CPI.

Sales outside the U.S. in 2025 composed approximately 61% of Abbott's revenue. Abbott believes that disclosing product pricing relative to the global CPI is an appropriate way for investors and other stakeholders to best understand pricing for products across our diversified, global businesses.

The global CPI is the total headline CPI for each country weighted by Abbott's geographic revenue exposure. For more on Abbott pricing, see [Abbott's 10-K filing for 2025](#).

Disclosure of pricing information

Given the breadth of our product offerings, each Abbott business sells products using a variety of contracting methodologies. Businesses use a variety of price concessions in their sales contracting, including point-of-sale discounts, rebates, and wholesaler chargebacks. These price concessions can be for single- or multi-product sales and may include products from multiple business units (such as all medical device business units or rapid and molecular diagnostics). Price concessions may be based upon factors such as volume, market share, and purchase commitments, or result from competitive bidding processes and are generally documented in executed contracts, purchase orders, and term sheets. Point-of-sale discounts are reflected in invoices that show the discounted prices, and rebates are documented in written agreements, with rebate calculations provided at the time rebate payments are made.

Our customers span the globe and include federal, state, and local governments, hospitals, group purchasing organizations, wholesalers, individual HCPs, and consumers. We maintain pricing flexibility to meet the needs of our diverse customers, large and small, and to help ensure that our essential healthcare products are available and affordable across the globe wherever we do business.

Antimicrobial resistance

We are committed to doing our part to counter the growing risk of drug-resistant bacteria. For more information on how we are reducing antimicrobial resistance (AMR) risk, see [abbott.com](#).

Data

Data privacy and security governance

Our centralized governance model helps us to implement our security and privacy processes, standards, and principles related to data collection, use, sharing, and security. Executive management takes an active role in the development of our cybersecurity and privacy programs. Internal Audit includes IT infrastructure and systems in its scope of review, and our Board of Directors receives regular updates on program progress.

Privacy and cybersecurity oversight committees

The Chief Ethics and Compliance Officer and Divisional Vice President for Global Privacy oversee our Global Privacy Office. Established oversight committees support the Privacy Office, with further assistance from dedicated global privacy professionals, country-specific privacy champions, and operational committees that engage key stakeholders at the product and business levels.

The Cybersecurity Privacy Executive Committee oversees Abbott's cybersecurity and privacy programs. The committee brings together corporate officers from Legal, Ethics and Compliance, Finance, Human Resources, Quality, and Information Technology, along with each of Abbott's businesses, to advise and oversee the cybersecurity and privacy programs.

Abbott's senior cybersecurity and privacy leaders also provide regular progress updates to the Board of Directors and Board Committees. Both the Audit Committee and Public Policy Committee have responsibilities related to cybersecurity and data privacy.

*Excludes the impacts of business acquisitions/divestitures and foreign exchange.

**Global CPI is calculated using the total headline CPI for each country weighted by Abbott's geographic revenue exposure. CPI values are gathered from S&P Global, which sources data from each country's respective statistical agency or reporting institution. Revenue data for weighting is consistent with the net sales price change as reported in Abbott's annual 10-K filing.

Cybersecurity management

Our Chief Information Security Officer (CISO) leads Abbott's cybersecurity strategy and program, as well as the cybersecurity and privacy incident response team. This team is responsible for monitoring the detection of cybersecurity incidents and executing Abbott's cybersecurity incident response process as needed. The CISO reports to Abbott's Chief Information Officer (CIO). The CIO has overall responsibility for the cybersecurity program and organization and reports to our Chairman and CEO.

Workforce

Employee recruitment, development, and retention

Talent management is overseen by our Executive Vice President, Human Resources — who reports directly to our Chairman and CEO — and corporate officers, all of whom carry human capital goals.

To support our future employee pipeline, we recruit and partner with more than 30 different universities. For example, we maintain a presence at the University of Illinois Urbana-Champaign Research Park and teach a class at Prairie View A&M University. We regularly visit these schools, giving us access to a competitive pool of talented students to consider for internship opportunities. Our career site employs AI to enhance the application process, streamlining user experiences with tailored content, and a personalized chatbot to help identify roles.

As well as supporting those who already work for Abbott, we want to give the next generation opportunities to launch their careers. Through our STEM internship program, we offer high school students an opportunity to kick-start a career in healthcare. We also engage organizations such as AMIE and the Society of Women Engineers.

Learning and progression opportunities

We hired almost 17,000 new, external employees in 2025. Our open positions include those filled by external hires, internal hires, and promotions. Last year, we provided more than 417,000 job and development opportunities. Additionally, we hosted a Global Development Week in 2025, in which more than 27,000 unique employees participated for more than 76,400 hours.

Key-talent programs

We identify high-potential employees early in their careers, and offer training that's specific to their roles and areas of the business. Employees who participate in programs such as our Emerging Leaders Program also expand their internal networks as they meet colleagues from different parts of the company and work with peers on important projects that span our businesses.

Developing our future leaders

In addition to the vast curriculum available to all employees, we offer various programs to support the personal development of emerging leaders.

• New-leader program:

Designed to support new managers in making a successful transition to managerial roles while honing leadership potential. Instruction is delivered over 12–14 weeks, with five virtual, instructor-led sessions, as well as various self-paced modules and on-the-job activities.

• GM (general manager) acceleration program:

Designed to accelerate the readiness for GM or commercial leadership roles. The program includes business and strategic development, including an opportunity to identify and defend business strategy.

• Global citizen development program:

Brings together early-career employees to prepare them to be next-generation leaders. Cohorts of approximately 35 employees — from different divisions, functions, and geographies — complete blended learning sessions to develop leadership skills, build business acumen, and develop a strong network. The program spans six months, and includes critical business challenges where participants apply the things they've learned.

• Emerging leaders program:

A global development program that identifies and develops cross-division talent for future leadership roles. The program spans five months and includes a virtual workshop to build broad leadership and communication skills, as well as coaching and motivating skills. The program also includes private coaching, periodic cohort meetings, and a final group webinar to reflect on learnings and refine goals for progress.

Speak to the World

Employees have the opportunity to learn a new language, get better at one they already know, and gain a deeper understanding of global cultures. Employees can learn more than 16 languages, improve skills through practical online exercises, receive personalized learning recommendations, and join virtual trainer-led conversation classes. The cultural awareness tool fosters connections among colleagues and prepares them for global ambitions. The program includes personalized cultural profiles with cultural comparison tools, and self-paced digital content to enhance intercultural awareness.

Talent management reviews

Our senior leadership conducts talent management reviews (TMRs) by division and function to review succession plans for our most critical positions. As part of these discussions, senior leadership considers employees with leadership potential who are early in their careers and discusses how they can continue to develop that talent. Our Board of Directors conducts an annual TMR to review succession plans and development actions for our senior positions, as well as discuss the overall health of our talent pipeline.

“Real Talk. Real Impact.”

“Real Talk. Real Impact.” is Abbott’s approach to effective and agile conversations between managers and employees. In addition to our formal, annual goal-setting and performance assessment process, we also encourage an ongoing dialogue, asking managers and employees to have regular conversations throughout each quarter about how the organization is doing, how the employee is performing, and how they can make a bigger impact.

The dialogue can be initiated by either employee or manager and can follow different formats or scenarios. During these conversations, managers also seek to identify barriers and determine how they can better support the employee and their career aspirations.

We also offer employees the opportunity to participate in 360-degree assessments, 180-degree assessments, and self-assessments. These provide multi-perspective feedback from managers, colleagues, peers, direct reports, and others. Results from the assessment present an expanded understanding of an employee’s strengths and development needs.

Continuing to learn and grow

On average, Abbott employees receive 26 hours of training and development per year. In 2025, we continued offering training on AI and Microsoft Copilot to prepare our employees for the future of healthcare. We launched a new course focused on applying advanced prompting techniques to orchestrate multi-step workflows, design simple multi-agent workflows to enhance efficiency and collaboration, and recognize how AI will continue evolving and how to stay future-ready.

Family support

In 2025, we continued our family care support services for U.S. employees through our partnership with Care.com. This includes a complimentary premium membership to help find and manage care for children, seniors, pets, and the home. Additionally, employees have 24/7 access to free care specialists for personalized support. The service also offers resources for parents of neurodiverse children, educational support such as college advisory services, and elder care assistance, including patient advocacy, care coordination, and caregiving support.

Parental leave is available to eligible birth and adoptive parents in the U.S., providing up to eight workweeks (i.e., up to 320 work hours or an equivalent part-time workweek) of paid time off following the birth or legal adoption of a child. Parental leave may be used in one-week increments, up to one year from the date of birth or adoption of a new child. In 2025, more than 1,500 employees took parental leave: 41.8% female, 58.1% male, and 0.1% undisclosed. Outside the U.S., we comply with all laws regarding parental leave, which may require more expansive benefits.*

Flexible work options

Abbott supports and encourages flexibility, both formally and informally, and offers a wide variety of flexible work options, including as-needed flex time, compressed workweek, telecommuting/remote work, reduced workweek/part-time hours, and job share.

Financial and retirement benefits

In 2025, approximately 15,000 employees across 75 countries were eligible to participate in Abbott’s long-term incentive program. Abbott offered our employee stock purchase plan in 63 countries, with upward of 39% of eligible employees participating.

Employee giving and volunteering

Abbott offers a comprehensive Employee Giving Program in the U.S. and Puerto Rico, through which the company:

- Matches employees’ donations to eligible nonprofit organizations
- Matches 100% of eligible donations
- Pays all processing fees so every cent goes to the charity of choice

The program includes an annual donation drive as part of Abbott’s long-standing Employee Giving Campaign, which has existed for half a century. During the 2025 campaign, 81% of employees pledged \$14.4 million** to more than 11,000 charitable organizations in a single month.

We provide U.S. employees eight hours per year of paid time off to volunteer in their local communities.

Health and Safety

Abbott’s EHS organization reports to the Chief Operations and Procurement Officer, who reports to our Chief Financial Officer. EHS professionals and safety teams at each Abbott site work to implement internal EHS programs.

The Divisional Vice President of EHS chairs our EHS Leadership Council, which is made up of business and global EHS leaders who develop and drive our EHS programs, including those related to employee health and safety.

*Abbott does not track return and retention rates by leave usage.

**This figure includes employee donations and Abbott Fund donation matches. It also reflects payroll deduction pledges that are deducted during the 2026 calendar year and may be subject to change based on individual employee decisions.

Occupational health services

Our Global Occupational Health Services (GOHS) team develops and maintains occupational health policies, procedures, and guidelines; trains relevant employees; and consults on regulatory compliance. Together with the EHS team, the GOHS team leads our response to public health emergencies with the potential to impact our employees and our business.

Today, more than 145 occupational health professionals support employee health and well-being at Abbott, and treat illnesses and injuries. They also conduct regular screenings and health education programs. Site and divisional leaders track implementation of occupational health and well-being initiatives using a Global Health Scorecard.

Fostering a culture of health and safety

In addition to our dedicated EHS Policy, we utilize several technical and management standards, including:

- Risk Assessment and Self-Assessment Management Standard to assess and mitigate health and safety risks
- Training and Awareness Management Standard to inform employees of risks and job-specific hazards
- Topic-specific technical standards, e.g., Fleet Safety, Control of Hazardous Energy, Confined Spaces, Ergonomics, Electrical Safety, Biological Safety, and Working at Heights
- Emergency Preparedness Standard to establish requirements for emergency preparedness planning for health and safety on-site and in surrounding communities

Our [EHS policies and technical standards](#) are detailed online.

Engaging employees

EHS employees are trained on relevant regulatory requirements and Abbott's standards. We further engage employees in health and safety efforts through evaluations of health and safety leaders against annual EHS performance goals, dedicated forums for discussing priority EHS issues, and our annual EHS Awards Program.

Our EHS Excellence Awards recognize individuals or teams that improve our health and safety performance, improve our carbon footprint, reduce waste, and drive efficiency. In 2025, we awarded 14 EHS Excellence Awards in Air and Energy, Water, Waste, Health and Safety, and Management Systems categories.

Our 2025 health and safety performance

We consistently update our protocols to safeguard against occupational injuries and illness. Each division actively implements initiatives to drive improvements while maintaining and evolving our existing practices. We also provide targeted training in key programs, such as ergonomic workstation improvements and targeted stretching programs.

At the end of 2025, 27 Abbott sites were certified to International Organization for Standardization (ISO) 45001:2018. Seventeen of those sites are manufacturing, and 10 sites are non-manufacturing. We evaluate commercial operations, manufacturing, and R&D sites on a regular basis. Using an EHS scorecard, senior leadership monitors performance with results used to identify corrective actions.

Abbott's overall recordable injury or illness rate* in 2025 for contractors and employees was 0.30 cases per 100 workers. The recordable rate for contractors was 0.20 cases per 100 workers, and for employees it was 0.31 cases per 100 workers. As part of Abbott's EHS programs, there are procedures to investigate work-related injuries, ill health, diseases, and incidents. The EHS Event Reporting and Management Procedure details how work-related injuries and illnesses are reported, recorded, and managed.

Environment

EHS governance

Abbott's global EHS organization is managed and monitored by a single function.

Three leadership councils support implementation of EHS programs, covering concepts from product and facility design to operations to sales and service.

• Global Operations Council

Oversees operations strategy across manufacturing, supply chain, engineering, and EHS

• Commercial EHS Executive Council

Sets EHS priorities, goals, and objectives for commercial operations

• EHS Leadership Council

Sets EHS strategy and supports execution of programs. Builds company awareness and sharing of EHS best practices

Environmental policies, compliance, and auditing

We maintain policies and standards that align with the core values of Abbott. It is the responsibility of every worker to adhere to our policies and to report practices or conditions that are inconsistent with our policies or that pose recognized or unacceptable risks to human health or the environment. In addition, each employee is committed to following our policies when conducting business activities. Our comprehensive global audit program monitors compliance with applicable EHS regulations. It also identifies potential risks to our business and employees. We evaluate EHS risk factors for each site annually, using insights to determine audit frequency. Following audits, corrective action plans are developed, implemented, and monitored where needed. The audit program also informs standards and regulatory training requirements for relevant employees through the identification of potential risks to business.

Our [EHS policies and technical standards](#) are available online.

* Abbott reports case rates per 100 workers, equivalent to 200,000 hours worked. Our recordable case-rate incidents include any work-related injuries resulting in death, days away from work, restricted work, transfer to another job, medical treatment beyond first aid, loss of consciousness, and significant illness or injury diagnosed by a licensed healthcare professional.

Integration and alignment on EHS requirements

Abbott develops multiyear integration plans to align acquisitions with our EHS management practices, standards, and policy. Integration progress is monitored and verified by an internal EHS compliance audit. Our EHS Policy requires that EHS liability and compliance evaluations are completed on acquisitions and divestitures of property and businesses. Abbott assesses EHS liability and compliance risk prior to making decisions on mergers and acquisitions. Compliance with our EHS Policy is also incorporated into all new acquisitions.

EHS management system certifications

We consider Leadership in Energy and Environmental Design (LEED) certification when building new facilities, and have certified 21 projects under LEED standards, including one platinum, four gold, and eight silver certifications. Additionally, we utilize our Energy and Environmental Impact Tool to identify and model energy-efficient and environmentally sustainable concepts for inclusion in the capital project design. We also consider external certifications — such as ISO — where they add business value. By the end of 2025, about 56% of manufacturing sites had been certified under ISO 14001:2015 (Environmental Management Systems) and/or ISO 50001:2018 (Energy Management Systems) standards, meaning about 70% of our square footage for sites with manufacturing are covered by these ISO certifications.

2025 Environmental certifications

Total sites certified to ISO 50001:2018 and/or ISO 14001:2015	80
Total ISO 14001:2015 certifications	64
Manufacturing sites certified	44
Non-manufacturing sites certified	20
Total ISO 50001:2018 certifications	32
Manufacturing sites certified	17
Non-manufacturing sites certified	15

Assessing our climate risk

Our Global EHS team — along with key Abbott functions such as Legal, Regulatory, Supply Chain, Sustainability, Risk Management, Business Continuity, and Finance — monitors emerging climate- and sustainability-related trends and regulations. This allows us to analyze potential business impacts, understand risk exposure, and develop appropriate mitigation strategies. The TCFD outlines how companies should report on climate-related risks and mitigation strategies. Our TCFD index details our disclosures. We also share information in our latest [CDP Disclosure Response \(2025\)](#).^{*} The environmental metrics we track and report against are available on [Page 51](#).

Energy management

Abbott's energy policy, technical standards, and guidelines drive Abbott's energy management program. Elements of the program include the integration of energy efficiency concepts into business operations, goal-setting, and strategic planning. Our progress toward established targets and objectives is routinely monitored through the review of performance metrics. Concepts such as energy awareness are advanced throughout our energy community of practice (CoP). Additionally, our internal standard requires employees receive general awareness training on the impact their actions have on targets. We seek opportunities for improvement by conducting periodic energy audits and through the evaluation of emerging technologies. Our Global Energy Council monitors, evaluates, and reduces total energy consumption; negotiates energy contracts; and promotes financially beneficial conservation and alternative energy projects. Through our CoPs and award programs, we encourage a culture of continuous improvement and share best practices.

2025 energy consumption

The total energy consumption (Scope 1 and 2) in 2025 was approximately 13,950,000 gigajoules. The total electricity purchased was about 4,500,000 gigajoules. Abbott's total energy consumption that is sourced from the grid totals about 25%, and about 7% is sourced from renewable sources.

Transportation efficiency

We have replaced about 75% of the United Kingdom fleet with electric vehicles, with a plan to transition the remainder of the U.K. fleet by the end of 2027.

We continue to support our employees' efforts to reduce their commuting impacts by providing on-site EV charging stations. For example, in 2025, we installed new EV charging stations at sites in Princeton, New Jersey, United States, and Singapore for employee use.

Water management

Wherever we use and discharge water, we work to minimize the impact, whether that be quality, quantity, or other concerns for those who rely on this essential natural resource.

Our water position statement, water management technical standard, and water efficiency guidelines detail expectations for water management planning and monitoring Abbott's impact on resources in communities where we operate by:

- Implementing management plans and targets for mitigating risks
- Engaging key local stakeholders to fully understand water-related risks
- Identifying opportunities to reduce quantity and magnitude of water-related impacts

Our water communities of practice are cross-divisional, collaborative networks focused on increasing employee awareness of water sustainability measures through training, enhancing organizational knowledge around water systems, and transferring knowledge, lessons learned, and best practices.

^{*}2025 CDP Corporate Questionnaire responses reflect 2024 reporting year.

Managing water risks

We use a context-based approach to water management, annually assessing for resilience using the World Resources Institute (WRI) Aqueduct, a global water-risk mapping tool. This tool helps us to analyze local water stress and evaluate against our internal water-use intensity. In line with water stewardship principles, this mapping process is used to help us understand where we source and discharge water, providing deeper insight into the impact our operations have on local basins. The analysis also allows us to tailor our water management systems accordingly to reduce impacts at sites identified as exposed to water stress risks.

Water management requirements depend on water stress and water use. All of our sites must comply with internal and external requirements, regardless of their context. We also apply stronger mitigation measures for sites with higher intensity water-use operating in areas of water stress as detailed below.

- High Water Use: We evaluate local water risks, identify opportunities to mitigate water-related risk, set and track water targets, and engage local stakeholders
- Medium-to-Low Water Use: We evaluate local water risks, identify opportunities to mitigate water-related risk, and set and track water targets

Total water withdrawn in 2025 was about 13,973 megaliters. Approximately 48% of water used was withdrawn from regions with high or extremely high baseline water stress. Total water consumption was about 2,526 megaliters. In 2025, approximately 52% of water was consumed from regions with high or extremely high baseline water stress.

Read more about how we manage water risks in our [2025 CDP Corporate Questionnaire](#).*

Waste management

Our standards and guidelines include a range of waste management strategies, such as:

- Incorporating preventive maintenance and process design to eliminate waste generation
- Performing opportunity assessments to identify methods to reduce waste streams, reduce waste hazards, and manage materials in accordance with circular economy principles to minimize environmental impacts
- Providing waste management awareness to employees on waste disposal practices and relevant reduction, reuse, and recycling programs
- Processing waste reduction through diagnosing and fixing problems that would otherwise result in waste generation
- Reducing waste through product design, material input, and purchasing decisions
- Partnering across other value chains to promote beneficial use
- Segregating waste material properly

We also maintain a waste community of practice (CoP) that raises awareness on waste management, shares best practices, reviews performance metrics, and advances waste targets.

Managing hazardous and chemical waste

We are focused on reducing the proportion of waste classified as hazardous (current profile is around 12% of our 2025 waste footprint). Our waste management standard has requirements for proper management of hazardous waste and for decontaminating biohazardous waste prior to final disposal. It also details training requirements for any Abbott employee or contractor working with waste.

Regulated air emissions

Any Abbott facilities using substances containing ozone-depleting substances or hazardous/toxic air pollutants, as classified by local environmental protection agencies, adhere to applicable regulations. They also abide by Abbott's technical standards to help ensure protection of human and environmental health. Our Supplier Guidelines establish that the same standards are expected of Abbott suppliers.

Biodiversity

Recognizing the vital role protecting biodiversity and ecosystems plays in environmental management, we maintain technical standards designed to mitigate unpermitted environmental releases. Each Abbott facility must comply with these standards as well as relevant external regulations.

Product stewardship

Product stewardship focuses on reducing and restricting the use of hazardous substances in products, packaging, and manufacturing processes from design through end of life. For information on our product stewardship program and conflict minerals position statement, see [abbott.com](#).

Products collected through takeback

We look for opportunities to reduce waste going to landfills by working to collect our diagnostic products for recycling, refurbishing, and energy recovery when possible. In one of our various takeback programs, we collected and refurbished about 740 Abbott-produced instruments and diverted approximately 290 metric tons of product waste from landfill in 2025. Some of Abbott's takeback programs are driven by government regulations, while others are proactive initiatives. For more information on our chemical, hazardous chemical, and conflict minerals management, see [abbott.com](#).

Quality

Quality governance

Our operations cross multiple jurisdictions, with 89 manufacturing sites and oversight from more than 100 quality and regulatory agencies. Our quality framework drives regulatory compliance wherever we operate.

The Vice President, Regulatory, Quality, and Compliance, oversees quality globally, reporting to our Chairman and CEO. Executive management review of the quality system takes place quarterly to reinforce alignment with Abbott's quality policy and objectives, as well as relevant regulations. Quality and operation heads also review quality and compliance metrics, including improvement plans on a quarterly basis. Business-specific quality and regulatory leaders are responsible for business-specific quality systems, updating each business leader on progress. The Board's Public Policy Committee reviews quality metrics, industry progress, and emerging issues.

Commercial quality

Commercial quality assurance groups help supply chain processes maintain product quality and compliance.

The "One Abbott" Commercial Affiliate (OCA) initiative establishes common management procedures for:

- Operational excellence
- Customer satisfaction
- Supply chain assurance
- Organization and professional development

It also aligns systems for managing suppliers, documentation, warehouse controls, distribution controls, nonconformance, and corrective and preventive action.

Training and certification

New employees are trained on quality management system (QMS) elements, with an annual QMS refresher course delivered to existing and part-time personnel. In addition, business-level good manufacturing training offerings and corporate-level quality courses support employees with product quality responsibilities. Each business also offers tailored division- and site-specific trainings.

In 2025, we updated 40 courses to align with the FDA Quality Management System Regulation (QMSR) which was effective February 2, 2026. We also offered enhanced training for auditors on presentation skills, delivering and receiving feedback, strengthening teamwork, and data visualization. We continuously monitor industry hot topics, recalls, and audit findings to understand where we can augment our training offerings. Additionally in 2025, we provided funding for pursuit of American Society for Quality (ASQ) and Regulatory Affairs Professionals Society (RAPS) certifications.

Quality plant of the year

We believe in recognizing and showcasing best-in-class work, so, every year, we name one small and one large "Quality Plant of the Year." We invite employees to submit nominations detailing quality performance to our panel of judges, which is composed of senior leaders from a variety of functions. To determine the winning plants, semifinalists are invited to present to a panel.

Supplier quality monitoring program

Abbott maintains a comprehensive, risk-based program to ensure that all suppliers impacting our regulated products and QMS meet our quality standards. Each supplier is required to have a documented and established QMS that is appropriate for the specific products or services they provide to Abbott.

Suppliers are classified based on the potential risk level associated with their products or services. Their performance is actively monitored using specific performance criteria, with reviews conducted quarterly to annually depending on their risk classification.

In addition, periodic re-evaluations are conducted to ensure continued compliance and capability.

Audits and evaluations are conducted to verify that suppliers can meet our requirements, maintain adequate QMS elements, and comply with applicable regulations and standards. Abbott selects suppliers with demonstrated operational capabilities and an effective QMS. For high-risk suppliers, on-site audits and quality agreements are implemented to further ensure compliance and performance.

Safety of clinical trial participants

Abbott follows all applicable regulations in the countries where we conduct clinical trials or register products. We also follow nationally and internationally accepted standards, such as the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use Guideline for Good Clinical Practice (GCP), the principles of the Declaration of Helsinki, ISO 14155, ISO 20916, and other standards. We train employees and clinical sites on the proper conduct of clinical trials and employ both external and internal oversight of trials.

When planning our clinical trials, Abbott identifies and reduces controllable risks to patients. Either our Institutional Review Board (IRB) or our Independent Ethics Committee reviews any proposed research prior to commencement to assure patient protections. The informed consent procedures and consent form documents for any clinical trial must conform to all relevant legal statutes and governmental regulations. During the course of a trial, patients can report any concerns to the IRB. We monitor our trials on an ongoing basis to help ensure compliance with Abbott standards and identify any unforeseen risks to patient safety. This includes audits of contract research organizations that conduct or manage trials on behalf of Abbott. If Abbott becomes aware of trial misconduct, we report it to the appropriate authorities. No GCP inspections by regulatory agencies of the company or clinical trial investigators led to trial or investigator termination in 2025.

Clinical trial registrations and results disclosure

Abbott registers and discloses the results of all applicable and/or covered clinical trials, regardless of outcome, in a publicly accessible clinical trials registry, such as ClinicalTrials.gov. For branded generic medicines, this means that we register and disclose the results of interventional clinical trials in patients as designated by national laws and regulations. For medical devices and diagnostics, this means we register interventional clinical trials of health outcomes and pediatric post-marketing surveillance trials as designated by national laws and regulations.

Abbott is committed to transparency and sharing important information about the clinical trials we sponsor. We recognize that there are important public health benefits to making clinical trial information available to HCPs, patients, and the public. Our registrations and results disclosures adhere to all applicable national laws and regulations in countries where we operate.

Clinical trial data sharing

The regulatory environment around the sharing of clinical trial data for research—while safeguarding confidentiality and patient privacy—is evolving. We integrated with stakeholders' to identify different approaches for sharing clinical trial data with scientific and medical researchers to advance medical science while protecting confidential information.

Marketing and labeling

For Safety Data Sheets for our formulation products, see Section 13 of our [Safety Data Sheets](#). We also provide dismantling instructions for Abbott's Diagnostics business, as well as waste handling and disposal instructions, in our international Technical Library, which is available to our customers.

Supply Chain

Supply chain governance

We maintain a governance structure that provides oversight of supply chain-related activities, including sustainability, which report through our Chief Operations and Procurement Officer and ultimately to the Chief Financial Officer and our Chairman and CEO. We have established global policies that guide our efforts across the supplier life cycle, including supplier selection, performance, and relationship management. Each Abbott business is responsible for its respective supply chain, with enterprise efforts coordinated through our Global Operations Council.

Abbott's supply chain sustainability programs and processes are governed by Global Procurement, while accountability for execution is integrated into each Abbott business. Program performance is reported to executive leadership regularly. These programs and processes are designed to help ensure the products we make — and those made for us — are sourced and produced responsibly.

Controls and implementation

To uphold the values represented in our Supplier Guidelines and other applicable policies, we have established controls and relevant training to support our due diligence activities.

We are integrating social responsibility clauses in applicable procurement contracts, detailing our values and expectation that suppliers comply with our Supplier Guidelines and remediate identified issues.

Supplier and procurement professional training

We use a variety of methods to communicate and share our Supplier Guidelines, and expect our suppliers to understand and comply with them. Further, suppliers are expected to train their own employees to meet the expectations detailed in the Guidelines. Likewise, Abbott's procurement professionals are required to complete training on the Supplier Guidelines, human rights, our supply chain sustainability due diligence efforts, and initiatives to improve the sustainability of our supply chain.

Partnering across the supply chain with external stakeholders

Through our partnerships, we engage across our supply chain to address shared risks and opportunities, including but not limited to:

- Education and mentoring to improve sustainability awareness and management performance
- Connecting to explore business continuity solutions and opportunities to source, design, produce, and distribute products in ways that respect the environment, society, and human health
- Solutions to reduce shared sustainability impacts across Abbott and with our suppliers

Additional guiding policies

• Global EHS Policy:

Guides strategic stakeholder, supplier, and contractor engagement to help ensure compliance with EHS regulations and applicable Abbott standards

• Supplier Inclusion Guidelines:

Describes Abbott's commitment to building a resilient, inclusive supply chain by expanding meaningful business opportunities for micro, small, and medium-sized suppliers globally

• Position Statement on Access to Clean Water:

Sets supplier requirements on transparency for water management practices and educating suppliers on the importance of protecting water resources

- **Climate Responsible Energy Policy:**

Encourages suppliers to reduce emissions and improve energy efficiency

- **Animal Welfare Policy:**

Guides work with animal-related suppliers and contract laboratories, including expectations that animal use in any testing or process should occur only after alternatives have been fully explored and rejected

- **Green Procurement Guidelines:**

A resource available to the Procurement team to identify environmentally preferable goods and services and request them from suppliers

Ethics and Governance

Risk management

Our Office of Ethics and Compliance (OEC) has embedded risk assessment into Abbott's global compliance program. It oversees periodic compliance risk assessments and monitors the external risk environment, including evolving industry best practices and government guidance. OEC risk assessments are completed at least annually for the countries in which we operate and for the business activities in which we engage. These assessments include elements such as the affiliate business footprint, the external environment (including local regulations and enforcement as well as the Corruption Perceptions Index rating for the country), the controls associated with business activities, and prior internal monitoring, investigations, or audit findings. The results of these assessments help inform OEC activities, including training, monitoring, and other actions.

We also maintain an Anti-Corruption Compliance Enhancement (ACE) program that focuses on in-person reviews of business activities in selected countries in order to identify potential opportunities for continuing enhancements to our program.

Risk management framework

A Three Lines Model is integrated into our risk management governance approach. Elements include the following:

- **First Line:** Management, who directs our actions; manages operations in line with legal, regulatory, and ethical expectations; and allocates resources to achieve objectives
- **Second Line:** Corporate oversight functions, who provide expertise, training, and support around policies and risk management practices from development through implementation, followed by monitoring and continuous feedback
- **Third Line:** An internal audit function conducting independent assurance activities — assessing performance against policies and standards, identifying areas for improvement, and validating corrective action

These lines of responsibility are reflected in the risk governance framework supporting our financials, ethics and compliance, data security, workforce, sustainability, quality, and supply chain efforts.

Governing ethical processes

Abbott's Chief Ethics and Compliance Officer (CECO) is the corporate officer responsible for leading our global ethics and compliance program and managing our OEC. The CECO provides regular briefings to our Chairman and CEO, executive leaders, the Board of Directors, and the Public Policy Committee. The CECO chairs Abbott's Business Conduct Committee (BCC), a team of senior management accountable to Abbott's Chairman and CEO. The BCC meets regularly to discuss potential risk areas and mitigation measures; reviews compliance program performance and metrics, including plans for improvements; and evaluates legal and regulatory changes and best practices.

In addition, dedicated business- and affiliate-level committees monitor compliance, provide employee training and engagement, and meet to discuss emerging issues. OEC staff members support each business and corporate function to support appropriate ethics and compliance program implementation. Outside the U.S., regional OEC teams oversee the compliance program for all countries in which Abbott conducts business, including implementation of regional- or country-specific compliance requirements where necessary.

Ethics and Compliance Week

Each year, Abbott holds an Ethics and Compliance Week to drive employee awareness on anti-bribery and anti-corruption, as well as other business conduct-related topics. In 2025, our theme was "Every Decision Matters: Own Your Role in Global Compliance" reminding employees that everyone plays a vital part in upholding our commitment to honesty, integrity, and fairness. We kicked off with more than 78,000 employees across the company engaging with Ethics and Compliance Week emails from our Chairman and CEO, and CECO highlighting Abbott's commitment to compliance. In addition, employees received compliance-related messages from their divisional leaders to highlight compliance initiatives and activities available during Ethics and Compliance Week. Other interactive regional and local engagement activities, including training and knowledge checks, resulted in an estimated 24,300 engagements with employees. We also hosted an "Ethics in Action — Safeguarding Abbott Together" panel composed of senior leaders from across our business divisions to highlight how every decision we make can affect our patients, customers, colleagues and the communities we service. Over 1,600 employees from around the world attended the panel discussion.

Code of Business Conduct and Global Business Standards

Our Code of Business Conduct (Code), available in over two dozen languages, is foundational to ethical conduct at Abbott. Every employee is required to read and certify adherence to the Code annually. It, and other policies, are designed to align with laws, regulations, and industry guidelines issued by medical technology trade associations, including AdvaMed, APACMed, MedTech Europe, and Mecomed.

Our Code contains a section dedicated to promoting and selling our products with honesty and integrity. We expect product materials and communications to be balanced and truthful, consistent with the approved label in the countries we operate in, and consistent with scientific evidence. We require compliance with each country's laws and regulations that govern how, where, and when we are permitted to promote medical devices, diagnostics, nutritional products, and medicines. Our Code also explains that we may not promote or presell a product that has not yet been approved or cleared by the relevant regulatory body, and any requested information beyond the scope of approved product labeling must be directed to the appropriate medical or scientific function for response.

These principles are also carried through to our Ethics and Compliance Global Policy on Business Standards (Global Business Standards), along with the expectation that all promotional materials are properly reviewed and approved in accordance with applicable laws and company standards. To further support this compliance, we also maintain systems designed to help support business-wide alignment between our Global Infant Formula Marketing Policy and laws in our countries of operation.

Code of Business Conduct training

Upholding the highest ethical standards is the responsibility of everyone at Abbott. Legal and Ethics Resource Network (LERN) is our global compliance training platform available to all employees and third-party workers. LERN content, including courses and certifications, is available in over two dozen languages. The LERN program also shares practical guidance on recognizing and responding to legal and ethical issues. The LERN curriculum includes annual certifications on the Code, conflicts of interest, and other training and education courses. A key focus of the curriculum is interactions with healthcare professionals.

Employees are assigned LERN courses based on their role and responsibilities.* In 2025, course topics included overviews of our Code, conflicts of interest, fraud and anti-corruption, protecting sensitive information, and Global Business Standards. We also introduced a Time-Distanced Knowledge Check that included a short quiz on topics covered during prior-year training. The 2025 LERN curriculum included three new or fully revised courses with incorporated interactive features and knowledge checks interspersed throughout the content.

Interacting with healthcare professionals

We commit to interacting and communicating responsibly and in compliance with local regulations with healthcare professionals, patients, and consumers about our products and services. Where required, we report payments and other transfers of value made to healthcare professionals to relevant organizations or oversight bodies. Interactions are regularly monitored and audited, as determined on a risk basis.

Reporting concerns

Our Code emphasizes employees' ability and responsibility to report noncompliance concerns, including those related to workplace discrimination or harassment. We strive to create a safe work environment without fear of retaliation. This applies to whistleblowing, or anyone reporting violations in good faith, with anti-retaliation principles and language included in our Global Compliance Policy on Reporting Concerns, Global Business Standards, and human resources policies, including Employee Problem-Solving, Workplace Harassment, and Violence in the Workplace. Abbott encourages employees and others to report instances of retaliation. We investigate reports, identify remedial actions as appropriate, and appropriately discipline employees as needed.

We have defined avenues and processes for asking questions and reporting suspected or actual violations of our Code, policies, or procedures. In addition to reporting to managers, the OEC, or Legal, this includes our SpeakUp tool, through which employees and external parties, including suppliers, can confidentially and — where permitted — anonymously raise concerns of potential misconduct. The SpeakUp tool is available in multiple languages and can be accessed by telephone, email, or internet 24 hours a day, seven days a week.

Our Employee Problem-Solving Policy supports information exchange and concern resolution. It applies to all Abbott employees, except where local laws or collective bargaining agreements dictate otherwise.

*Applies to both full- and part-time employees.

Auditing and monitoring

Our Sales and Marketing Compliance Audit function and OEC-led monitoring process assess compliance with our Global Business Standards and Local Procedures. Our Compliance Audit function has the primary responsibility to plan, direct, and manage sales and marketing compliance audits of global operations such as select third parties supporting Abbott's businesses, including those promoting our products to customers on our behalf. Compliance audits cover the following: U.S. federal healthcare programs (when applicable), Abbott's policies, anti-bribery and anti-corruption laws, privacy laws, and local industry codes on ethical business practices. The audit scope is designed to assess the effectiveness of the compliance program and includes transactional testing of compliance activities related to Abbott's interactions with customers and the responsible promotion and marketing of our products. Risk assessments are performed to determine the schedule and scope of audits.

Audit reports are distributed to local and corporate management and include detailed findings and remediation points, which are subsequently tracked for implementation to help hold business leaders accountable and make necessary improvements to processes in a timely manner. Yearly results are summarized for both the Audit Committee and Public Policy Committee of the Board of Directors.

OEC personnel supporting each Abbott business unit and country perform an annual risk assessment to identify areas of potential compliance risk. Based on assessment outcomes, they then establish monitoring plans for the year, which includes selecting a risk-based sampling of interactions with healthcare professionals (HCPs) — such as educational events, engagements with HCPs for services, and provision of sample or evaluation product — and reviewing supporting documentation to assess compliance with Abbott's policies. "Live monitoring" programs may also be utilized, in which compliance professionals directly observe HCP interactions. Monitoring data is analyzed and trended over time to identify potential signals or patterns requiring further evaluation.

OEC identifies actions designed to address the root causes of monitoring findings, including disciplinary actions where warranted. Issues detected through auditing and monitoring are analyzed, investigated if necessary, and reported to management.

Investigations

All reports of potential Code violations, including those related to discrimination and harassment, are thoroughly investigated. Any employee violating our Code of Business Conduct, policies, or procedures is subject to appropriate disciplinary action, which may include termination. Employees refusing to cooperate in investigations — or knowingly reporting false concerns or ones intended to threaten, intimidate, or retaliate — may also be subject to disciplinary action. Disciplinary actions can range from coaching and retraining to verbal or written warnings, financial penalties, or termination. Managers are made aware of disciplinary actions associated with investigations and may take this into account when conducting performance assessments. In addition, Abbott's recoupment policy allows the company to seek recoupment of incentive compensation and/or existing awards or reduce future awards if it is determined that a senior executive engaged in significant misconduct or failed in a supervisory capacity.

The Ethics and Compliance Officer (or delegated vendor/personnel) responsible for investigations adds every potential Code violation report — including those related to discrimination and harassment — to a database. These reports are categorized by issue type and investigated by the appropriate function to determine if action is required. Periodic audits of this process help ensure investigations are conducted thoroughly and appropriately. We regularly report on investigations to our Board Committees as well as senior management.

Third-party compliance

Third parties with whom Abbott works (for example, distributors and marketing partners promoting and selling Abbott products) are expected to hold themselves to the same compliance standards as Abbott. We detail our expectations in the Third-Party Guidelines, available online in multiple languages. In addition, our Third-Party Compliance Process is designed to address and mitigate risks arising from third parties interacting with government officials or HCPs on our behalf outside the U.S. Abbott personnel are required to ensure our process is completed before engaging third-parties. Potential partners must answer detailed questionnaires while an external vendor engaged by Abbott performs due diligence background checks on risks, including:

- Anti-competitive behavior
- Corruption
- Fraud
- Government-imposed sanctions
- Human rights and labor abuses
- Money laundering
- Organized crime
- Privacy and cybersecurity
- Quality
- Terrorism

Abbott also provides third parties with training on its Third-Party Guidelines and anti-corruption compliance program. An e-learning platform provides and tracks required online training for third parties undergoing due diligence. The training is available in multiple languages and must be viewed and acknowledged by third parties before they can successfully complete Abbott's due diligence screening process. In 2025, approximately 3,800 third-parties completed our Third-Party Compliance Process.

Where risks are identified, appropriate remedial action is taken, including additional contract terms, auditing, monitoring, training, or rejection. We routinely update the Third-Party Compliance Process to continually protect against bribery and corruption risks.

Protecting our right to operate

As a publicly traded company, we are subject to external auditing of our books and records, with results periodically reported to the Board's Audit Committee. We comply with the U.S. Foreign Corrupt Practices Act, the U.K. Bribery Act, and all other applicable anti-corruption and anti-bribery laws. To protect our reputation and right to operate, we must work to ensure we never provide or accept anything of value to gain an improper advantage or inappropriately influence the use of our products. Our Global Anti-Corruption Policy, available in over two dozen languages, prohibits bribery and corruption in any form. Employees complete annual training on this and other related policies and procedures.

Raising employee awareness

On International Anti-Corruption Day, our Chief Ethics and Compliance Officer sent a company-wide communication, available in multiple languages, to raise awareness of Abbott's commitment to combat and prevent bribery and corruption. The communication includes links to important compliance resources, such as our Global Anti-Corruption Policy, LERN training system, Abbott's Third-Party Due Diligence process, and our SpeakUp portal to raise concerns.

Internal controls for bribery and anti-corruption

Abbott has implemented a series of internal controls designed to address bribery and corruption risks, including the following:

- Risk assessments: Identify potential risk areas and mitigation measures designed to discourage improper behavior
- Policies, procedures, and training: Guidelines, training, and education to raise awareness of anti-bribery and anti-corruption
- SpeakUp tool: For employees and external parties to raise potential misconduct concerns
- Investigations: For all reports of potential violations, together with appropriate remediation or disciplinary action when needed

- OEC approval: Approval by OEC may be required for activities or interactions that may potentially present bribery or corruption risk, such as the lawful distribution of items of medical utility, including textbooks or anatomical models intended for the HCPs' treatment of patients
- Independent Internal Audit team: Reports to the Audit Committee and verifies policy and procedure compliance

Preventing anti-competitive practices

We commit to complying with competition laws wherever we operate.* These laws apply to several business areas, including competitor relationships, prices and terms of sale, and marketing and trade practices. Employees are encouraged to contact our Legal team or OEC for guidance regarding competitor interactions and to report inappropriate conversations. Reports can also be made through our Ethics and Compliance helpline.

Ethical marketing

Our commitment to ethical marketing includes the foundational principle that we do not promote or presell a product that has not yet been approved or cleared by the relevant regulatory body for the location or usage in question. If a healthcare professional asks about uses for Abbott products that are beyond the scope of approved labeling (sometimes referred to as "off-label" uses), the inquiry should be directed to the designated function for such inquiries in each Abbott business, which normally resides in Medical Affairs.

Business ethics

We respect the expertise of healthcare professionals who provide guidance about healthcare treatment options and healthy living. Healthcare professionals, such as physicians, pharmacists, nurses, researchers, or laboratory staff, must use their independent judgment to decide the best course of care for their patients based on their training and expertise. We are committed to working with healthcare professionals to provide them with timely and accurate information to assist them in making decisions and providing advice to their patients. We can achieve our mission of supporting health only through a truly collaborative approach.

We continue to reinforce a culture of integrity and compliance, engaging every employee in upholding ethical behaviors. LERN is our global training platform available to all employees and third-party workers. LERN content, including courses and certifications, is available in over two dozen languages. It informs employees of all aspects of our Code, with practical guidance on recognizing and responding to legal and ethical issues, with a key focus on interactions with healthcare professionals.

Product, supply chain, and employee security

Our team of experienced security professionals and subject matter experts executes a variety of programs focused on employee and product safety. For more information on our programs for safeguarding employee security, protecting product authenticity and intellectual property, crisis management, securing our supply chain, and managing business continuity, see abbott.com.

Political participation

The Abbott Employee Political Action Committee contributes to U.S. federal, state, and local candidates and political organizations. We support those that we believe understand how government actions impact medical access and will promote continued medical progress. In 2025, Abbott reported nearly \$4.6 million in U.S. federal lobbying. Additionally, Abbott remains in the first tier on the Center for Political Accountability Zicklin Index of Corporate Political Disclosure and Accountability.

For additional information on our corporate political participation, public policy engagement principles, and trade association memberships, see the [Corporate Political Participation page](#) of our website.

*Laws that prohibit agreements and practices that eliminate or discourage competition.

Global Reporting Initiative (GRI) Content Index

Abbott has reported the information cited in this GRI content index for the period January 1 — December 31, 2025 with reference to the GRI Standards (2021). All references are to pages within this Global Sustainability Report 2025 unless stated otherwise.

GRI 1: Foundation 2021

GRI Standard	GRI Disclosure	Location
General Disclosures		
GRI 2: General Disclosures 2021	2-1 Organizational details	Contacting Abbott Global locations and contacts Form 10-K
	2-2 Entities included in the organization's sustainability reporting	Scope of this report, Page 47
	2-3 Reporting period, frequency, and contact point	January 1–December 31, 2025, published annually responsibility@abbott.com
	2-4 Restatements of information	Metrics endnotes, Page 58
	2-5 External assurance	Independent Limited Assurance Statement External assurance, Page 47
	2-6 Activities, value chain, and other business relationships	Global locations and contacts About Abbott, Page 04 Form 10-K, Page 78
	2-7 Employees	Employees, Page 50 Employee recruitment, development, and retention, Page 60 Our people and culture
	2-9 Governance structure and composition	Sustainability governance and prioritization, Page 45 Board of Directors and Committees 2026 Proxy Statement, The Board of Directors and its Committees, Pages 15-25
	2-10 Nomination and selection of the highest governance body	Board of Directors and Committees 2026 Proxy Statement, The Board of Directors and its Committees, Pages 15-25
	2-11 Chair of the highest governance body	Board of Directors and Committees 2026 Proxy Statement, The Board of Directors and its Committees, Pages 15-25

GRI Standard	GRI Disclosure	Location
GRI 2: General Disclosures 2021	2-12 Role of the highest governance body in overseeing the management of impacts	Sustainability governance and prioritization, Page 45 2026 Proxy Statement, The Board of Directors and its Committees, Pages 15-25 2025 CDP corporate questionnaire: 4.3.1*
	2-13 Delegation of responsibility for managing impacts	Sustainability governance and prioritization, Page 45 2026 Proxy Statement, The Board of Directors and its Committees, Pages 15-25
	2-14 Role of the highest governance body in sustainability reporting	Sustainability governance and prioritization, Page 45
	2-15 Conflicts of interest	Governance guidelines, II. Director Responsibilities, XII. Code of Business Conduct
	2-16 Communication of critical concerns	2026 Proxy Statement, Audit Committee, Page 20 Processes for investigations and corrective actions, Page 43 Governing ethical processes, Page 67 Reporting concerns, Page 68 Auditing and monitoring, Page 69 Due to confidentiality constraints, Abbott does not report the total number and nature of critical concerns.
	2-17 Collective knowledge of the highest governance body	Governance guidelines, VII. Director Orientation and Continuing Education
	2-18 Evaluation of the performance of the highest governance body	2026 Proxy Statement, Board Evaluation Process, Page 22 2026 Proxy Statement, Compensation Link to Sustainability, Pages 34-36
	2-19 Remuneration policies	2026 Proxy Statement, Executive Compensation, Pages 26-74 Financial well-being, Page 27 Financial and retirement benefits, Page 61 2025 CDP corporate questionnaire: 4.5.1*

*2025 CDP Corporate Questionnaire responses reflect 2024 reporting year.

Global Reporting Initiative (GRI) Content Index

GRI Standard	GRI Disclosure	Location
GRI 2: General Disclosures 2021	2-20	Process to determine remuneration 2026 Proxy Statement, Executive Compensation, Pages 26-74
	2-21	Annual total compensation ratio 2026 Proxy Statement, CEO Pay Ratio, Page 69
	2-22	Statement on sustainable development strategy Chairman and CEO letter, Page 03
	2-23	Policy commitments Human rights, Page 28 Supply chain governance, Page 66 Risk management, Page 67 Abbott Policies Code of Business Conduct Supplier Guidelines
	2-24	Embedding policy commitments Sustainability governance and prioritization, Page 45 Risk management, Page 67 Code of Business Conduct
	2-25	Processes to remediate negative impacts Supply Chain Due Diligence Disclosures Ethics and governance, Pages 67-70 Code of Business Conduct
	2-26	Mechanisms for seeking advice and raising concerns Human rights, Page 28 Processes for reporting concerns, Page 43 Reporting concerns, Page 68 Code of Business Conduct Supply Chain Due Diligence Disclosures SpeakUp Tool
	2-27	Compliance with laws and regulations Occupational health services, Page 62 Environmental policies, compliance, and auditing, Page 62 Governing ethical processes, Page 67 Form 10-K, Pages 04, 06, 12-20, 25 When public disclosure criteria are met, the total amount of monetary losses as a result of legal proceedings is included in our 2025 Annual Report . SpeakUp Tool
	2-28	Membership associations Stakeholder engagement, Page 48
	2-29	Approach to stakeholder engagement Stakeholder engagement, Page 48 2023 Global Sustainability Report, Page 50

GRI Standard	GRI Disclosure	Location
Material Topics		
GRI 3: Material Topics 2021	3-1	Process to determine material topics Stakeholder engagement, Page 48 2023 Global Sustainability Report, Page 50
	3-2	List of material topics 2023 Global Sustainability Report, Page 50
Economic		
Economic Performance		
GRI 3: Material Topics 2021	3-3	Management of material topics 2023 Global Sustainability Report, Page 50 Sustainability governance and prioritization, Page 45 2025 Annual Report, Financial Report, Pages 36-82 2026 Proxy Statement, Pages 05-07, 19-21, 34-36
GRI 201: Economic Performance 2016	201-1	Direct economic value generated and distributed 2025 Annual Report, Financial Report, Pages 36-82
	201-2	Financial implications and other risks and opportunities due to climate change 2025 CDP Corporate Questionnaire, 2.2.2* Task Force on Climate-Related Financial Disclosures (TCFD) Index, Pages 82-84
	201-3	Defined benefit plan obligations and other retirement plans 2025 Annual Report, Post-Employment Benefits, Pages 54-57 2026 Proxy Statement, Pension Benefits, Pages 62-65
Indirect Economic Impacts		
GRI 3: Material Topics 2021	3-3	Management of material topics 2023 Global Sustainability Report, Page 50 Advance health access through partnership, Pages 09-10 Make access and affordability core to new product innovation, Page 16 Access and affordability, Page 59
GRI 203: Indirect Economic Impacts 2016	203-1	Infrastructure investments and services supported Advance health access through partnership, Pages 09-10 Sustainable Development Goals (SDG) Index, Pages 85-86

*2025 CDP Corporate Questionnaire responses reflect 2024 reporting year.

Global Reporting Initiative (GRI) Content Index

GRI Standard	GRI Disclosure	Location
GRI 203: Indirect Economic Impacts 2016	203-2 Significant indirect economic impacts	Advance health access through partnership, Pages 09-10 Form 10-K: Item 1A Risk Factors, Pages 09-16 Transform care for chronic diseases, malnutrition, and infectious diseases, Page 17 Innovate for access and affordability, Pages 15-20 A multifaceted supply chain, Page 40 Access and affordability, Page 59 Sustainable Development Goals (SDG) Index, Pages 85-86
Procurement Practices		
GRI 3: Material Topics 2021	3-3 Management of material topics	2023 Global Sustainability Report, Page 50 Strong, resilient global supplier network, Pages 39-41 Controls and implementation, Page 66 Supply Chain Due Diligence Disclosures
Anti-Corruption		
GRI 3: Material Topics 2021	3-3 Management of material topics	2023 Global Sustainability Report, Page 50 Standards of business conduct, Pages 42-45 Governing ethical processes, Page 67 Protecting our right to operate, Page 70 Abbott Anti-Corruption Overview
GRI 205: Anti-Corruption 2016	205-1 Operations assessed for risks related to corruption	Risk management, Page 44 Protecting our right to operate, Page 70
GRI 205: Anti-Corruption 2016	205-2 Communication and training about anti-corruption policies and procedures	Ethics and integrity, Page 43 Protecting our right to operate, Page 70
Anti-Competitive Behavior		
GRI 3: Material Topics 2021	3-3 Management of material topics	2023 Global Sustainability Report, Page 50 Standards of business conduct, Pages 42-45 Governing ethical processes, Page 67 Protecting our right to operate, Page 70 Abbott Anti-Corruption Overview 2026 Proxy Statement, Pages 05-07, 19-21, 34-36

GRI Standard	GRI Disclosure	Location
GRI 206: Anti-Competitive Behavior 2016	206-1 Legal actions for anti-competitive behavior, anti-trust, and monopoly practices	When public disclosure criteria are met, monetary losses as a result of legal proceedings are included in our 2025 Annual Report
Environmental		
Materials		
GRI 3: Material Topics 2021	3-3 Management of material topics	2023 Global Sustainability Report, Page 50 Protect a healthy environment, Pages 29-35 A multifaceted supply chain, Page 40 Waste management, Page 64 Controls and implementation, Page 66 Environment, health, and safety policies 2026 Proxy Statement, Our Commitment to Sustainability, Pages 06-07
GRI 301: Materials 2016	301-1 Materials used by weight or volume	Packaging, Page 35
	301-2 Recycled input materials used	Packaging, Page 35
	301-3 Reclaimed products and their packaging materials	Packaging, Page 35
Energy		
GRI 3: Material Topics 2021	3-3 Management of material topics	2026 Proxy Statement, Our Commitment to Sustainability, Pages 06-07 Protect a healthy environment, Pages 13-14 Our 2025 energy and greenhouse gas reduction performance, Pages 30-31 Energy and greenhouse gas emissions, Pages 30-31 2023 Global Sustainability Report, Page 50 Energy and Emissions Global Performance, Pages 51-54 Energy management, Page 63 Environment, health, and safety policies Independent Limited Assurance Statement

Global Reporting Initiative (GRI) Content Index

GRI Standard	GRI Disclosure	Location
GRI 302: Energy 2016	302-1 Energy consumption within the organization	Energy and emissions global performance, Page 54
	302-2 Energy consumption outside of the organization	Energy and greenhouse gas emissions, Pages 30-31 Abbott estimates emissions associated with upstream and downstream energy consumption in Scope 3. See 2025 CDP Corporate Questionnaire: 7.8*
	302-3 Energy intensity	Energy and emissions global performance, Page 54
	302-4 Reduction of energy consumption	Energy and greenhouse gas emissions, Pages 30-31 Energy and emissions global performance, Page 54
Water and Effluents		
GRI 3: Material Topics 2021	3-3 Management of material topics	2023 Global Sustainability Report, Page 50 Protect a healthy environment, Pages 13-14 A unified approach to environmental programs, Page 30 Water stewardship, Pages 32-33 Water management, Pages 63-64 Environment, health, and safety policies 2026 Proxy Statement, Our Commitment to Sustainability, Pages 06-07 Independent Limited Assurance Statement
GRI 303: Water and Effluents 2018	303-1 Interactions with water as a shared resource	Water stewardship, Pages 32-33 Water management, Pages 63-64 Position statement on access to clean water, Page 66 2025 CDP Corporate Questionnaire, 2.2.2, 3.1, 9.15.2*
	303-2 Management of water discharge-related impacts	Protect a healthy environment, Pages 13-14 A unified approach to environmental programs, Page 30 Water stewardship, Pages 32-33 Water management, Pages 63-64 Environmental Antimicrobial Resistance Disclosures 2025 CDP Corporate Questionnaire, 3.11*
	303-3 Water withdrawal	Water stewardship, Pages 32-33 Water global performance, Page 55 Water management, Pages 63-64 2025 CDP Corporate Questionnaire, 9.2, 9.2.2, 9.2.7*

GRI Standard	GRI Disclosure	Location
	303-4 Water discharge	Water stewardship, Pages 32-33 Water global performance, Page 55 Water management, Pages 63-64 2025 CDP Corporate Questionnaire, 9.2, 9.2.2, 9.2.8*
	303-5 Water consumption	Water stewardship, Pages 32-33 Water global performance, Page 55 Water management, Pages 63-64 2025 CDP Corporate Questionnaire, 9.2.2*
Emissions		
GRI 3: Material Topics 2021	3-3 Management of material topics	Protect a healthy environment, Pages 13-14 A unified approach to environmental programs, Page 30 Energy and greenhouse gas emissions, Pages 30-31 Regulated air emissions, Page 64 Environmental, health, and safety policies 2026 Proxy Statement, Our commitment to sustainability, Pages 6-7 Independent Limited Assurance Statement
GRI 305: Emissions 2016	305-1 Direct (Scope 1) GHG emissions	Our 2025 energy and greenhouse gas reduction performance, Pages 30-31 Energy and emissions global performance, Pages 51-54 2025 CDP Corporate Questionnaire: 7.6*
	305-2 Energy indirect (Scope 2) GHG emissions	Our 2025 energy and greenhouse gas reduction performance, Page 30-31 Energy and emissions global performance, Pages 51-54 2025 CDP Corporate Questionnaire: 7.7*
	305-3 Other indirect (Scope 3) GHG emissions	Our 2025 energy and greenhouse gas reduction performance, Pages 30-31 Energy and emissions global performance, Pages 51-54 2025 CDP Corporate Questionnaire: 7.8*
	305-4 GHG emissions intensity	Energy and emissions global performance, Pages 51-54 2025 CDP Corporate Questionnaire: 7.45*
	305-5 Reduction of GHG emissions	Energy and greenhouse gas emissions, Pages 30-31 Energy and emissions global performance, Page 51 2025 CDP Corporate Questionnaire, 7.10, 7.10.1*

*2025 CDP Corporate Questionnaire responses reflect 2024 reporting year.

Global Reporting Initiative (GRI) Content Index

GRI Standard	GRI Disclosure	Location
GRI 305: Emissions 2016	305-6 Emissions of ozone-depleting substances	Energy and emissions global performance, Page 53 Regulated air emissions, Page 64 2025 CDP Corporate Questionnaire, 7.15.1*
	305-7 Nitrogen oxides (NOx), sulfur oxides (SOx), and other significant air emissions	Energy and emissions global performance, Page 51 Regulated air emissions, Page 64 2025 CDP Corporate Questionnaire, 7.15.1*
Waste		
GRI 3: Material Topics 2021	3-3 Management of material topics	2023 Global Sustainability Report, Page 50 A unified approach to environmental programs, Page 30 Waste management, Pages 33-34, 64 Environment, health, and safety policies 2026 Proxy Statement, Our commitment to sustainability, Pages 06-07 Independent Limited Assurance Statement
GRI 306: Waste 2020	306-1 Waste generation and significant waste-related impacts	Waste management, Pages 33-34, 64
	306-2 Management of significant waste-related impacts	Waste management, Pages 33-34, 64 Reuse and responsible waste management, Page 41 Product Stewardship Disclosures
	306-3 Waste generated	Waste global performance, Page 56
	306-4 Waste diverted from disposal	Waste global performance, Pages 56-57
	306-5 Waste directed to disposal	Waste global performance, Pages 56-57
Supplier Environmental Assessment		
GRI 3: Material Topics 2021	3-3 Management of material topics	2023 Global Sustainability Report, Page 50 Strong, resilient global supplier network, Pages 39-41 Controls and implementation, Page 66 Supply Chain Due Diligence Disclosures Environment, health, and safety policies 2026 Proxy Statement, Our commitment to sustainability, Pages 06-07

GRI Standard	GRI Disclosure	Location
GRI 308: Supplier Environmental Assessment 2016	308-1 New suppliers that were screened using environmental criteria	Controls and implementation, Page 66 Third-party compliance, Page 69 Supply Chain Due Diligence Disclosures
	308-2 Negative environmental impacts in the supply chain and actions taken	Strong, resilient global supplier network, Pages 39-41
Social		
Employment		
GRI 3: Material Topics 2021	3-3 Management of material topics	2023 Global Sustainability Report, Page 50 Build the diverse, innovative workforce of tomorrow, Pages 11-12 Build the workforce of tomorrow, Pages 24-28 Workforce, Pages 60-61 Code of Business Conduct 2026 Proxy Statement, Our commitment to sustainability, Pages 06-07
GRI 401: Employment 2016	401-1 New employee hires and employee turnover	2025 Employee turnover rate (global), Page 50
	401-2 Benefits provided to full-time employees that are not provided to temporary or part-time employees	Eligibility for non-salary benefits follows local regulations and practices. In most countries, this means we offer benefits to fulltime employees and part-time employees working more than a certain number of hours. We typically provide benefit programs above and beyond government requirements. Abbott Benefits, Supporting your well-being
	401-3 Parental leave	Family support, Page 61 Abbott Benefits, Supporting your well-being

*2025 CDP Corporate Questionnaire responses reflect 2024 reporting year.

Global Reporting Initiative (GRI) Content Index

GRI Standard	GRI Disclosure	Location
Labor/Management Relations		
GRI 3: Material Topics 2021	3-3 Management of material topics	2023 Global Sustainability Report, Page 50 Build the workforce of tomorrow, Pages 24-28 Workforce, Pages 60-61 Code of Business Conduct 2026 Proxy Statement, Our commitment to sustainability, Pages 06-07
GRI 402: Labor/Management Relations 2016	402-1 Minimum notice periods regarding operational changes	We treat all individuals with respect and communicate openly and with as much notice as practical given varying circumstances. We follow all locally required notice periods.
Occupational Health and Safety		
GRI 3: Material Topics 2021	3-3 Management of material topics	2023 Global Sustainability Report, Page 50 Employee well-being, Pages 26-27 Human rights, Page 28 Health and safety, Pages 61-62 Environment, health, and safety policies 2026 Proxy Statement, Our commitment to sustainability, Pages 06-07
GRI 403: Occupational Health and Safety 2018	403-1 Occupational health and safety management system	EHS governance, Page 62 Health and safety, Pages 61-62
	403-2 Hazard identification, risk assessment, and incident investigation	Environmental policies, compliance, and auditing, Page 62
	403-3 Occupational health services	Health and safety, Pages 61-62
	403-4 Worker participation, consultation, and communication on occupational health and safety	Health and safety, Pages 61-62
	403-5 Worker training on occupational health and safety	Health and safety, Pages 61-62
	403-6 Promotion of worker health	Employee well-being, Pages 26-27 Abbott Benefits, Supporting your well-being
	403-7 Prevention and mitigation of occupational health and safety impacts directly linked by business relationships	Managing supplier risk, Page 40

GRI Standard	GRI Disclosure	Location	
GRI 403: Occupational Health and Safety 2018	403-8 Workers covered by an occupational health and safety management system	Global Environment, Health & Safety Policy Abbott Global Environment, Health and Safety Standards 100% of employees and contractors are covered by this management system. Our data has been audited internally by the governance group and verified by an external auditor.	
	403-9 Work-related injuries	Lost time injury and illness case rate, Page 50 Health and safety, Pages 61-62	
	403-10 Work-related ill health	Employee well-being, Pages 26-27 Health and safety, Pages 61-62	
Training and Education			
GRI 3: Material Topics 2021	3-3 Management of material topics	Build the diverse, innovative workforce of tomorrow, Pages 11-12 Enterprise cybersecurity, Page 23 Employee development, Page 26 Anti-harassment training, Page 28 Training and communications, Page 43 Continuing to learn and grow, Page 61 Fostering a culture of health and safety, Page 62 Training and certification, Page 65 Supplier and procurement professional training, Page 66 Code of Business Conduct training, Page 68 Employee Training Disclosures	
	GRI 404: Training and Education 2016	404-1 Average hours of training per year per employee	Continuing to learn and grow, Page 61
	404-2 Programs for upgrading employee skills and transition assistance programs	Enterprise cybersecurity, Page 23 Employee development, Page 26 Anti-harassment training, Page 28 Training and communications, Page 43 Continuing to learn and grow, Page 61 Fostering a culture of health and safety, Page 62 Training and certification, Page 65 Supplier and procurement professional training, Page 66 Code of Business Conduct training, Page 68 Employee Training Disclosures	

Global Reporting Initiative (GRI) Content Index

GRI Standard	GRI Disclosure	Location
Diversity and Equal Opportunity		
GRI 3: Material Topics 2021	3-3 Management of material topics	2023 Global Sustainability Report, Page 50 Build the diverse, innovative workforce of tomorrow, Pages 11-12 Valuing every employee, Page 26 Supply Chain Diversity and Resilience 2026 Proxy Statement, Our commitment to sustainability, Pages 06-07
GRI 405: Diversity and Equal Opportunity 2016	405-1 Diversity of governance bodies and employees	Valuing every employee, Page 26 2026 Proxy Statement, The Board of Directors and its Committees, Pages 15-25, Board oversight, Pages 18-21
	405-2 Ratio of basic salary and remuneration of women to men	Abbott does not currently report this data on a global basis. Information is reported in select countries where public disclosure is required.
Child Labor		
GRI 3: Material Topics 2021	3-3 Management of material topics	2023 Global Sustainability Report, Page 50 Ensure a resilient, diverse, and responsible supply chain, Page 13 Human rights, Page 28 Supplier Guidelines 2026 Proxy Statement, Board oversight, Pages 18-21
GRI 408: Child Labor 2016	408-1 Operations and suppliers at significant risk for incidents of child labor	Human rights, Page 28 Managing supplier risk, Page 40 Strategic supply chain initiatives, Page 41 Supply Chain Due Diligence Disclosures Directive on the Supply Chain Due Diligence Act The Annual Report on Due Diligence and Transparency in Relation to Child Labour Norwegian Transparency Act Statements Fighting Against Forced Labour and Child Labour in Supply Chains Act Statements
Forced or Compulsory Labor		
GRI 3: Material Topics 2021	3-3 Management of material topics	2023 Global Sustainability Report, Page 50 Ensure a resilient, diverse, and responsible supply chain, Page 13 Human rights, Page 28 Supplier Guidelines 2026 Proxy Statement, Board oversight, Pages 18-21

GRI Standard	GRI Disclosure	Location
GRI 409: Forced or Compulsory Labor 2016	409-1 Operations and suppliers at significant risk for incidents of forced or compulsory labor	Managing supplier risk, Page 40 Strategic supply chain initiatives, Page 41 Supply Chain Due Diligence Disclosures Directive on the Supply Chain Due Diligence Act Norwegian Transparency Act Statements Fighting Against Forced Labour and Child Labour in Supply Chains Act Statements
Local Communities		
GRI 3: Material Topics 2021	3-3 Management of material topics	2023 Global Sustainability Report, Page 50 Innovate for access and affordability, Pages 07-10 Transform Care for chronic diseases, malnutrition, and infectious diseases, Page 17 Advance health access through partnerships, Pages 18-20 2026 Proxy Statement, Board oversight, Pages 18-21
	GRI 413: Local Communities 2016	413-1 Operations with local community engagement, impact assessments, and development programs
	413-2 Operations with significant actual and potential negative impacts on local communities	Transform care for chronic diseases, malnutrition, and infectious diseases, Page 17 Advance health access through partnerships, Pages 18-20 Access and affordability, Page 59

Global Reporting Initiative (GRI) Content Index

GRI Standard	GRI Disclosure	Location
Supplier Social Assessment		
GRI 3: Material Topics 2021	3-3 Management of material topics	2023 Global Sustainability Report, Page 50 Ensure a resilient, diverse, and responsible supply chain, Page 13 Managing supplier risk, Page 40 Supplier and procurement professional training, Page 66 Supply Chain Diversity and Resilience 2026 Proxy Statement, Board oversight, Pages 18-21
GRI 414: Supplier Social Assessment 2016	414-1 New suppliers that were screened using social criteria	Managing supplier risk, Page 40 Strategic supply chain initiatives, Page 41
	414-2 Negative social impacts in the supply chain and actions taken	Ensure a resilient, diverse, and responsible supply chain, Page 13 Managing supplier risk, Page 40 Strategic supply chain initiatives, Page 41 Supply Chain Due Diligence Disclosures
Public Policy		
GRI 3: Material Topics 2021	3-3 Management of material topics	2023 Global Sustainability Report, Page 50 Political participation, Page 70 Corporate political participation 2026 Proxy Statement, Board oversight, Pages 18-21
GRI 415: Public Policy 2016	415-1 Political contributions	Corporate political participation, Corporate contributions Abbott's latest federal lobbying disclosure filings can be found on our website. The Public Policy Committee of the Abbott Board of Directors reviews an annual report of our advocacy priorities.

GRI Standard	GRI Disclosure	Location
Customer Health and Safety		
GRI 3: Material Topics 2021	3-3 Management of material topics	2023 Global Sustainability Report, Page 50 Commitment to our customers, Pages 36-38 Quality, Pages 65-66 Governing ethical processes, Page 67
GRI 416: Customer Health and Safety 2016	416-1 Assessment of the health and safety impacts of product and service categories	Quality management system, Page 37
	416-2 Incidents of noncompliance concerning the health and safety impacts of products and services	Quality management system, Page 37 Regulatory agency feedback, Page 38
Marketing and Labeling		
GRI 3: Material Topics 2021	3-3 Management of material topics	2023 Global Sustainability Report, Page 50 Ethics and integrity, Page 43 Governing ethical processes, Page 67 Advertising and marketing approach Our Global Policy on the Marketing of Infant Formula, Pages 08, 10 Code of Business Conduct 2026 Proxy Statement, Board oversight, Pages 18-21
GRI 417: Marketing and Labeling 2016	417-1 Requirements for product and service information and labeling	Ethics and integrity, Page 43 Marketing and labeling, Page 66 Governing ethical processes, Page 67 Abbott Corporate Privacy Policy Advertising and marketing approach Our Global Policy on the Marketing of Infant Formula, Pages 08, 10
	417-2 Incidents of non-compliance concerning product and service information and labeling	Ethics and integrity, Page 43 Marketing and labeling, Page 66 Governing ethical processes, Page 67 Abbott Corporate Privacy Policy Advertising and marketing approach Our Global Policy on the Marketing of Infant Formula, Pages 08, 10
	417-3 Incidents of noncompliance concerning marketing communications	When public disclosure criteria are met, monetary losses as a result of legal proceedings associated with false marketing claims are included in our 2025 Annual Report

Sustainability Accounting Standards Board (SASB) Index

Abbott is reporting under the Sustainability Accounting Standards Board (SASB) standards. The following index provides content aligning with disclosures related to the Medical Equipment and Supplies Standard, Biotechnology and Pharmaceuticals Standard, and Processed Foods Standard. Unless otherwise noted, all data disclosed is as of December 31, 2025.

Metric	2025 Disclosure
Medical Equipment and Supplies Standard	
Affordability and Pricing	
HC-MS-240a.1: Ratio of weighted average rate of net price increases (for all products) to the annual increase in the U.S. Consumer Price Index	Affordability & pricing, Page 49 Pricing, Page 59
HC-MS-240a.2: Description of how price information for each product is disclosed to customers or to their agents	Disclosure of pricing information, Page 59
HC-MS-240a.3: Percentage change in: (1) weighted average list price and (2) weighted average net price across product portfolio compared to previous reporting period	Not currently reportable
Product Safety	
HC-MS-250a.1: (1) Number of recalls issued, (2) total units recalled	Regulatory agency feedback, Page 38
HC-MS-250a.2: Products listed in any public medical product safety or adverse event alert database	FDA's MedWatch Safety Alerts for Human Medical Products Database

Metric	2025 Disclosure
HC-MS-250a.3: Number of fatalities associated with products	FDA's MedWatch Safety Alerts for Human Medical Products Database
HC-MS-250a.4: Number of enforcement actions taken in response to violations of good manufacturing practices (GMP) or equivalent standards, by type	Regulatory agency feedback, Page 38
Ethical Marketing	
HC-MS-270a.1: Total amount of monetary losses as a result of legal proceedings associated with false marketing claims	When public disclosure criteria are met, monetary losses as a result of legal proceedings associated with false marketing claims are included in our 2025 Annual Report
HC-MS-270a.2: Description of code of ethics governing promotion of off-label use of products	Ethical marketing, Page 70
Product Design and Life-Cycle Management	
HC-MS-410a.1: Discussion of process to assess and manage environmental and human health considerations associated with chemicals in products, and meet demand for sustainable products	Product Stewardship Disclosures
HC-MS-410a.2: Total amount of products accepted for take-back and reused, recycled or donated, broken down by: (1) devices and equipment and (2) supplies	Products collected through takeback, Page 64

Sustainability Accounting Standards Board (SASB) Index

Metric	2025 Disclosure
Supply Chain Management	
HC-MS-430a.1: Percentage of (1) entity's facilities and (2) Tier 1 suppliers' facilities participating in third-party audit programs for manufacturing and product quality	1. Regulatory agency feedback, Page 38 2. Relevant Tier 1 suppliers participate in third-party auditing programs. Suppliers are classified according to risk level of potential impacts; evaluation frequency is determined based on this, ranging from every two years (for high risk) to four years (for low risk). Additional details can be found in the Quality and Supply Chain sections: Pages 36-41
HC-MS-430a.2: Description of efforts to maintain traceability within the distribution chain	Product, Supply Chain, and Employee Security Disclosures
HC-MS-430a.3: Description of the management of risks associated with the use of critical materials	Supply chain resilience, Page 40 Designing for supply, Page 40 Product Stewardship Disclosures Supply Chain Due Diligence Disclosures
Business Ethics	
HC-MS-510a.1: Total amount of monetary losses as a result of legal proceedings associated with bribery or corruption	When public disclosure criteria are met, the total amount of monetary losses as a result of legal proceedings associated with bribery or corruption is included in our 2025 Annual Report
HC-MS-510a.2: Description of code of ethics governing interactions with health care professionals	Business ethics, Page 70
HC-MS-000.A: Number of units sold by product category	Not disclosed.
Biotechnology and Pharmaceuticals	
Safety of Clinical Trial Participants	
HC-BP-210a.1: Discussion, by region, of management process for ensuring quality and patient safety during clinical trials	Safety of clinical trial participants, Page 65 Animal welfare policy, Page 67

Metric	2025 Disclosure
HC-BP-210a.2: Number of inspections related to clinical trial management and pharmacovigilance that resulted in: (1) entity voluntary remediation or (2) regulatory or administrative actions taken against the entity	Not disclosed.
HC-BP-210a.3: Total amount of monetary losses as a result of legal proceedings associated with clinical trials in developing countries	When public disclosure criteria are met, monetary losses as a result of legal proceedings associated with clinical trials are included in our 2025 Annual Report
Access to Medicines	
HC-BP-240a.1: Description of actions and initiatives to promote access to health care products for priority diseases and in priority countries as defined by the Access to Medicine Index	Equitable access to healthcare is a priority for Abbott. We work globally across more than 160 countries, many of which are priority countries, to promote access to healthcare. This includes some priority diseases. Abbott in numbers, Page 04 Innovate for access and affordability, Pages 07-10
Ethical Marketing	
HC-BP-270a.1: Total amount of monetary losses as a result of legal proceedings associated with false marketing claims	See HC-MS-270a.1
HC-BP-270a.2: Description of code of ethics governing promotion of off-label use of products	See HC-MS-270a.2

Sustainability Accounting Standards Board (SASB) Index

Metric	2025 Disclosure
Employee Recruitment, Development, and Retention	
HC-BP-330a.1: Discussion of talent recruitment and retention efforts for scientists and research and development staff	Employee recruitment, development, and retention, Page 60 2026 Proxy Statement, Pages 07, 35
HC-BP-330a.2: (1) Voluntary and (2) involuntary turnover rate for: (a) executives/senior managers, (b) mid-level managers, (c) professionals, and (d) all others	2025 Employee turnover rate (global), Page 50
Processed Foods Standard	
Energy Management	
FB-PF-130a.1: (1) Total energy consumed (2) percentage grid electricity (3) percentage renewable	Our 2025 energy and greenhouse gas reduction performance, Pages 30-31
Water Management	
FB-PF-140a.1: (1) Total water withdrawn, (2) total water consumed; percentage of each in regions with High or Extremely High Baseline Water Stress	Managing water risks, Page 64
FB-PF-140a.2: Number of incidents of non-compliance associated with water quality permits, standards and regulations	In 2025, Abbott received no Notices of Violation related to wastewater discharges.
FB-PF-140a.3: Description of water management risks and discussion of strategies and practices to mitigate those risks	No inherent water-related risks with the potential to have a substantive strategic impact on the business have been identified. To address water-related risks and help ensure our businesses' resilience, Abbott's Business Continuity and Crisis Management, EHS, Engineering, and Supply Chain organizations work to implement measures that allow us to help ensure business continuity and minimize the impacts from physical water-related risks. Likewise, a core part of Abbott's business strategy includes reducing our water footprint in our operations and engaging our value chain in strategic sourcing categories. Water management principles, Page 32 Managing water risks, Page 64 2025 CDP Corporate Questionnaire 2.2.2, 3.1.1, 5.1.2.1*

Metric	2025 Disclosure
Packaging Life-Cycle Management	
FB-PF-410a.1: (1) Total weight of packaging, (2) percentage made from recycled or renewable materials, and (3) percentage that is recyclable, reusable, or compostable	Packaging, Page 35
FB-PF-410a.2: Discussion of strategies to reduce the environmental impact of packaging throughout its lifecycle	Packaging, Page 35

*2025 CDP Corporate Questionnaire responses reflect 2024 reporting year.

Task Force on Climate-Related Financial Disclosures (TCFD) Index

Managing risks and opportunities

We are committed to identifying and reducing climate-related risks that may have the potential to impact our operations, supply chain, and distribution network. We maintain an identification process for opportunities to address emerging climate change-related healthcare needs and increase operating efficiencies by reducing climate-related impacts. We have determined that climate-related risks and opportunities exist for Abbott at the site and regional levels but are limited at a global scale.

Risks

We analyze physical and transitional risks resulting from current and emerging regulations, and assess and manage them through our risk management processes, which identify opportunities to build resilience in both our operations and our business processes. We regularly update risk management, standards, and programs to align with global best practices and regulatory requirements and aim to anticipate emerging risks and upcoming regulatory changes.

The EHS team — along with key Abbott functions such as Legal, Regulatory, Supply Chain, Sustainability, Risk Management, Business Continuity, and Finance — monitors emerging climate-related trends and regulations to analyze potential impacts and risk exposure and develop appropriate management strategies. We use scenario risk modeling to understand the implications of climate-related risks. Abbott's Business Continuity and Crisis Management organizations implement measures to help business continuity and attempt to help minimize the impacts of physical climate-related risks. These physical risks fall into two categories: acute and chronic.

Acute physical risks associated with climate change include unforeseen extreme weather events. We have developed strategies for mitigating and responding to them across our supply chain. Our Business Continuity and Crisis Management organization works with our EHS, Engineering, and Supply Chain groups to strengthen business resilience against weather events and other forms of extreme disruption. In 2025, we encountered a wave of severe weather events globally. Our team faced diverse challenges, yet, through planning and rapid response, we maintained the resilience of our supply chain.

Our Engineering and EHS policies and management standards consider chronic physical risks, such as water scarcity, and require sites to conduct regular risk and opportunity evaluations and implement mitigation strategies.

Abbott is a global organization with 89 manufacturing facilities, a diverse geographical supply chain and distribution network, and site-level business continuity planning. These factors, and our mature business continuity and crisis management programs, lessen the potential for a material business impact from climate-related physical risks, such as effects of severity of weather.

Climate-related risks include transition risks that relate to emerging expectations and regulations around GHG emission management. These include carbon limits and taxes, enhanced reporting obligations, costs to transition to lower-emissions technologies, and increased costs of goods and services. In response to this, our business strategy includes reducing operational energy and carbon footprint and engaging our supply chain in strategic sourcing categories.

Task Force on Climate-Related Financial Disclosures (TCFD) Index

Opportunities

As part of our product R&D and climate risk management processes, we consider climate change-related opportunities. These fall into two main categories:

- Increased operating efficiencies through achieving carbon reduction targets
- The opportunity to advance our mission to help people live their fullest lives by meeting changing healthcare and nutrition needs

Since 2004, Abbott has set public carbon reduction targets to drive our efforts to reduce our climate-related impacts as well as improve our operating efficiencies. Although climate-related opportunities exist and are incorporated into our 2030 Sustainability Plan, they are not anticipated to have a substantive impact on our business.

Our 2030 Sustainability Plan outlines the ways in which Abbott is responding to increased humanitarian needs due to severe weather events, new disease threats, and changes in the spread of disease. We will do so in line with our priority of innovating for access and affordability, which characterized our company's global response to the COVID-19 pandemic. We will continue to respond to humanitarian needs in line with our caring value and primarily through our philanthropic organization and product donations.

We're also taking action to support people's health as the world experiences climate change and extreme weather events, focusing on two areas: tracking and finding solutions for emerging health threats, and preparing frontline systems and communities. Across our business and in collaboration with others, we're working to identify and address emerging health issues, strengthen underlying systems, and help build more resilient communities.

Task Force on Climate-Related Financial Disclosures (TCFD) Index

Disclosure	2025 Response
Governance	
a) Describe the Board's oversight of climate-related risks and opportunities.	Abbott is committed to strong corporate governance that aligns with stakeholder interests. The Board oversees Abbott's sustainability policies and practices through its Public Policy Committee. Specific risk areas of focus for the Public Policy Committee include, among others, sustainability, environment, social responsibility and regulatory compliance. For more details on its oversight of climate risks and opportunities, see Pages 62-63 of the Environment section and Abbott's 2025 CDP Corporate Questionnaire, 4.1.2 .*
b) Describe management's role in assessing/managing climate-related risks and opportunities.	Abbott's commitment to sustainable business is integrated across our organization. The management team leads our sustainability activities. See Page 45 of the Governance section and CDP 4.3, 4.3.1, 4.5, and 4.5.1 * for more information.
Strategy	
a) Describe the climate-related risks and opportunities the organization has identified over the short, medium, and long term.	Abbott is a global organization with 89 manufacturing facilities, a diverse geographical supply chain and distribution network, and site-level business continuity planning. These factors, and our mature business continuity and crisis management programs, lessen the potential for a substantive business impact from climate-related physical risks, such as effects of severity of weather. For more information, see CDP 2.1, 2.2, 2.2.1, 2.2.2, 2.2.7, 2.4, 3.1, 3.6, and 3.6.1 .*
b) Describe the impact of climate-related risks and opportunities on the organization's businesses, strategy, and financial planning.	We factor climate-related risks and opportunities into our financial planning and business strategy, including in our products and services, supply chain, investments in R&D, and operations. For more information on these impacts, see CDP 2.2.2, 2.4, 5.1, 5.1.1, 5.1.2, and 5.11 .*
c) Describe the resilience of the organization's strategy, taking into consideration different climate-related scenarios, including a 2-degree C or lower scenario.	Abbott's Global EHS team — along with key Abbott functions such as Legal, Regulatory, Supply Chain, Sustainability, Risk Management, Business Continuity and Finance — monitors emerging environmental-related trends and regulations to analyze potential impacts and risk exposure and develop appropriate management strategies. We use scenario risk modeling to understand the implications of risks. Our Business Continuity and Crisis Management organization works with our EHS, Engineering, and Supply Chain groups to strengthen business resiliency against weather events and other forms of extreme disruption. Our Engineering and EHS policies and standards consider chronic physical risks, such as water scarcity (from CDP 5.1.2.3 *). For more information on these scenarios and the resilience of Abbott's climate strategy, see CDP 2.2.2, 5.1, 5.1.1, 5.1.2, and 5.11 .*

Disclosure	2025 Response
Risk Management	
a) Describe the organization's process for identifying and assessing climate-related risks.	Abbott is committed to reducing climate-related risks that may have the potential to impact our operations, supply chain, and distribution network. These include potential physical risks as well as emerging transition risks. We have various risk management processes, which assess climate-related risks across the organization to help minimize risks to our businesses and operations. For more details on our process for identifying and assessing risks, see CDP 2.1, 2.2.1, 2.2.2, and 2.4 .*
b) Describe the organization's processes for managing climate-related risks.	Abbott has a process for managing the potential physical and transition risks identified in our assessment process. We have several tools, committees, and organizations that identify and manage these risks. For more details, see CDP 2.1, 2.2.1, 2.2.2, and 2.4 .*
c) Describe how processes for identifying, assessing, and managing climate-related risks are integrated into the organization's overall risk management.	Climate risks are embedded into our risk assessment and management process and play a critical role in our business and continuity strategies. For more details on how climate is integrated into our overall risk management, see CDP 2.1, 2.2.1, 2.2.2, and 2.4 .*
Metrics and Targets	
a) Disclose the metrics used by the organization to assess climate-related risks and opportunities in line with its strategy and risk management process.	We track a number of climate-related metrics, in addition to our Scope 1, 2, and 3 emissions for our carbon footprint. For these metrics, see CDP 7.1-7.10, 7.12, 7.15, 7.16, 7.17, 7.20, 7.22, 7.29, 7.30, 7.45, 7.52, 7.53, 7.54, and 7.55 *; Pages 30-31 of the Energy and Greenhouse Gas Emissions section; and Pages 51-54 of the Appendix.
b) Disclose Scope 1, Scope 2, and, if appropriate, Scope 3 GHG emissions and the related risks.	Under our 2030 Sustainability Plan, we have set near-term science-based targets to reduce our absolute Scope 1 and 2 emissions by 30% from the 2018 baseline by the end of 2030 (the target boundary includes land-related emissions and removals from bioenergy feedstock). We also set a scope 3 supplier engagement target. To track these, we disclose our carbon footprint for all three scopes annually. For these metrics and related risks, see CDP 7.1-7.10, 7.12, 7.15, 7.16, 7.17, 7.20, 7.22, 7.29, 7.30, 7.45, 7.52, 7.53, 7.54, and 7.55 *; Pages 30-31 of the Energy and Greenhouse Gas Emissions section; and Pages 51-54 of the Appendix.
c) Describe the targets used by the organization to manage climate-related risks and opportunities, and performance against targets.	We assess and manage our risks and opportunities, and under our 2030 Sustainability Plan, we have set near-term science-based targets to reduce our absolute Scope 1 and 2 emissions by 30% from the 2018 baseline by the end of 2030 (the target boundary includes land-related emissions and removals from bioenergy feedstock). We also set a scope 3 supplier engagement target. For more information, see CDP 7.52, 7.53, and 7.54 .* Pages 30-31 of the Energy and Greenhouse Gas Emissions section, and Page 51 of the Appendix.

*2025 CDP Corporate Questionnaire responses reflect 2024 reporting year.

Sustainable Development Goals (SDG) Index

In a bid to drive global impact, we work to align our priorities, material issues, and actions with the United Nations SDGs.



Goal one: No poverty

End poverty in all its forms everywhere.


Targets:
1.1 / 1.4 / 1.5

Building resilience against disasters

- 2025 Global Sustainability Report, [Page 20](#)
- [Going Beyond Disaster Relief to Disaster Resilience](#)

Creating economic opportunities in Tanzania

- Abbott Fund Tanzania's dairy cow program in Bantu village provides self-employment for farmers through the creation of an agricultural ecosystem that boosts both farming and livestock economic productivity. In 2025, Bantu farmers average monthly income was \$87, an increase from the average monthly baseline income of \$36 in 2023.
- [2024 Global Sustainability Report, Page 19](#)



Goal two: Zero hunger

End hunger, achieve food security and improved nutrition, and promote sustainable agriculture.

Targets:
2.1 / 2.2 / 2.4

Delivering Food is Medicine program in Stockton, California


- 2025 Global Sustainability Report, [Page 18](#)
- [2024 Global Sustainability Report, Page 17](#)
- [Increasing Access to Healthy Food](#)
- [New Research on Abbott's Healthy Food Rx Program](#)

Helping families access healthy food

- Through our longstanding partnership with the Global Foodbanking Network, we are increasing access to fresh fruits and vegetables for families in Mexico and Colombia. In 2025, approximately 2,900 children benefited from nutritious foods offered through local school-based programs.
- In 2025, more than 1,100 children in Tanzania received nutritious meals through our school-based programs and income-generating activities.
- 2025 Global Sustainability Report, [Pages 10, 19](#)
- [2024 Global Sustainability Report, Page 96](#)
- [Supporting Local Families](#)

Enhancing food systems for nutritional sustainability in Tanzania

- 2025 Global Sustainability Report, [Page 09](#)



Goal three: Good health and well-being

Ensure healthy lives and promote well-being for all at all ages.

Targets:
3.1 / 3.2
3.3 / 3.4 / 3.8

Advancing access to affordable healthcare


- 2025 Global Sustainability Report, [Pages 07, 08, 09, 16](#)
- [2024 Global Sustainability Report, Page 10](#)
- [Advancing Access to Affordable Healthcare in India](#)

Transforming care for malnutrition and chronic diseases

- 2025 Global Sustainability Report, [Pages 07, 08, 17](#)
- [2024 Global Sustainability Report, Page 08](#)
- [Abbott Center For Malnutrition Solutions](#)
- [Malnutrition and the MUAC Z-Score Tape](#)

Building a resilient health workforce to advance maternal and child health in Malawi

- 2025 Global Sustainability Report, [Page 09](#)
- [2024 Global Sustainability Report, Page 09](#)



Goal four: Quality education

Ensure inclusive and equitable quality education and promote lifelong learning opportunities for all.

Targets:
4.1 / 4.2
4.3 / 4.4 / 4.5

Building and strengthening schools in Tanzania

- In Tanzania, through the Kimberly and Miles White Primary School, the National Children's Home, and the Miles and Kimberly White High School, we are supporting more than 1,500 children and students with educational services and access to nutrition and medical care.
- [2024 Global Sustainability Report, Page 19](#)
- [2023 Global Sustainability Report, Pages 78, 119](#)

Delivering school-based education and community health models to improve kindergarten readiness

- Our partnership with Easterseals is increasing access to health and social services for children at their Head Start programs in Chicago, better equipping them to succeed. At the end of the 2024-2025 school year, 79% of children were ready for kindergarten exceeding Easterseals' Head Start national figure of 60%.
- [2024 Global Sustainability Report, Page 96](#)
- [Abbott Fund and Easterseals Launch Three-Year Partnership](#)

Supporting Abbott's workforce

- 2025 Global Sustainability Report, [Pages 11, 12, 25-27](#)

Preparing college students for in-demand career paths

- Abbott, a founding member of AMIE, partners with AMIE, industry, and government leaders to prepare students for engineering and computer science careers. Key initiatives include a course to introduce students to the medical device industry with Prairie View A&M University and building a cybersecurity talent pipeline with Microsoft and RTX Corporation, now spanning Jackson State University, Prairie View A&M University, and the University of Maryland Eastern Shore.

Sustainable Development Goals (SDG) Index

Goal five: gender equality Targets: 5.1

Achieve gender equality and empower all women and girls.

Inspiring youth in the field of STEM

- Abbott's Singapore High School STEM Internship offers students the opportunity to explore diverse STEM fields and technologies, gain guidance from Abbott mentors, contribute to meaningful projects, and build essential life skills. Now in its fifth year, the program has seen steady growth since its inception in 2021 from 7 to 25 interns, with 60% female representation, and to date, 90 students have completed the program.
- [Changing the Face of STEM | Abbott U.S.](#)
- [2024 Global Sustainability Report, Page 24](#)

Creating economic opportunities for female farmers in India

- [2025 Global Sustainability Report, Page 41](#)
- [2024 Global Sustainability Report, Page 41](#)

Goal six: clean water and sanitation Targets: 6.3/6.4/6.8

Ensure availability and sustainable management of water and sanitation for all.

Water quality

- [2025 Global Sustainability Report, Pages 32, 33](#)
- [Protecting Water in Communities](#)

Water stewardship certifications

- [2025 Global Sustainability Report, Page 32](#)
- [2024 Global Sustainability Report, Page 32](#)
- [Abbott Environmental Policy](#)

Water stewardship in our manufacturing operations

- [2025 Global Sustainability Report, Page 32](#)
- [2024 Global Sustainability Report, Page 32](#)

Reducing risk of antimicrobial resistance (AMR) in wastewater

- [2025 Global Sustainability Report, Page 59](#)
- [2024 Global Sustainability Report, Page 66](#)
- [Environmental Antimicrobial Resistance Disclosures](#)

Goal eight: decent work and economic growth Targets: 8.2/8.3

Promote sustained, inclusive, and sustainable economic growth, full and productive employment, and decent work for all.

Expanding operations and creating jobs in Ireland

- [2024 Global Sustainability Report, Page 29](#)
- [New Abbott Manufacturing Facility in Kilkenny](#)

Creating economic opportunities for dairy farmers in India

- [2025 Global Sustainability Report, Page 41](#)
- [2024 Global Sustainability Report, Page 41](#)

Building a pipeline of local healthcare workers in Stockton, California

- Through our partnership with University of the Pacific, 89 students have received scholarships, and 67 of these students have graduated with degrees in Social Work, Nursing, and Clinical Nutrition with a sub-specialty in diabetes management.
- [2024 Global Sustainability Report, Page 97](#)
- [Building Stockton's Healthcare Workforce](#)

Goal twelve: responsible consumption and production Targets: 12.5

Ensure sustainable consumption and production patterns.

Waste impact

- [2025 Global Sustainability Report, Pages 33, 34](#)
- [2024 Global Sustainability Report, Page 33](#)

Packaging impact

- [2025 Global Sustainability Report, Page 35](#)
- [2024 Global Sustainability Report, Page 35](#)

Waste at manufacturing operations

- [2025 Global Sustainability Report, Page 34](#)
- [2024 Global Sustainability Report, Page 34](#)

Goal thirteen: climate action Targets: 13.2

Take urgent action to combat climate change and its impacts.

Investing in energy efficiency projects

- [2025 Global Sustainability Report, Pages 30, 31](#)
- [2024 Global Sustainability Report, Pages 31, 32](#)

Reduce absolute scope 1 and 2 emissions

- [2025 Global Sustainability Report, Pages 30, 31](#)
- [2024 Global Sustainability Report, Pages 31, 32](#)

Investing in electrification and renewable energy

- [2025 Global Sustainability Report, Pages 30, 31, 54](#)
- [2024 Global Sustainability Report, Pages 30, 31, 58](#)

Goal seventeen: partnerships for the goals Targets: 17.6/17.16/17.17

Strengthen the means of implementation and revitalize the Global Partnership for Sustainable Development.

Strengthening healthcare and communities in Tanzania

- [2025 Global Sustainability Report, Page 09](#)
- [2024 Global Sustainability Report, Pages 09, 19](#)
- [2023 Global Sustainability Report, Pages 09, 18, 119, 122, 125](#)
- [Abbott's Long-Term Partnership with the Government of Tanzania](#)

Tackling diabetes in Stockton, California

- [2025 Global Sustainability Report, Page 18](#)
- [2024 Global Sustainability Report, Pages 08, 17](#)
- [Advancing Health Access in Stockton](#)

Bringing quality healthcare to rural communities in Rwanda

- [2024 Global Sustainability Report, Pages 10, 18](#)
- [Expanding Health Access in Rwanda](#)

Delivering scalable, integrated solutions for infectious diseases through Abbott's Pandemic Defense Coalition

- [2025 Global Sustainability Report, Page 08](#)
- [2024 Global Sustainability Report, Page 08](#)

Back cover:

Jenny Barcoe, a building services engineer, surveys the roof and solar panels at the Kilkenny, Ireland, facility.



Abbott Sustainability
100 Abbott Park Road
Department 0383
Abbott Park, IL 60064-6048

responsibility@abbott.com

www.abbott.com/sustainability



FSC
Logo
Placement



ABBOTT